Identification of SARA Compounds
in Adipose Tissue
Final Report
By
Jon D. Onstot
John S. Stanley
For National Human Monitoring Program
Field Studies Branch (TS-798)
Exposure Evaluation Division
Office of Pesticides and Toxic Substances
401 M Street, SW
Washington, DC 20460
Attn: Ms. Janet Remmers, Work Assignment Manager
Dr. Joseph J. Breen, OTS Project Officer
EPA Contract No. 68-02-4252
Work Assignment No. 23
MRI Project No. 8862-A23
August 31,1989
U.S. Environmental Protection Agency
Region 5, Library (PL-12J)
77 West Jackson Boulevard, 12th Floor
Chicago, IL 60604-3590
-------
DISCLAIMER
This document has been reviewed and approved for publication by the Office of
Toxic Substances, Office of Pesticides and Toxic Substances, U.S. Environ-
mental Protection Agency. The use of trade names or commercial products does
not constitute Agency endorsement or recommendation for use.
-------
PREFACE
This report describes the methodology and results of a study to
determine levels of selected volatile and semivolatile organic compounds
selected for the Superfund Amendments and Reauthorization Act (SARA),
Title III, Section 313 listing, in human adipose tissue.
This work was conducted for the EPA's Office of Toxic Substances,
Field Studies Branch (EPA Contract No. 68-02-4252, Work Assignment 23,
Ms. Janet Remmers, Work Assignment Manager, and Dr. Joseph Breen, Project
Officer). The HRGC/MS data used in this study were originally generated under
EPA Contract No. . 68-02-3538, Work Assignment 8. In the original study,
46 composite samples were prepared from individual specimens obtained from the
Environmental Protection Agency's National Human Adipose Tissue Survey (EPA
NHATS fiscal year 1982 (FY82)) repository.
This report was prepared by Mr. Jon Onstot with assistance from
Dr. John S. Stanley, MRI Work Assignment Leader. Additional work for this
task was performed by Mr. Fred Forman and Ms. Audrey Zoog.
MIDWEST RESEARCH INSTITUTE
C. Constant
Program Manager
Reviewed:
Jack Balsinger
Quality Assurance Coordinator
>hn E. Going, Director
Chemical Sciences Department
m
-------
TABLE OF CONTENTS
Page
Preface 111
List of Figures vii
List of Tables vii
Executi ve Summary i x
I. Introduct i on 1
A. Broad Scan Analysis Strategy 1
B. Characterization of Unidentified Peaks 2
C. Work Assignment Objectives 2
D. Significance 3
E. Organization of This Report 3
II. Recommendations 4
A. Analysis of Other NHATS FY Datafiles 4
B. Recovery Efficiency Studies 4
C. Analysis of Future NHATS Samples 4
III. Experimental Procedure 5
A. Selection of Target Compounds 5
B. Compilation of Physical Data 15
C. Final Selection of Analytes 15
D. Prediction of GC Retention Values 16
E. Target Compound Analysis 33
F. GC/MS Analysis of Authentic Standards 34
IV. Results 37
V. Discussion 43
A. Limitations of the FY82 Data 43
B. Retention Prediction 43
C. Additional Problems Associated with VOA
Analysi s 44
D. Additional Problems Associated with SMV
Analys is 44
E. Comparison of Authentic Standards to Tentatively
Identified Targets 44
F. Comparison of Frequency of Occurrence Results
to Unidentified Peaks Study 48
G. Possible Sources of Identified Compounds 48
VI. References 51
-------
TABLE OF CONTENTS (continued)
Page
Appendix AVolatile Composite Summary Reports A-l
Appendix B6% Florisil Fraction Semivolatile Composite Summary
Reports B-1
Appendix C--15/50 Florisil Fraction Semivolatile Composite Summary
Reports C-l
Appendix D~Incidence of VOA SARA/ECAO Target Analytes in FY82
Adipose Composites 0-1
Appendix EIncidence of 6% SMV SARA/ECAD Target Analytes in
FY82 Adipose E-l
Appendix FIncidence of 15/50% SMV SARA/ECAD Target Analytes in
FY82 Adipose F-l
Appendix G--Comparison Plots of Sample vs. Reference Mass Spectra
for Compounds Identified in FY82 Composites G-l
-------
LIST OF FIGURES
Number Title Page
1 Regression plot of volatiles with known boiling point
vs. RRT 20
2 Regression plot of semivolatiles with known boiling point
vs. RRT 22
LIST OF TABLES
Number Title Page
1 Cross Reference of Compounds Considered for Target Compound
Analysis 6
2 GC Parameters of GC/MS Systems Used for Predicting RRT 18
3 FY82 Broad Scan Target Analytes Used to Predict Volatile
RRT Values for SARA/ECAD Compounds 19
4 FY82 Broad Scan Target Analytes and Unidentified Peaks
Compounds Used to Predict Semi volatile RRT Values for
SARA/ECAD Analytes 21
5 Semivolatile Compounds Which Were Manually Determined
in the FY82 Data 23
6 List of Volatile Target Analytes 24
7 List of Semivolatile Target Analytes 26
8 SARA Compounds Eliminated from Consideration as Target
Analytes 29
9 RRT Comparison of Selected Broad Scan Targets
1984 Analysis vs. 1989 Analysis 36
10 SARA/ECAD Compounds Identified in FY82 Adipose Composites
VOA Fraction 38
11 SARA/ECAD Compounds Identified in FY82 Adipose Composites
6% SMV Fraction 39
12 SARA/ECAD Compounds Identified in FY82 Adipose Composites
15/50% SMV Fraction 40
13 Volatile Compounds Not Detected in FY82 Adipose Composites.. 41
14 Semivolatile Compounds Not Detected in FY82 Adipose
Composites 42
15 Volatile Compounds with Non-Specific Mass Spectra 45
16 Semivolatile Compounds with Non-Specific Mass Spectra 45
17 Comparison of Authentic Standards vs. Observed Targets 46
18 Frequency of Occurrence of ECAD Analytes in Original
Unidentified Peaks Study and Current Study 49
vii
-------
EXECUTIVE SUMMARY
The National Human Adipose Tissue Survey (NHATS) provides the EPA
Office of Toxic Substances with a unique mechanism for establishing exposure
of the general U.S. population to toxic compounds. This monitoring program
has been used primarily for establishing exposure trends for organochlorine
pesticides and PCBs. In 1984, the list of target compounds was expanded to
include other volatile (VOA) and semivolatile organic (SMV) compounds as part
of an effort to expand the use and capabilities of the NHATS program. This
effort was undertaken to detect other potentially toxic compounds that might
be entering the environment. This expanded target list was used in the broad
scan analysis of adipose specimens collected during the FY82 (Stanley 1986).
A follow-up study was directed at identifying high resolution gas chroma-
tography/mass spectrometry (HRGC/MS) peaks in the FY82 data which had not been
identified in the broad scan study (Onstot 1987). However, the latter study
left open the possibility that additional compounds of interest might still be
present in the data.
In the current study, an expanded list of target compounds was
selected for analysis and was applied to the FY82 HRGC/MS data. Target com-
pounds were selected from three existing listings: the Superfund Amendments
and Reauthorization Act (SARA) Title III, Section 313 toxic chemical listing
(Fed. Reg. 53:30); the SARA Section 110 listing (Fed. Reg. 52:74); and a list-
ing of priority compounds which were tentatively identified in a previous
study of the same data (Onstot 1987a, Onstot 1987b, Price 1987), hereafter
referred to as the Existing Chemicals Assessment Division (ECAD) Listing.
From these listings, 61 volatile and 120 semivolatile target compounds were
selected and searched in the FY82 data. Application of target compound
analysis (TCA) to 46 composited adipose tissue samples collected during FY82
resulted in the identification of 13 volatile and 19 semivolatile compounds.
Frequency-of-occurrence data was compiled with respect to three age groups,
four census regions and nine census divisions. The compounds were identified
from three sample fractions: a volatile fraction and two semivolatile frac-
.tions produced from a cleanup step using 6% and 15/50% diethyl ether/hexane
column chromatography fractions, respectively. A list of compounds identified
in each of the sample fractions and frequencies of occurrence is shown below.
ix
-------
Volatile Compounds
No. Compound Frequency
1. 2-Amylfuran 46
2. Bromoheptane 4
3. Bromopentane 3
4. Butyraldehyde 45
5. Ethyl isovalerate 44
6. 1-Iodopentane 35
7. Isobutyraldehyde 43
8. Limonene . 46
9. Nonene 46
10. 3-Octen-2-one 45
11. Pentyl alcohol 38
12. Pentyl cyclohexane 10
13. Trichloroethylene 20
313 110
x
x
ECAD
x
X
X
X
X
X
X
X
No.
1.
2.
3.
4.
5.
6.
7.
8.
9.
6X Florisil Fraction Semi volatile Compounds
Compound Frequency 313 110
Anthracene 1
Blphenyl 9
Cymene 41
Dlbenzofuran 3
Limonene 41
Diphenyl ether 40
Safrole 4
1,2,4-Trimethylbenzene 42
2,6-Xylidene 11
x
x
X
X
ECAD
x
X
15/50% Florisil Fraction Semivolatile Compounds
No. Compound
1. Bis(2-ethylhexy1)adipate
2. Butyl glycol butyl phthalate
3. Carbaryl
4. o-Cresol
5. m,p-Cresol
6. Di-(2-ethylhexyl) phthalate (DEHP)
7. 2,4-Diaminotoluene
8. 2-Ethoxy benzaldehyde
9. 4-Pentyl benzaldehyde
10. 2-Phenyl phenol
Frequency 313 110 ECAD
8 x
8 x
1 x
38 xx
43 x
42 xx
20 x
6 x
9 x
22 x x
-------
I. INTRODUCTION
The National Human Adipose Tissue Survey (NHATS) is the main opera-
tive program of the National Human Monitoring Program (NHMP). The NHMP was
first established by the U.S. Public Health Service in 1967 and was sub-
sequently transferred to the U.S. Environmental Protection Agency in 1970.
During 1979 the program was transferred within EPA to the Exposure Evaluation
Division (EED) of the Office of Toxic Substances (OTS).
NHATS is an annual program to collect a nationwide sample of adipose
tissue specimens and to chemically analyze them for the presence of selected
toxic compounds. The objective of the NHATS program is to detect the level
and prevalences of these compounds in the general population. The NHATS data
are used to address part of OTS's mandate under the Toxic Substances Control
Act (TSCA) to assess chemical risk to the U.S. population. The specimens are
collected from autopsied cadavers and surgical patients according to a sta-
tistical survey design (Lucas, Pierson, Myers, Handy 1981). The survey design
ensures that specified geographical regions and demographic categories are
appropriately represented to permit valid and precise estimates of baseline
levels, time trends, and comparisons across subpopulations. Historically,
organochlorine pesticides and PCB residues have been selected for evaluation.
A. Broad Scan Analysis Strategy
In 1984, EPA/OTS recognized the need to provide a more comprehensive
assessment of the toxic substances that accumulate in adipose tissue than was
being provided at that time. An aggressive strategy to assess TSCA-related
substances that persist in the adipose tissue of the general U.S. population
was therefore developed by EED. The NHATS specimens collected during fiscal
year 1982 (FY82) were selected for a broad scan analysis of volatile and semi-
volatile organic TSCA-related chemicals (Mack, Stanley 1984).
The initiative to achieve a more comprehensive assessment necessi-
tated either the development of new methods or the modification of the exist-
ing -analytical procedures, specifically high resolution gas chromatography/
mass spectrometry (HRGC/MS). Data on organochlorine pesticides and PCB's
reported for the NHATS specimens up to the FY82 collection are based on packed
column gas chromatography/electron capture detector (PGC/ECD) analysis.
Under a previous work assignment program for EPA/OTS, Midwest
Research Institute (MRI) conducted the analysis of human adipose tissue as
composites for a specific list of organic compounds (Stanley 1986a, Stanley
1986b, Stanley 1986c, Stanley 1986d). Forty-six composites from the NHATS
FY82 collection period were analyzed for a target list of volatile and semi-
volatile organic compounds by high resolution gas chromatography/mass spec-
trometry (HRGC/MS). This analysis approach is hereafter referred to as broad
scan analysis.
-------
B. Characterization of Unidentified Peaks
Although broad scan analysis provided EPA/OTS with an expanded list
of potentially toxic compounds in adipose tissue, a much larger number of
peaks were observed in the HRGC/MS reconstructed ion chromatograms (RIC) that
were still not identified. A procedure was developed to automatically
characterize these unidentified peaks (Onstot 1986a, Onstot 1986b) based on a
forward library search approach. In this approach, an unknown mass spectrum
is compared to a library of reference mass spectra, as opposed to a reverse
search approach in which a single reference mass spectrum corresponding to a
target compound is compared to the spectra in a GC/MS file.
Application of the automated peak identification procedure resulted
in the tentative identification of 121 compounds in the VOA samples, 81 com-
pounds in the 6% Florisil SMV, and 96 compounds in the 15/5055 Florisil SMV
samples. However, a significant number of peaks were still unable to be
identified by the automated procedure, with 99 spectra from the volatile, 258
spectra from the 6% Florisil and 343 spectra from the 15/50% Florisil SMV
fractions remaining unidentified at the end of that study. A number of
reasons were cited to account for the inability of the procedure to identify
these unknown peaks, which included a mass scanning range that was not
suitable for the identification of unknown spectra, candidate mass spectra
which were obviously not represented in the reference mass spectral library,
and difficulties encountered in extracting high quality spectra from a complex
sample matrix such as adipose. In addition, the peak selection process
focused primarily on peaks which were visibly discernible above the total ion
current baseline. As a result, the unidentified peaks study left open the pos-
sibility that additional compounds of interest might still be present in the
data.
C. Work Assignment Objectives
A new approach for the identification of potentially significant
compounds in the FY82 data was formulated which would be less susceptible to
the problems encountered in the unidentified peaks study. The new approach
consisted of a return to the analysis of a specific list of target analytes,
as opposed to the forward library search approach used in the unidentified
peaks study. Although target compound analysis (TCA), based on the reverse
search approach, is more restrictive in the sense that identification is
limited to only those compounds which have been preselected for study, such an
approach provides a greater degree of selectivity and sensitivity than the
forward library search.
Three compound listings were selected as sources for environmentally
significant target compounds: the Superfund Amendments and Reauthorization
Act (SARA) Title III, Section 313 toxic chemical listing; the SARA Section 110
listing; and a listing of 16 priority compounds which were tentatively identi-
fied in the unidentified peaks study and targeted by the Existing Chemicals
Assessment Division (ECAD) of EPA as chemicals of interest. The latter
listing was included in order to provide a check for those compounds which
were identified in the original unidentified peaks study and which were deemed
at that time to be environmentally significant.
-------
The objectives for this task were to (1) evaluate the compounds in
the above listings and determine whether they might be applicable as target
compounds for the FY82 dataset; (2) categorize each candidate compound chosen
from the listings according to the fraction (VOA or SMV) in which they would
be expected to be observed, i.e., estimate their volatility; and (3) perform
TCA on the set of FY82 composite samples.
D. Significance
The significance of this study is twofold. First, the use of the
SARA listings for the selection of target compounds provides an opportunity
for EPA to correlate information gathered from other studies using these lists
with the information collected from the NHATS data. For example, the
Section 110 listing, which is a prioritized list of compounds chosen from the
717 hazardous substances currently identified under Section 102 of the Compre-
hensive Environmental Response, Compensation, and Liability Act (CERCLA),
represent compounds which have been determined to pose a potential human
health risk and which have been identified at National Priorities List
hazardous waste sites. Correlation of these human risk compounds with NHATS
data would allow EPA to more accurately assess the danger of these compounds
to the human population from environmental sources.
Secondly, compounds identified in this study may be selected for
inclusion in the broad scan analysis of future NHATS samples. This would
provide EPA with long-term bioaccumulation information which could be tracked
for possible long-term trends, which could in turn be correlated to environ-
mental levels determined from other studies as described above. The correla-
tion of trends between levels of environmental pollutants and human bioaccumu-
lation levels has been already been demonstrated through NHATS for several
compounds including polychlorinated biphenyls (PCBs), hexachlorobenzene (HCB)
and the DDT family.
E. Organization of This Report
Following this introductory section, Section II presents recommenda-
tions for pursuing future activities related to this study. Section III
presents the .experimental procedure and describes the process of selecting
target compounds, developing the necessary criterion for supporting qualita-
tive identification, and conducting the target compound analysis. The results
of this experimental effort are presented in Section IV and a discussion of
results and other findings is provided in Section V. Appendices A through C
present amounts for the identified compounds compared to their respective
internal standard response. Appendices D through F present the data in
additional detail based on comparisons of identified compounds within census
divisions and regions. Appendix G shows a representative mass spectral
comparison of each identified compound to the reference library.
-------
II. RECOMMENDATIONS
Recommendations for further activities in the area of TCA analysis
of NHATS samples may be divided into four major areas, described below.
A. Analysis of Other NHATS FY Datafiles
One of the results of the current study was the construction of a
mass spectral database for the quantisation of environmentally significant
target compounds. Application of this quantisation library to subsequent
NHATS samples would involve much less effort than was required in this study
since the target compound selection and the library construction steps would
not need to be repeated.
B. Recovery Efficiency Studies
In contrast to the broad scan study, no recovery efficiency studies
were performed to determine to what extent the target compounds could be
recovered by the extraction method used. Knowledge of extraction efficiencies
would be useful in two regards. First, some compounds would almost certainly
be found to be unrecoverable from adipose by the extraction method used on the
FY82 data and could be eliminated from further consideration as target com-
pounds in future studies. Secondly, recovery efficiency data would allow more
precise estimates of concentration levels for compounds identified in adipose
to be made.
C. Analysis of Future NHATS Samples
It is recommended that the compounds identified in this study be
included in any future target compound analyses for the NHATS project. In
this way, information regarding the incidence of occurrence in human adipose
for the compounds identified in this study will be accumulated in the same way
as for the compounds currently included in the Broad Scan target analyte
listing.
-------
III. EXPERIMENTAL PROCEDURE
The experimental procedure used in this study was comprised of three
major steps. The first step involved the selection of a list of target com-
pounds from the SARA and ECAD compound listings. In the second step, a table
of GC retention indices was compiled for the selected target compounds.
Retention values were either derived from experimental data or were predicted
using a regression plot of boiling points vs retention indices of compounds
with known retention. The third step involved the setup of the target com-
pound analysis (TCA) search libraries and subsequent TCA analysis of the FY82
data. These three steps are described in detail in the following sections.
A. Selection of Target Compounds
As stated in the introduction, the list of target compounds used in
this study were chosen from three primary sources: the Superfund Amendments
and Reauthorization Act (SARA) Title III, Section 313 toxic chemical listing
of 308 chemical substances and 20 chemical categories; the SARA Section 110
listing of 108 hazardous substances most commonly found at facilities on the
CERCLA National Priorities List; and a listing of 16 priority compounds which
were tentatively identified in the original unidentified peaks study (Onstot,
1986a) that have been targeted by ECAD as chemicals of interest.
One compound, 1-iodopentane, was tentatively identified in a vola-
tile composite after completion of the original unidentified peaks study and
thus was not included in that report. This compound was included in the vola-
tile target analyte list in order to determine its frequency of occurrence in
the other volatile composites. One compound, diphenyl ether, is listed in
this report as a target compound even though it is not a member of the SARA
listings. However, as a result of the GC/MS analysis of authentic standards
for this study, the compound originally thought to be 2-phenyl phenol in the
6% fraction composites was actually identified as diphenyl ether. Thus, for
reporting purposes, diphenyl ether is listed as a target analyte so that it
may be included in the tables of identified compounds.
A number of compounds from the above listings were found to be
common to more than one list. A cross-reference was compiled which lists each
unique compound vs the source listings, as well as the list of original broad
scan target analytes. The cross-reference listing is shown in Table 1, with
compounds arranged in alphabetical order. Three-hundred and forty-nine unique
compounds were identified from a combined total of 432 entries in the 313,
110, and"ECAD listings, with 83 compounds found to be represented in more than
one listing. In some instances, compounds found in more than one listing were
assigned different names. Inconsistencies in nomenclature were resolved by
comparison of CAS registry numbers. In addition to the individual compounds
listed in the Section 313 listing, 20 chemical categories are also listed.
Most of these classes are comprised of metallic compounds and complexes such
as antimony, arsenic, barium, cadmium, copper and lead, and are not amenable
to GC/MS analysis. Three chemical categories composed of organic compounds
were listed: chlorophenols, glycol ethers, and polybrominated biphenyls
(PBBs). Chlorophenols and PBBs were included as analytes in the broad scan
survey. The glycol ethers were not considered for this study.
-------
Table 1 - Cross Reference of Compounds Considered for Target Compound Analysis
Listing (b)
No
1
2
3
4
5
6
7
8
9
10
1 1
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
Compound Name (a)
Acetaldehyde
Acetamide
Acetone
Acetonitrile
2-Acetylaminofluorene
Acrolein
Acrylamide
Acrylic Acid
Acrylonitrile
Aldrin
Ally! Chloride
Aluminum (fume or dust)
Aluminum Oxide
1 -Amino-2-methylanthraquinone
2-Aminoanthraquinone
4-Aminoazobenzene
4-Aminobiphenyi
Ammonia
Ammonium nitrate (solution)
Ammonium sulfate (solution)
2-Amyl furan
Aniline
p-Anisidine
o-Anisidine
o-Anisidine hydrochloride
Anthracene
Antimony
Arsenic
Asbestos (friable)
Barium
Benzal chloride
Benzamide
Benzene
Benzidine
Benzo(a)anthracene
Benzo(a)pyrene
Benzo(b)fluoranthene
Benzole acid
Benzoic trichloride ([Trichloromethyljbenzene)
Benzoyl chloride
Benzoyl peroxide
Benzyl chloride
Beryllium
8-BHC (c)
a-BHC (c)
8-BHC (c)
Lindane {g-BHC} (c)
Biphenyl
C.A.S.*
75-07-0
60-35-5
67-64-1
75-05-8
53-96-3
107-02-8
79-06-1
79-10-7
107-13-1
309-00-2
107-05-1
7429-90-5
1344-28-1
82-28-0
117-79-3
60-09-3
92-67-1
7664-41-7
6484-52-2
7783-20-2
3777-69-3
62-53-3
104-94-9
90-04-0
134-29-2
120-12-7
7440-36-0
7440-38-2
1332-21-4
7440-39-3
98-87-3
55-21-0
71-43-2
92-87-5
56-55-3
50-32-8
205-99-2
65-85-0
98-07-7
98-88-4
94-36-0
100-44-7
7440-41-7
319-86-8
319-84-6
319-85-7
58-89-9
92-52-4
313
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
110 BS ECAD
X
X
X X
X
X
X
X
X X
X
X
X
X
X
X
X X
X X
X X
X
-------
Table 1 - Cross Reference of Compounds Considered for Target Compound Analysis
Llstlna (b)
No
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
"80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
Compound Name (a)
Bis(2-chloro-1-methylethyl)ether
Bis(2-chloroethyl)ether
Bis(2-ethylhexyl)adipate
Bis(chloromethyl)ether
Bromoform
Bromoheptane
Bromomethane
Bromopentane
1 ,3-Butadiene
Butyl Acrylate
tert-Butyl alcohol
n-Butyl Alcohol
sec-Butyl alcohol
Butyl benzyl phthalate
Butyl glycol butyl phthalate
1,2-Butylene oxide
Butyraldehyde
C.I. Acid Blue 9, diammonium salt
C.I. Acid Blue 9, disodium salt
C.I. Acid Green 3
C.I. Basic Green 4
C.I. Basic Red 1
C.I. Direct Black 38
C.I. Direct Blue 6
C.I. Direct Brown 95
C.I. Disperse Yellow 3
C.I. Food Red 15
C.I. Food Red 5
C.I. Solvent Orange 7
C.I. Solvent Yellow 14
C.I. Solvent Yellow 3
C.I. ^Solvent Yellow 34
C.I. Vat Yellow 4
Cadmium
Calcium cyanamide
Captan
Carbaryl
Carbon disulfide
Carbon tetrachloride
Carbonyl sulfide
Catechol
Chloramben
Chlordane
Chlorine
Chlorine dioxide
p-Chloro-m-cresol
Chloroacetic acid
2-Chloroacetophenone (Tear gas)
C.A.S.*
108-60-1
111-44-4
103-23-1
542-88-1
75-25-2
629-04-9
74-83-9
110-53-2
106-99-0
141-32-2
75-65-0
71-36-3
78-92-2
85-68-7
85-70-1
106-88-7
123-72-8
2650-18-2
3844-45-9
4680-78-8
569-64-2
989-38-8
1937-37-7
2602-46-2
16071-86-6
2832-40-8
81-88-9
3761-53-3
3118-97-6
842-07-9
97-56-3
492-80-8
128-66-5
7440-43-9
156-62-7
133-06-2
63-25-2
75-15-0
56-23-5
463-58-1
120-80-9
133-90-4
57-74-9
7782-50-2
10049-04-4
59-50-7
79-11-8
532-27-4
313 110
X
X X
X
X X
X X
X X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X X
X
X
X
X X
X X
X
X
X
X X
X
X
X
X
X
BS ECAD
X
X
X
X
X
X
-------
Table 1 - Cross Reference of Compounds Considered for Target Compound Analysis
No
97
98
99
100
101
102
103
104
105
106
107
108
109
110
1 11
112
113
1 14
115
116
117
1 18
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
Compound Name (a)
Chlorobenzene
Chlorobenzilate
Chlorodibromomethane
Chloroethane
Chloroform
Chloromethane
Chioromethyl methyl ether
Chloroprene
Chlorothalonil
Chromium
Chrysene
Cobalt
Copper
p-Cresidine
o-Cresol (o-methylphenol)
p-Cresol (p-methylphenol)
m-Cresol (m-methylphenol)
Cresols, Mixed (d)
Cumene (isopropylbenzene)
Cumene hydroperoxide
Cupferron
Cyanide (e)
Cyclohexane
Cymene (isopropyltoluene)
2,4-D
4,4'-DDD (f)
4,4'-DDE (f)
4,4'-DDT (f)
Decabromodiphenyl oxide
Di-(2-ethylhexyl)phthalate {Bis(2-ethyihexyl)phthalate}
Di-n-octyl phthalate
Diallate
2,4-Diaminoanisole
2,4-Diaminoanisole sulfate
4,4'-Diaminodiphenyl ether
2,4-Diaminotoluene
Diaminotoluene (mixed isomers)
Diazomethane
Dibenz(a,h)anthracene
Dibenzofuran
1 ,2-Dibromo-3-chloropropane
1 ,2-Dibromoethane (Ethylene bromide)
Dibutyl phthalate (Di-n-butyl phthalate}
1 ,2-Dichlorobenzene
1 ,4-Dichlorobenzene
1 ,3-Dichlorobenzene
Oichlorobenzenes (mixed isomers)
3,3'-Dichlorobenzidine
C.A.S.*
108-90-7
510-15-6
124-48-1
75-00-3
67-66-3
74-87-3
107-30-2
126-99-8
1897-45-6
7440-47-3
218-01-9
7440-48-4
7440-50-8
120-71-8
95-48-7
106-44-5
108-39-4
1319-77-3
98-82-8
80-15-9
135-20-6
57-12-5
110-82-7
99-87-6
94-75-7
72-54-8
72-55-9
50-29-3
1163-19-5
117-81-7
117-84-0
2303-16-4
615-05-4
39156-41-7
101-80-4
95-80-7
25376-45-8
334-88-3
53-70-3
132-64-9
96-12-8
106-93-4
84-74-2
95-50-1
106-46-7
541-73-1
25321-22-6
91-94-1
313
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Llstlna (b)
110 BS ECAD
X X
X X
X
X X
X
X
X X
X
X
X
X
X X
X X
X X
X
X
X
X X
X X
X X
X X
X
-------
Table 1 - Cross Reference of Compounds Considered for Target Compound Analysis
No
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
Compound Name (a)
Dichlorobromomethane {Bromodichloromethane}
Dichlorodifluoromethane (Freon 12)
1 ,2-Dichloroethane
1 ,1 -Oichloroethane
1 ,2-Dichloroethylene {1 ,2-Dichloroethene}
Dichloromethane {Methylene Chloride}
2,4-Dichlorophenol
1 ,2-Dichloropropane
1 ,3-Dichloropropylene
Dichlorvos
Dicofol
Dieldrin
Diepoxy butane
Diethanolamine
Diethyl phthalate
Diethyl sulfate
3,3'-Dimethoxybenzidine
1,1 -Dimethyl hydrazine
2,4-Dimethyl phenol
Dimethyl phthalate
Dimethyl sulfate
4-Dimethylaminoazobenzene
3,3'-Dimethylbenzidine (o-Tolidine)
Dimethylcarbamyl chloride
4,6-Dinitro-o-cresol {4,6-Dinitro-2-methylphenol}
2,4-Dinitrophenol
2,4-Dinitrotoluene
2,6-Dinitrotoluene
1 ,4-Dioxane
p-Dioxin
1,2-Diphenyl hydrazine
Endrin (g)
Endrin Aldehyde (g)
Epichlorohydrin
2-Ethoxy benzaldehyde
2-Ethoxyethanol
Ethyl acrylate
Ethyl chloroformate
Ethyl isovalerate
Ethylbenzene
Ethylene
Ethylene glycol
Ethylene oxide {Oxirane}
Ethylene thiurea
Ethyleneimine (Aziridine)
Fluometuron
Fluoranthene
Fluorotrichloromethane (Freon 11)
C.A.S.*
75-27-4
75-71-8
107-06-2
75-34-3
540-59-0
75-09-2
120-83-2
78-87-5
542-75-6
62-73-7
115-32-2
60-57-1
1464-53-5
111-42-2
84-66-2
64-67-5
119-90-4
57-14-7
105-67-9
131-11-3
77-78-1
60-11-7
119-93-7
79-44-7
534-52-1
51-28-5
121-14-2
606-20-2
123-91-1
1745-01-6
122-66-7
72-20-8
7421-93-4
106-89-8
613-69-4
110-80-5
140-88-5
541-41-3
108-64-5
100-41-4
74-85-1
107-21-1
75-21-8
96-45-7
151-56-4
2164-17-2
206-44-0
75-69-4
313
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Llstlna (b)
110 BS ECAD
X X
X
X
X
X
X X
X X
X
X X
X X
X
X
X
X
X
X
X
X
X
X X
X X
X
X
X X
X
X X
X
-------
Table 1 - Cross Reference of Compounds Considered for Target Compound Analysis
No
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
Compound Name (a)
Formaldehyde
Freon 113
Heptachlor (h)
Heptachlor Epoxide (h)
Hexachloro-1 ,3-butadiene
Hexachlorobenzene
Hexachlorocyclopentadiene
Hexachloroethane
Hexachloronaphthalene
Hexamethylphosphoramide
1-Hexene
Hydrazine
Hydrazine sulfate
Hydrochloric acid
Hydrogen cyanide
Hydrogen fluoride
Hydroquinone
lndeno(1 ,2,3-cd)pyrene
Isobutyraldehyde
Isophorone
Isopropyl alcohol
4,4'-lsopropylidenediphenol
Lead
Limonene
Maleic anhydride
Maneb
Manganese
Melamine
Mercury
Methanol
Methoxychlor
2-Methoxyethanol
Methyl acrylate
Methyl ethyl ketone {2-Butanone}
Methyl hydrazine
Methyl iodide
Methyl isobutyl ketone {4-Methyl-2-pentanone}
Methyl isocyanate
Methyl methacrylate
Methyl tert-butyl ether
Methylene bromide
4,4'-Methylenebis(2-chloroaniline)
4,4'-Methylenebis(N,N-dimethyl)benzenamine
Methylenebis(phenylisocyanate) (MBI)
4,4'-Methylenedianiline
Michler's ketone
Molybdenum trioxide
Mustard gas (1,1'-Thiobis[2-chloro-]ethane)
C.A.S.*
50-00-0
76-13-1
76-44-8
1024-57-3
87-68-3
118-74-1
77-47-4
67-72-1
1335-87-1
680-31-9
592-41-6
302-01-2
10034-93-2
7647-01-0
74-90-8
7664-39-3
123-31-9
193-39-5
78-84-2
78-59-1
67-63-0
80-05-7
7439-92-1
138-86-3
108-31-6
12427-38-2
7439-96-5
108-78-1
7439-97-6
67-56-1
72-43-5
109-86-4
96-33-3
78-93-3
60-34-4
74-88-4
108-10-1
624-83-9
80-62-6
1634-04-4
74-95-3
101-14-4
101-61-1
101-68-8
101-77-9
90-94-8
1313-27-5
505-60-2
Llstina (b)
313 110 BS EGAD
X
X
XXX
X X
X X
XXX
X
X X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X X
X
X
X
X
X
X X
X
X
X
X
X X
X
X
X X
X
X
X
X
X
X
X
X
X
X
X
10
-------
Table 1 - Cross Reference of Compounds Considered for Target Compound Analysis
Listlna (b)
No
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
Compound Name (a)
N,N-Dimethylaniline
N-Nitroso-N-ethylurea
N-Nitroso-N-methylurea
N-Nitrosodi-n-butylamine
N-Nitrosodi-n-propylamine
N-Nitrosodiethylamine
N-Nitrosodimethylamine
N-Nitrosodiphenylamine
N-Nitrosomethylvinylamine
N-Nitrosomorpholine
N-Nitrosonornicotine
N-Nitrosopiperidine
Naphthalene
B-Naphthylamine
a-Naphthylamine
Nickel
Nitric acid
Nitrilotriacetic acid
5-Nitro-o-anisidine
Nitrobenzene
4-Nitrobiphenyl
Nitrofen
Nitrogen mustard
Nitroglycerin
2-Nitrophenol
4-Nitrophenol
2-Nitropropane
p-Nitrosodiphenylamine
Nonene
Octachloronaphthalene
3-Octen-2-one
Osmium tetroxide
Parathion
Pentachlorophenol (PCP)
1-Pentyl Alcohol
4-Pentyl benzaldehyde
Pentyl cyclohexane
Peracetic acid
Phenanthrene
Phenol
2-Phenyl phenol (o-Phenol phenol)
p-Phenylenediamine
Phosgene
Phosphoric acid
Phosphorus (yellow or white)
Phthalic anhydride
Picric acid
Polychlorinated biphenyls (PCB'S)
C.A.S.*
121-69-7
759-73-9
684-93-5
924-16-3
621-64-7
55-18-5
62-75-9
86-30-6
4549-40-0
59-89-2
16543-55-8
100-75-4
91-20-3
91-59-8
134-32-7
7440-02-0
7697-37-2
139-13-9
99-59-2
98-95-3
92-93-3
1836-75-5
51-75-2
55-63-0
88-75-5
100-02-7
79-46-9
156-10-5
124-11-8
2234-13-1
1669-44-9
20816-12-0
56-38-2
87-86-5
71-41-0
6853-57-2
4292-92-6
79-21-0
85-01-8
108-95-2
90-43-7
106-50-3
75-44-5
7664-38-2
7723-14-0
85-44-9
88-89-1
1336-36-3
313 110
X
X
X
X
X X
X
X X
X X
X
X
X
X
X X
X
X
X X
X
X
X
X X
X
X
X
X
X
X
X
X
X
X
X
X X
X
X
X X
X
X
X
X
X
X
X
X X
BS ECAD
X X
X
X
X
X
X
X
X
X
X
11
-------
Table 1 - Cross Reference of Compounds Considered for Target Compound Analysis
Listing (b)
No
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
Compound Name (a)
Propane sulfone
8-Propiolactone
Propionaldehyde
Propoxur
Propylene
Propylene oxide
Propyleneimine
Pyridine
Quinoline
Quinone
Quintozene (Pentachloronitrobenzene)
Saccharin
Safrole
Selenium
Silver
Sodium hydroxide (solution)
Sodium sulfate (solution)
Styrene
Styrene oxide
Su If uric acid
Terephthalic acid
1,1 ,2,2-Tetrachloroethane
Tetrachloroethylene {Tetrachloroethene}
Tetrachlorvinphos
Thallium
Thioacetamide
4,4'-Thiodianiline
Thiourea
Thorium dioxide
Titanium dioxide
Titanium tetrachloride
Toluene
Toluene-2,4-diisocyanate
Toluene-2,6-diisocyanate
o-Toluidine
o-Toluidine hydrochloride
Toxaphene
Triaziquinone
Trichlorfon
1 ,2,4-Trichlorobenzene
1,1,1 -Trichloroethane
1,1.2-Trichloroethane
Trichloroethylene {Trichloroethene}
2,4,6-Trichlorophenol
2,4,5-Trichlorophenol
Trifluralin
1 ,2,4-Trimethylbenzene
Tris(2,3-dibromopropyl) phosphate
C.A.S.#
1120-71-4
57-57-8
123-38-6
114-26-1
115-07-1
75-56-9
75-55-8
110-86-1
91-22-5
106-51-4
82-68-8
81-07-2
94-59-7
7782-49-2
7440-22-4
1310-73-2
7757-82-6
100-42-5
96-09-3
7664-93-9
100-21-0
79-34-5
127-18-4
961-11-5
7440-28-0
62-55-5
139-65-1
62-56-6
1314-20-1
13463-67-7
7550-45-0
108-88-3
584-84-9
91-08-7
95-53-4
636-21-5
8001-35-2
68-76-8
52-68-6
120-82-1
71-55-6
79-00-5
79-01-6
88-06-2
95-95-4
1582-09-8
95-63-6
126-72-7
313 110 BS ECAD
X
X
X
X
X
X
X
X
X
X
X
X
X
X X
X X
X
X
X X
X
X
X
XXX
XXX
X
X X
X
X
X
X
X
X
XXX
X
X
X
X
XXX
X
X
XXX
XXX
XXX
X X
XXX
X X
X
X
X
12
-------
Table 1 - Cross Reference of Compounds Considered for Target Compound Analysis
Listing (b)
No
337
338
339
340
341
342
343
344
345
346
347
348
349
Compound Name (a)
Urethane (Ethyl carbamate)
Vanadium (fume or dust)
Vinyl acetate
Vinyl bromide
Vinyl chloride
Vinylidene chloride {1,1-Dichloroethene}
o-Xylene
p-Xylene
m-Xylene
Xylene (mixed isomers) (d)
2,6-Xylidine
Zinc
Zineb
C.A.S.*
51-79-6
7440-62-2
108-05-4
593-60-2
75-01-4
75-35-4
95-47-6
106-42-3
108-38-3
1330-20-7
87-62-7
7440-66-6
12122-67-7
313
X
X
X
X
X
X
X
X
X
X
X
X
X
110 BS ECAD
X
X
X
X
X
X
X
Total
308
108
49
16
Section 313 Chemical Categories
No Compound Name
313
110
BS ECAD
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Antimony Compounds
Arsenic Compounds
Barium Compounds
Berylium Compounds
Cadmium Compounds
Chlorophenois (d)
Chromium Compounds
Cobalt Compounds
Copper Compounds
Cyanide Compounds
Glycol Ethers
Lead Compounds
Manganese Compounds
Mercury Compounds
Nickel Compounds
Polybrominated Biphenyls
Selenium Compounds
Silver Compounds
Thallium Compounds
Zinc Compounds
X
X
X
X
X
X X
X
X
X
X
X
X
X
X
X
X X
X
X
X
X
Notes:
a. Alternate names are shown in parentheses; names used in the Section 110 listing are shown in braces
b. Listing headers are as follows:
313 - SARA Section 313 Compounds
13
-------
Table 1 - Cross Reference of Compounds Considered for Target Compound Analysis
Listing (b)
No Compound Name (a) C.A.S.* 313 110 BS ECAD
110 - SARA Section 110 Compounds
BS - FY82 Broad Scan Target Analytes
ECAD - Existing Chemicals Assessment Division/NHMP Workgroup Compounds
c. BHC's are classed as a single target substance in the Section 110 listing
d. Individual isomers are also listed; the mixed substance was not considered as a separate candidate in this study.
e. Cyanide is included in the Section 313 listing under the Chemical Categories grouping as "Cyanide Compounds'.
f. ODD, DOE and DDT are classed as a single target substance in the Section 110 listing.
g. Endrin and endrin aldehyde are classed as a single target substance in the Section 110 listing.
h. Heptachlor and heptachlor epoxide are classed as a single target substance in the Section 110 listing.
14
-------
A large number of compounds from the SARA listings, including those
from chemical classes such as inorganic gases, metals, metal salts, and dyes
were eliminated a priori because these compound classes are not chromato-
graphable under conditions used to generate the FY82 data.
B. Compilation of Physical Data
Physical data, consisting of boiling point, melting point, empirical
formula, molecular weight, vapor pressure and existing GC retention indices,
when available, were compiled for the candidate compounds. This information
was used to divide the candidate list into two sublists corresponding to the
volatile and semivolatile sample fractions. Existing GC information was con-
sidered the most reliable source for predicting in which sample fraction a
compound would be found, and was given priority over other physical data. Two
resources for GC retention information, EPA Method 1624/1625 (Rev. C, 1986),
and EPA Report "GC/MS Suitability Testing of RCRA Appendix VIII and Michigan
List Analytes" (Lucas 1987), proved useful in dividing the candidate list into
volatile and semivolatile (VOA and SMV, respectively) sublists. Both of these
references employed sample preparation and analysis schemes similar to the
NHATS analyses. Lucas also listed a number of compounds from the Appen-
dix VIII/Michigan lists which were found to be unsuitable for GC/MS analysis,
many of which were common to the SARA lists. Compounds reported as unamenable
to GC/MS analysis in the Lucas report were eliminated from further considera-
tion as target analytes in this study.
In the absence of existing GC retention or volatility information,
prediction was based primarily on boiling point. A boiling point of 150ฐC was
used as the lower limit in the selection of semivolatile compounds, while com-
pounds having boiling points below that value were assigned to the volatile
list. However, a considerable amount of overlap between the volatile and the
semivolatile fraction was observed, when the boiling points of the ECAD com-
pounds in the two fractions were compared with the last observed volatile ECAD
compound, pentyl cyclohexane, having a boiling point of 202ฐC. Limonene, with
a boiling point of 178ฐC, was observed in both the volatile and 6% SMV frac-
tions in the unidentified peaks study. As stated previously, experimentally
derived GC retention data were preferred over boiling point alone, and as a
result pentyl cyclohexane was assigned to the VOA fraction and limonene was
included in both the VOA and SMV fractions. However, regardless of whether
existing volatility data or boiling point was used as the determining
criterion, no compound was added to the SMV fraction with a boiling point less
than 150ฐC, which corresponds to the boiling point range for C3 alky! benzenes
such as cumene and 1,2,4-trimethylbenzene.
C. Final Selection of Analytes
Two limitations of the FY82 data itself affected the final selection
of compounds for the target list. The first limitation was that the FY82
semivolatile samples were analyzed using a lower mass limit of 100 amu. Thus,
compounds with a molecular weight below 100 amu were not detected at the time
of analysis. As a result, a lower molecular weight limit of 110 amu was
employed to eliminate candidate compounds whose mass spectra would not produce
a sufficient number of mass peaks above 100 amu for reliable spectral matching
15
-------
to take place. Examples of such compounds are phenol (mol. wt. 94) and
diepoxybutane (mol. wt. 86). However, one exception to the 110 amu limit was
made for cresols, which exhibit a distinctive M/M-1 isotope pattern at 107 and
108 amu. This isotope pattern, along with known GC retention and boiling
point information, was sufficient to provide a reasonable degree of confidence
for tentative identification of the three cresol isomers.
The second limitation to the existing FY82 data was that the GC con-
ditions used in the VOA analysis precluded the observation of compounds with
boiling points lower than approximately 40ฐC. A few compounds from the SARA
listings had boiling points below 40ฐC and were eliminated from further
consideration. Examples of compounds with low boiling points are chloro-
methane (BP -98ฐC) and ethylene (BP -104ฐC).
It should be noted that no recovery efficiency studies were per-
formed to determine whether the candidate compounds could actually be
recovered from adipose by the procedures used to generate the FY82 data. As a
result, no candidate compounds were eliminated from consideration solely on
the basis of their expected recoverability or recovery efficiency. Although
recovery information would have been useful in eliminating unrecoverable com-
pounds from the final list of target analytes, the time required to generate
such data would have been much greater than performing target compound
analysis for the compounds themselves. However, by using this approach it
also follows that a negative identification of a target analyte did not
necessarily constitute a negative identification in the FY82 adipose itself
but rather demonstrated that the compound was not observed in the FY82 HRGC/MS
data itself. Further studies to determine recovery efficiencies for the
target analytes would allow a more accurate assessment to be made regarding
the applicability of certain compounds to this analysis.
D. Prediction of GC Retention Values
In order for the target compound analysis procedure to search a
GC/MS run for an analyte, two pieces of information pertaining to the analyte
must be available to the procedure: the compound's mass spectrum and its
relative retention time, determined against an internal standard. Since
'experimentally determined GC retention data could not be found for all candi-
date target compounds, a scheme for predicting relative retention values was
used. In this scheme, compounds with known relative retention time (RRT)
values and boiling points were selected and a regression curve of RRT vs.
boiling point was computed. Predicted RRT values were then obtained via
interpolation for compounds with known boiling points. Sources of known RRT
values included data from the broad scan and unidentified peaks studies, EPA
Methods 1624/1625, and the Lucas study. Boiling points were located from a
number of sources, including the CRC Handbook of Chemistry and Physics, the
Merck Index, and others.
16
-------
Since RRT values from several different sources were used to create
the regression curves, some normalization of RRT values was required. In
particular, the semivolatile RRT values from the Lucas report differed by
approximately 22% from those reported in the Method 1624/1625 protocol and the
original broad scan study. The Lucas RRT values were adjusted to reflect this
difference prior to their application in the regression computations. There
was relatively close agreement of RRT values between the various sources, due
primarily to similar GC conditions as shown in Table 2. However, it was found
that there was a higher correlation of regression when only in-house generated
retention values derived from the broad scan analytes were used. Thus, only
RRTs from the broad scan survey were used to predict RRTs for the candidate
target compounds in this study. Although the number of broad scan analytes
was considerably smaller than the total number of compounds with RRT values
from other sources, the broad scan analytes provided a more accurate predic-
tion of RRT because they more closely represented the actual GC conditions in
effect at the time of analysis.
A commercially available statistical computer program (StatView
512+, Brainpower, Inc.) was used to generate the regression plots of boiling
point versus measured RRT. The program then automatically computed the
predicted RRT values for the remaining candidate compounds. The regression
curves for VOA and SMV compounds are shown in Figures 1 and 2 and tabular
listings of RRT values and boiling points for VOA and SMV compounds used in
the regression computations are shown in Tables 3 and 4, respectively. A
polynomial regression was used for the volatiles, which provided a better
approximation for that data than the linear regression used for the
semivolatiles.
For a small number of semivolatile candidate target compounds,
neither retention data nor boiling points could be located. As a result,
retention could not be predicted for these compounds by the above scheme. In
these cases, an alternative searching scheme based on manual examination of
mass chromatograms was employed, which is described in the TCA analysis
description below. A listing of compounds which were manually determined is
-provided in Table 5.
Reference mass spectra for the selected target compounds were
located in the NBS Library of Mass Spectra (Heller, Milne 1983) containing
42,222 compounds. Seven compounds were not represented in the NBS library and
were eliminated from further consideration as target compounds.
At this point, all unsuitable compounds had been eliminated from the
candidate target compound listing, with all remaining compounds comprising the
final target compound list. The final lists of compounds selected for vola-
tile and semivolatile TCA analysis is shown in Tables 6 and 7, respectively.
Compounds eliminated from further consideration as target analytes for this
study are listed in Table 8. This table includes all eliminated compounds,
including broad scan analytes and compounds eliminated a priori. A brief
justification for elimination is provided for each compound.
17
-------
Table 2 - GC Parameters of GC/MS Systems Used for Predicting RRT
GC/MS System
GC Column
Carrier Gas
GC Program
Semlvolatlle Analysis
Method 1624/1625 30 meter DB-5 fused silica cap. column
0.25 mm ID, .25 micron film thickness
He, ca 30cm/sec.
5 min. at 30 C
8 C/min. to 280 C
hold until end of run
Broad Scan Study
30 meter DB-5 fused silica cap. column
0.25 mm ID, .25 micron film thickness
He, ca 30cm/sec.
2 min. at 60 C
10 C/min. to 310 C
hold until end of run
Lucas
30 meter DB-5 fused silica cap. column
0.25 mm ID, .25 micron film thickness
He, ca 30cm/sec.
4 min at 30 C
8 C/min. to 300
until end of run
Volatile Analysis
Method 1624/1625 2.4 meter 1% SP-1000 packed column
2mm ID
He, 30 ml/min.
6 min. at 40 C
8 C/min. to 240 C
hold until end of run
Broad Scan Study
30 meter DB-5 fused silica cap. column
0.25 mm ID, .25 micron film thickness
He, ca 30cm/sec.
5 min. at 30 C
6 C/min. to 125 C
hold until end of run
Lucas
6 ft. x 2 mm ID glass packed column
1% SP1000 on Carbopack B 60/80
He, 30 ml/min.
3 min. at 45 C
8 C/min to 220 C
hold until end of run
18
-------
Table 3
FY82 Broad Scan Target Analytes Used to Predict
Volatile RRT Values for SARA/ECAD Compounds
No. Compound Name Boiling Pt C (a) RRT (b)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
2-Bromo1 -chloropropane
Chloroform
1 ,1 ,1 -Trichloroethane
Benzene
Dichlorobromomethane
Toluene
1 ,1 ,2-Trichloroethane
Dibromochloromethane
Tetrachloroethylene
Chlorobenzene
Ethylbenzene
p-Xylene
Bromoform
Styrene
1 ,1 ,2,2-Tetrachloroetnane
1 ,2-Dichlorobenzene
117
59
74
80
90
111
113
120
121
131
136
138
149
146
147
180
1.000
0.405
0.458
0.498
0.648
0.947
0.996
1.162
1.257
1.555
1.681
1.715
1.852
1.907
2.102
2.898
Notes:
a. Boiling points obtained from one or more of the following sources:
CRC Handbook of Chemistry and Physics 57th Edition
Merck Index 10th Edition 1983
Eastman Chemical Catalog 1988
Aldrich Chemical Catalog 1988-1989
EPA Method 1624/1625 Rev C
Chemical Hazardous Resource Information Service, DOT 1984
Int. Agency for Res. on Cancer, Monographs Vol. 1-42
Hazardous Substances Database, an online service of the
National Library of Medicine
b. Relative retention values derived from the FY82 Broad Scan Study (Stanley, 1986b)
19
-------
3'
2.5
2
ฃ 1.5-
40
y = .377 - 8.227E-3X + 1.2642E-4x2
60 80
100 120 140
Boiling Pt
160 180 200
Note: Plot based on RRT data shown in Table 3.
Figure 1. Regression plot of volatiles with known boiling point vs. RRT.
20
-------
Table 4
FY82 Broad Scan Target Analytes and Unidentified Peaks Compounds
Used to Predict Semivoiatile RRT Values for SARA/ECAD Analytes
No.
Boiling Pt C (a)
RRT
Source (b)
1
2
3
4
5
6
7
8
9
10
1 1
12
13
14
15
16
17
18
19
20
21
22
D10 Anthracene
Cumene
Trimethylbenzene
Cymene
Umonene
Xylidene
Safrole
Biphenyl
o-Phenyl Phenol
1 ,2-Dichlorobenzene
1 ,2,4-Trichlorobenzene
Naphthalene
2,4,6-Trichlorophenol
Acenaphthene
Acenaphthylene
Pentachlorobenzene
Fluorene
Hexachlorobenzene
6-BHC
Fluoranthene
Pyrene
Chrysene
340
152
170
175
178
213
233
256
286
181
214
218
246
279
270
277
293
322
323
375
393
448
1.000
0.263
0.287
0.315
0.319
0.459
0.582
0.669
0.683
0.353
0.486
0.495
0.646
0.765
0.775
0.793
0.845
0.946
0.976
1.189
1.224
1.422
UP
UP
UP
UP
UP
UP
UP
UP
UP
BS
BS
BS
BS
BS
BS
BS
BS
BS
BS
BS
BS
BS
Notes:
a. Boiling points obtained from one or more of the following sources:
CRC Handbook of Chemistry and Physics 57th Edition
Merck Index 10th Edition 1983
Eastman Chemical Catalog 1988
Aldrich Chemical Catalog 1988-1989
EPA Method 1624/1625 Rev C
Chemical Hazardous Resource Information Service, DOT 1984
Int. Agency for Res. on Cancer, Monographs Vol. 1-42
Hazardous Substances Database, an online service of the
National Library of Medicine
b. RRT values obtained from the following sources:
UP - Original Unidentified Peaks Study (Onstot 1987)
BS - FY82 Broad Scan Study (Stanley 1986a,b,c,d)
21
-------
1.6-
y = 4.140E-3X - .395, R-squarad: .989
1.4-
1.2-
1
.8
.6
.4
100
150
200
250
300
BP
350
400
450
500
Note: Plot based on RRT data shown in Table 4.
Figure 2. Regression plot of semivolatiles with known boiling point vs. RRT.
22
-------
Table 5
Semivolatile Compounds Which Were Manually Determined
in the FY82 Data
No. Compound Name CAS No.
1 1-Amino-2-methylanthraquinone 82-28-0
2 2,4-D 94-75-7
3 2,4-Diaminoanisole 615-05-4
4 4,4'-Diaminodiphenyl ether 101-80-4
5 4,4'-Thiodianiline 139-65-1
6 4,6-Dinitro-o-cresol 534-52-1
7 4-Pentyl benzaldehyde 6853-57-2
8 Bis(2-ethylhexyl)adipate 103-23-1
9 Butyl glycol butyl phthalate 85-70-1
1 0 Chloramben 133-90-4
1 1 Chlorobenzilate 510-15-6
1 2 Decabromodiphenyl oxide 1163-19-5
13 Dicofol 115-32-2
14 Maneb 12427-38-2
15 Melamine 108-78-1
16 Michler's ketone 90-94-8
17 Picric acid 88-89-1
18 Propoxur 114-26-1
19 Tris(2,3-dibromopropyl) phosphate 126-72-7
23
-------
Table 6
List of Volatile Target Analytes
No.
1
2
3
4
5
6
7
8
9
10
1 1
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
Compound Name
Acetone
Acetonitrile
Acrolein
Acrylic Acid
Acrylonitrile
Ally! Chloride
2-Amyl furan
Bromoheptane (d)
Bromopentane
Butyl Acrylate
tert-Butyl alcohol
n-Butyl Alcohol
sec-Butyl alcohol
1,2-Butylene oxide
Butyraldehyde
Carbon disulfide
Carbon tetrachloride
Chloroprene
Cyclohexane
Diallate
1 ,2-Dibromoethane (Ethylene bromide)
1 ,2-Dichloroethane
1,1-Dichloroethane
1 ,2-Oichloroethylene
1 ,2-Oichloropropane
1 ,3-Dichloropropylene
1,4-Oioxane
Epichlorohydrin
2-Ethoxyethanol
Ethyl acrylate
Ethyl chloroformate
Ethyl isovalerate
Ethyleneimine (Aziridine)
Freon 1 13
1-Hexene
1 -lodopentane
Isobutyraldehyde
Isopropyl alcohol
LJmonene ( d )
2-Methoxyethanol
Methyl acrylate
Methyl ethyl ketone {2-Butanone}
Methyl iodide
Methyl isobutyl ketone
Methyl methacrylate
Methyl tert-butyl ether
Methylene bromide
N-Nitroso-N-ethylurea
2-Nitropropane
p-Nitrosodiphenylamine
Nonenes (1-Nonene)
CAS No
67-64-1
75-05-8
107-02-8
79-10-7
107-13-1
107-05-1
3777-69-3
629-04-9
110-53-2
141-32-2
75-65-0
71-36-3
78-92-2
106-88-7
123-72-8
75-15-0
56-23-5
126-99-8
110-82-7
2303-16-4
106-93-4
107-06-2
75-34-3
540-59-0
78-87-5
542-75-6
123-91-1
106-89-8
110-80-5
140-88-5
541-41-3
108-64-5
151-56-4
76-13-1
592-41-6
628-17-1
78-84-2
67-63-0
138-86-3
109-86-4
96-33-3
78-93-3
74-88-4
108-10-1
80-62-6
1634-04-4
74-95-3
759-73-9
79-46-9
156-10-5
124-11-8
Formula
C3.H6.O
C2.H3.N
C3.H4.O
C3.H4.O2
C3.H3.N
C3.H5.CI
C9.H14.O
C7.H15.Br
C5.H11.Br
C7.H12.O2
C4.H10.O
C4.H10.O
C4.H10.O
C4.H8.O
C4.H8.O
C.S2
C.CL4
C4.H5.CI
C6.H12
C10.H17.O.N.S.CI2
C2.H4.Br2
C2.H4.CI2
C2.H4.CI2
C2.H2.CI2
C3.H6.CI2
C3.H4.CL2
C4.H8.O2
C3.H5.O.CI
C4.H10.O2
C5.H8.O2
C3.H5.O2.CI
C7.H14.O2
C2.H5.N
C2.CI3.F3
C6.H12
C5.H11.I
C4.H8.O
C3.H8.O
C10.H16
C3.H8.O2
C4.H6.O2
C4.H8.O
C.H3.I
C6.H12.O
C5.H8.O2
C5.H12.O
C.H2.Br2
C3.H7.O2.N3
C3.H7.O2.N
C12.H10.O.N2
C9.H18
Quan ion
(m/z)
58
41
55
72
53
76
138
135
71
73
59
56
59
42
72
76
117
53
84
234
107
62
63
96
63
75
88
62
72
55
63
85
42
151
55
198
72
59
136
45
85
72
127
100
100
73
172
74
43
198
56
B. Pt. (a)
57
82
53
141
77
45
na(c
179
130
145
82
117
100
63
75
47
77
59
81
150
131
83
57
48
96
104
101
115
135
100
93
135
56
na
na
na
64
83
178
124
81
80
43
118
101
55
97
103
120
145
148
RRT (b)
0.31!
0.55J
0.29J
1.73(
0.491
0.25<
} 2.70;
2.91J
1.44'
1.84"
0.55J
1.14-
0.81!
0.35<
0.47(
0.26:
0.49:
0.33:
0.54'
1.98!
1.471
o.se;
0.31!
0.27'
0.75;
0.88!
0.33;
1.10-
1.571
0.81!
0.70-
1.67-
0.31!
0.22;
o.se;
2.151
0.36
0.55!
2.89
1.30
0.54
0.53
0.25
1.16
0.83
0.30
0.76
0.87
1.21
1.81
1.93
24
-------
Table 6
List of Volatile Target Analytes
No.
52
53
54
55
56
57
58
59
60
61
Compound Name
3-Octen-2-one
Pentyl Alcohol (3-methyl-1-butanol)
Pentyl cyclohexane
(3-Propiolactone
Propionaldehyde
Propyleneimine
Pyridine
Quinone
Trichloroethylene {Trichloroethene}
Vinyl acetate
CAS No
1669-44-9
123-51-3
4292-92-6
57-57-8
123-38-6
75-55-8
110-86-1
106-51-4
79-01-6
108-05-4
Formula
C8.H14.O
C5.H12.O
C11.H22
C3.H4.O2
C3.H6.O
C3.H7.N
C5.H5.N
C6.H4.O2
C2.H.CI3
C4.H6.O2
Quan Ion
(m/z)
126
70
83
42
58
56
79
108
130
86
B. Pt. (a)
na
137
202
162
49
66
115
109
87
73
RRT (b)
2.959
1.622
3.556
2.363
0.278
0.385
1.104
0.981
0.619
0.441
Notes:
a. Boiling points obtained from one or more of the following sources:
CRC Handbook of Chemistry and Physics 57th Edition
Merck Index 10th Edition 1983
Eastman Chemical Catalog 1988
Aldrich Chemical Catalog 1988-1989
EPA Method 1624/1625 Rev C
Chemical Hazardous Resource Information Service, DOT 1984
Int. Agency tor Res. on Cancer, Monographs Vol. 1-42
Hazardous Substances Database, an online service of the
National Library of Medicine
b. RRT used in target compound analysis of samples, based on 2-bromo-1 -chloropropane internal standard.
RRT was either predicted as described in the text or obtained from one of the following sources:
GC/MS Suitability Testing of RCRA Appendix VIII and Michigan List Analytes' (Lucas 1987)
EPA Method 1624/25 (Rev. C, 1986)
c. Boiling point was unavailable.
d. Analyzed in both volatile and semivolatile fractions.
25
-------
Table?
List of Semivolatile Target Analytes
No.
1
2
3
4
5
6
7
8
9
10
1 1
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
Compound Name
2-Acetylaminofluorene
1 -Amino-2-methylanthraquinone
2-Aminoanthraquinone
4-Aminoazobenzene
4-Aminobiphenyl
o-Anisidine
p-Anisidine
Anthracene
Benzal chloride
Benzamide
Benzidine
Benzo(a)anthracene
Benzo(b)f!uoranthene
Benzo(a)pyrene
Benzole acid
Benzoic trichloride
Benzoyl chloride
Benzyl chloride
Lindane {g-BHC}
Biphenyl
Bis(2-chloro-1-methylethyl)ether
Bis(2-chloroethyl)ether
Bis(2-ethylhexyl)adipate
Bromoheptane (d)
Butyl glycol butyl phthalate
Captan
Carbaryl
Catechol
Chloramben
p-Chloro-m-cresol
2-Ctiloroacetophenone (Tear gas)
Chlorobenzilate
Chlorothalonil
p-Cresidine
m-Cresol (m-methylphenol)
o-Cresol (o-methylphenol)
p-Cresol (p-methylphenol)
Cumene (isopropylbenzene)
Cumene hydroperoxide
Cymene (isopropyltoluene)
2,4-D
Decabromodiphenyl oxide
Di-(2-ethylhexyl)phthalate (DEHP)
2,4-Diaminoanisole
4,4'-Diaminodiphenyl ether
2,4-Diaminotoluene
Dibenz(a,h)anthracene
Dibenzofuran
1 ,2-Dibromo-3-chloropropane
3,3'-Dichlorobenzidine
Dichlorvos
CAS No
53-96-3
82-28-0
117-79-3
60-09-3
92-67-1
90-04-0
104-94-9
120-12-7
98-87-3
55-21-0
92-87-5
56-55-3
205-99-2
50-32-8
65-85-0
98-07-7
98-88-4
100-44-7
58-89-9
92-52-4
108-60-1
1 1 1-44-4
103-23-1
629-04-9
85-70-1
133-06-2
63-25-2
120-80-9
133-90-4
59-50-7
532-27-4
510-15-6
1897-45-6
120-71-8
108-39-4
95-48-7
106-44-5
98-82-8
80-15-9
99-87-6
94-75-7
1163-19-5
117-81-7
615-05-4
101-80-4
95-80-7
53-70-3
132-64-9
96-12-8
91-94-1
62-73-7
Formula
C15.H13.O.N
C15.H11.O2.N
C14.H9.O2.N
C12.H11.N3
C12.H11.N
C7.H9.O.N
C7.H9.O.N
C14.H10
C7.H6.CI2 -
C7.H7.O.N
C12.H12.N2
C18.H12
C20.H12
C20.H12
C7.H6.O2
C7.H5.CI3
C7.H5.O.CI
C7.H7.Ci
C6.H6.CI6
C12.H10
C6.H12.O.CI2
C4.H8.O.CI2
C22.H42.O4
C7.H15.Br
C18.H24.O6
C9.H8.O2.N.S.CI3
C12.H11.O2.N
C6.H6.O2
C7.H5.O2.N.CI2
C7.H7.O.CI
C8.H7.O.CI
C16.H14.O3.CI2
C8.N2.CI4
C8.H11.O.N
C7.H8.O
C7.H8.O
C7.H8.O
C9.H12
C9.H12.O2
C10.H14
C8.H6.O3.CI2
C12.O.Br10
C24.H38.O4
C7.H10.O.N2
C12.H12.O.N2
C7.H10.N2
C22.H14
C12.H8.O
C3.H5.CLBr2
C12.H10.N2.CI2
C4.H7.O4.CI2.P
Quan Ion
(m/z)
181
237
223
197
169
108
108
178
125
105
184
228
252
252
105
159
105
126
181
154
121
142
129
135
149
264
144
110
205
142
105
251
266
122
108
108
107
105
105
119
162
800
149
123
200
121
278
168
157
252
109
B. Pt. (a)
na (c
na
na
360
302
224
116
340
205
228
400
435
480
495
249
221
197
179
323
256
187
178
na
179
na
na
na
246
na
235
244
na
350
235
202
191
202
152
153
175
na
na
386
na
na
283
525
287
196
na
140
RRT (b)
) 1.32ฃ
re
1.69<
1.42!
0.98!
0.601
0.66';
1.00^
0.53(
0.61:
1.161
1.31;
1.44!
1.48:
0.64;
0.58;
0.50"
0.43(
0.97!
0.66*
0.46f
0.44!
n;
0.431
1.27!
1.16!
1.071
0.67!
re
0.68!
0.66!
n:
1.051
0.801
0.521
0.511
0.53I
0.29;
0.34!
0.34!
n;
n;
1.40!
n;
re
0.65!
1 .67'
0.78-
0.52I
1.311
0.65:
26
-------
Table?
List of Semivolatile Target Analytes
No.
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
Compound Name
Dicofot
Diethyl sulfate
3,3'-Dimethoxybenzidine
2,4-Dimethyl phenol
Dimethyl sulfate
4-Dimethylaminoazobenzene
3,3'-Dimethylbenzidine (o-Tolidine)
Dimethylcarbamyl chloride
4,6-Dinitro-o-cresol
2,4-Dinitrophenol
2,4-Dinitrotoluene
2,6-Dinitrotoluene
Diphenyl ether (1,1'-Oxybisbenzene)
2-Ethoxy benzaldehyde
Fluometuron
Hexachloro-1 ,3-butadiene
Hexachlorocyclopentadiene
Hexachloroethane
Hexamethylphosphoramide
Hydroquinone
lndeno(1 ,2,3-cd)pyrene
Isophorone
4,4'-lsopropylidenediphenol
Limonene (
-------
Table 7
List of Semivolatile Target Analytes
No.
103
104
105
1 06
107
108
109
1 10
1 11
1 12
1 13
1 14
1 15
1 16
1 17
1 18
1 19
120
Notes:
a.
Compound Name
Picric acid
Propane sulfone
Propoxur
Quinoline
Quintozene (Pentachloronitrobenzene)
Safrole
Styrene oxide
Terephthalic acid
Tetracrtlorvinphos
4,4'-Thiodianiline
Toluene-2,4-diisocyanate
o-Toluidine
o-Toluidine hydrochloride
Trifluralin
1 ,2,4-Trimethylbenzene
Tris(2,3-dibromopropyl) phosphate
2,6-Xylidine
Zineb
Boiling points obtained from one or more of the f
CAS No
88-89-1
1120-71-4
114-26-1
91-22-5
82-68-8
94-59-7
96-09-3
100-21-0
961-11-5
139-65-1
584-84-9
95-53-4
636-21-5
1582-09-8
95-63-6
126-72-7
87-62-7
12122-67-7
ollowing sources:
Formula
C6.H3.O7.N3
C3.H6.O3.S
C11.H15.O3.N
C9.H7.N
C6.O2.N.CL5
C10.H10.O2
C8.H8.O
C8.H6.O4
C10.H9.O4.CI4.P
C12.H12.N2.S
C9.H6.O2.N2
C7.H9.N
C7.H10.N.CI
C13.H16.O4.N3.F3
C9.H12
C9.H15.O4.Br6.P
C8.H11.N
C4.H6.N2.S4.ZN
Quan Ion
(m/z)
229
122
110
129
295
162
120
149
329
216
174
106
106
306
105
201
106
144
B. Pt. (a)
na
180
na
238
328
233
194
288
na
na
251
201
242
na
170
na
213
na
RRT (b]
n
0.44!
0.88
0.64
1.20
0.59
0.49
0.82
1.19
n
0.72
0.51
0.66
0.94
0.32
n
0.47
1.98
b.
c.
d.
e.
CRC Handbook of Chemistry and Physics 57th Edition
Merck Index 10th Edition 1983
Eastman Chemical Catalog 1988
Aldrich Chemical Catalog 1988-1989
EPA Method 1624/1625 Rev C
Chemical Hazardous Resource Information Service, DOT 1984
Int."Agency for Res. on Cancer, Monographs Vol. 1-42
Hazardous Substances Database, an online service of the
National Library of Medicine
RRT used in target compound analysis of samples, based on d10-anthracene internal standard.
RRT was either predicted as described in the text or obtained from one of the following sources:
GC/MS Suitability Testing of RCRA Appendix VIII and Michigan List Analytes' (Lucas 1987)
EPA Method 1624/25 (Rev. C, 1986)
Boiling point was unavailable.
Analyzed in both volatile and semlvolatile fractions.
RRT was unavailable. Determination for this compound was performed via manual examination
of characteristic ion plots.
28
-------
Table 8
SARA Compounds Eliminated from Consideration as Target Analytes
No. Compound Name
CAS No. Comments
1 Acetaldehyde
2 Acetamide
3 Acrylamide
4 Aldrin
5 Aluminum (fume or dust)
6 Aluminum Oxide
7 Ammonia
8 Ammonium nitrate (solution)
9 Ammonium sulfate (solution)
10 Aniline
1 1 o-Anisidine hydrochloride
12 Antimony
13 Arsenic
14 Asbestos (friable)
15 Barium
16 Benzene
1 7 Benzoyl peroxide
18 Beryllium
19 3-BHC
20 a-BHC
21 B-BHC
22 Bis(chloromethyl)ether
23 Bromoform
24 Bromomethane
25 1,3-Butadiene
26 Butyl benzyl phthalate
27 C.. Acid Blue 9, diammonium salt
26 C.. Acid Blue 9, disodium salt
29 C. . Acid Green 3
30 C.. Basic Green 4
31 C. . Basic Red 1
32 C. . Direct Black 38
33 C.. Direct Blue 6
34 C.. Direct Brown 95
35 C. . Disperse Yellow 3
36 C.. Food Red 15
37 C.. Food Red 5
38 C. . Solvent Orange 7
39 C. . Solvent Yellow 14
40 C. . Solvent Yellow 3
41 C.. Solvent Yellow 34
42 C.. Vat Yellow 4
4 3 Cadmium
44 Calcium cyanamide
45 Carbonyl sulfide
46 Chlordane
47 Chlorine
75-07-0 Boiling pt toe low for VOA detn. (a)
60-35-5 Mol. wt. too low for SMV detn. (b)
79-06-1 Polar (c)
309-00-2 Broad scan target analyte (d)
7429-90-5 Inorganic
1344-28-1 Inorganic
7664-41-7 Inorganic
6484-52-2 Inorganic
7783-20-2 Inorganic
62-53-3 Mol. wt. too low for SMV detn.
134-29-2 Redundant (see Anisidine)
7440-36-0 Inorganic
7440-38-2 Inorganic
1332-21-4 Inorganic
7440-39-3 Inorganic
71-43-2 Broad Scan target analyte
94-36-0 Unstable
7440-41-7 Inorganic
319-86-8 Broad Scan Target Analyte
319-84-6 Broad Scan Target Analyte
319-85-7 Broad Scan Target Analyte
542-88-1 Unstable (c)
75-25-2 Broad scan target analyte
74-83-9 Boiling pt too low for VOA detn.
1 06-99-0 Boiling pt too low for VOA detn.
85-68-7 Broad Scan Target Analyte
2650-18-2 Nonvolatile, dye
3844-45-9 Nonvolatile, dye
4680-78-8 Nonvolatile, dye
569-64-2 Nonvolatile, dye
989-38-8 Nonvolatile, dye
1937-37-7 Nonvolatile, dye
2602-46-2 Nonvolatile, dye
16071-86-6 Nonvolatile, dye
2832-40-8 Nonvolatile, dye
81-88-9 Nonvolatile, dye
3761-53-3 Nonvolatile, dye
3118-97-6 Nonvolatile, dye
842-07-9 Nonvolatile, dye
97-56-3 Nonvolatile, dye
492-80-8 Nonvolatile, dye
128-66-5 Nonvolatile, dye
7440-43-9 Inorganic
156-62-7 Inorganic
463-58-1 BP too low for detn. (a)
57-74-9 Broad scan target analyte
7782-50-2 Inorganic
29
-------
Table 8
SARA Compounds Eliminated from Consideration as Target Analytes
No. Compound Name
CAS No. Comments
48 Chlorine dioxide 10049-04-4
49 Chloroacetic acid 79-11-8
50 Chlorobenzene 108-90-7
51 Chlorodibromomethane 124-48-1
52 Chloroethane 75-00-3
53 Chloroform 67-66-3
54 Chloromethane 74-87-3
55 Chloromethyl methyl ether 107-30-2
56 Chromium 7440-47-3
57 Chrysene 218-01-9
58 Cobalt 7440-48-4
59 Copper 7440-50-8
60 Cresols, Mixed 1319-77-3
61 Cupferron 135-20-6
62 Cyanide 57-12-5
63 4,4'-DDD 72-54-8
64 4,4'-DDE 72-55-9
65 4,4'-DDT 50-29-3
66 Di-n-octyl phthalate 117-84-0
67 2,4-Diaminoanisole sulfate 39156-41-7
68 Diaminotoluene (mixed isomers) 25376-45-8
69 Diazomethane 334-88-3
70 Dibutyl phthalate {Di-n-butyl phthalate} 84-74-2
71 1,2-Dichlorobenzene 95-50-1
72 1,4-Dichlorobenzene 106-46-7
73 1,3-Dichlorobenzene 541-73-1
74 Dichlorobenzenes (mixed isomers) 25321-22-6
75 Dichlorobromomethane 75-27-4
76 Dichlorodifluoromethane (Freon 12) 75-71-8
77 Dichloromethane {Methylene Chloride} 75-09-2
78 2,4-Dichlorophenoi 120-83-2
79 Dieldrin 60-57-1
80 Diepoxybutane 1464-53-5
81 Diethanolamine 1 1 1 -42-2
82 Diethyl phthalate 84-66-2
83 1,1-Dimethyl hydrazine 57-14-7
84 Dimethyl phthalate 131-11-3
85 p-Dioxin 1745-01-6
86 1,2-Diphenyl hydrazine 122-66-7
87 Endrm 72-20-8
88 Endrin Aldehyde 7421-93-4
89 Ethylbenzene 100-41-4
90 Ethylene 74-85-1
91 Ethylene glycol 107-21-1
92 Ethylene oxide {Oxirane} 75-21-8
93 Ethylene thiurea 96-45-7
94 Fluoranthene 206-44-0
30
Inorganic
Mol. wt. too low for SMV detn.
Broad scan target analyte
Broad scan target analyte
Boiling pt too low for VOA detn.
Broad scan target anaiyte
Boiling pt too low for VOA detn.
Unstable (c)
Inorganic
Broad scan target analyte
Inorganic
Inorganic
Isomers analyzed individually
Thermolabile (c)
Inorganic
Broad Scan Target Analyte
Broad Scan Target Analyte
Broad Scan Target Analyte
Broad scan target analyte
Redundant (see Diaminoanisole)
Isomers analyzed individually
Unstable
Broad scan target analyte
Broad scan target analyte
Broad scan target analyte
Broad scan target analyte
Broad scan target analyte
Broad scan target analyte
Boiling pt too low for VOA detn.
Broad scan target analyte
Broad Scan Target Analyte
Broad Scan Target Analyte
Mo!, wt. too low for SMV detn.
Mol. wt. too low for SMV detn.
Broad scan target analyte
Basic, polar (c)
Broad Scan target analyte
No available reference mass spectrum
Thermolabile (c)
Readily converted in endrin aldehyde
Broad Scan target analyte
Broad scan target analyte
Boiling pt too low for VOA detn.
Mol. wt. too low for SMV detn.
Boiling pt too low for VOA detn.
Mol. wt. too low for SMV detn.
Broad Scan Target Analyte
-------
Table 8
SARA Compounds Eliminated from Consideration as Target Analytes
No. Compound Name
CAS No. Comments
95 Fluorotrichloromethane (Freon 11)
96 Formaldehyde
97 Heptachlor
98 Heptachlor Epoxide
99 Hexachlorobenzene
100 Hexachloronaphthalene
101 Hydrazine
102 Hydrazine sulfate
103 Hydrochloric acid
1 04 Hydrogen cyanide
105 Hydrogen fluoride
106 Lead
1 07 Maleic anhydride
108 Manganese
109 Mercury
11 0 Methanol
111 Methyl hydrazine
11 2 Methyl isocyanate
11 3 Methylenebis(phenylisocyanale)
11 4 Molybdenum trioxide
11 5 Mustard gas
11 6 N-Nitroso-N-methylurea
11 7 N-Nitrosodiethylamine
11 8 N-Nitrosodimethylamine
119 N-Nitrosomethylvinylamine
120 N-Nitrosonornicotine
121 Naphthalene
122 Nickel
123 -'Nitric acid
124 Nitrilotriacetic acid
125 Nitrogen mustard
126 Nitroglycerin
127 Osmium tetroxide
128 Pentachlorophenol (PCP)
129 Peracetic acid
130 Phenanthrene
131 Phenol
132 Phosgene
133 Phosphoric acid
134 Phosphorus (yellow or white)
135 Polychlorinated biphenyls (PCB'S)
136 Propylene
137 Propylene oxide
138 Saccharin
139 Selenium
140 Silver
141 Sodium hydroxide (solution)
75-69-4 Boiling pt too low for VOA detn.
50-00-0 Polymerizes (c)
76-44-8 Broad scan target analyte
1024-57-3 Broad Scan Target Analyte
11 8-74-1 Broad scan target analyte
1335-87-1 No available reference mass spectrum
302-01-2 Unsuitable to method (c)
10034-93-2 Inorganic
7647-01-0 Inorganic
74-90-8 Inorganic
7664-39-3 Inorganic
7439-92-1 Inorganic
108-31-6 Mol. wt. too low for SMV detn.
7439-96-5 Inorganic
7439-97-6 Inorganic
67-56-1 Mol. wt. too low for VOA detn.
60-34-4 Basic, polar (c)
624-83-9 Boiling pt too low for VOA detn.
(MBI) 101-68-8 No available reference mass spectrum
1313-27-5 Inorganic
505-60-2 No available reference mass spectrum
684-93-5 Mol. wt. too low for SMV detn.
55-18-5 Mol. wt. too low for SMV detn.
62-75-9 Mol. wt. too low for SMV detn.
4549-40-0 Mol. wt. too low for SMV detn.
16543-55-8 No available reference mass spectrum
91-20-3 Broad scan target analyte
7440-02-0 Inorganic
7697-37-2 Inorganic
139-13-9 Acid
51-75-2 Unsuitable to method
55-63-0 Inorganic
20816-12-0 Inorganic
87-86-5 Broad Scan target analyte
79-21-0 Inorganic
85-01-8 Broad Scan Target Analyte
1 08-95-2 Mol. wt. too low for SMV detn.
75-44-5 Inorganic
7664-38-2 Inorganic
7723-14-0 Inorganic
1336-36-3 Broad scan target analyte
11 5-07-1 Boiling pt too low for VOA detn.
75-56-9 Boiling pt too low for VOA detn.
81-07-2 Non-volatile, polar (c)
7782-49-2 Inorganic
7440-22-4 Inorganic
1310-73-2 Inorganic
31
-------
Table 8
SARA Compounds Eliminated from Consideration as Target Analytes
No. Compound Name
CAS No. Comments
142 Sodium sulfate (solution) 7757-82-6
143 Styrene 100-42-5
144 Sulfuric acid 7664-93-9
145 1,1,2,2-Tetrachloroethane 79-34-5
146 Tetrachloroethylene {Tetrachloroethene} 127-18-4
147 Thallium 7440-28-0
148 Thioacetamide 62-55-5
149 Thiourea 62-56-6
150 Thorium dioxide 1314-20-1
151 Titanium dioxide 13463-67-7
152 Titanium tetrachloride 7550-45-0
153 Toluene 108-88-3
154 Toluene-2,6-diisocyanate 91-08-7
155 Toxaphene 8001-35-2
156 Triaziquinone 68-76-8
157 Trichlorfon 52-68-6
158 1,2,4-Trichlorobenzene 120-82-1
159 1,1,1-Trichloroethane 71-55-6
160 1,1,2-Trichloroethane 79-00-5
161 2,4,6-Trichlorophenol 88-06-2
162 2,4,5-Trichlorophenol 95-95-4
163 Urethane (Ethyl carbamate) 51-79-6
164 Vanadium (fume or dust) 7440-62-2
165 Vinyl bromide 593-60-2
166 Vinyl chloride 75-01-4
167 Vinylidene chloride {1,1-Dichloroethene} 75-35-4
168 o-Xylene 95-47-6
169 p-Xylerre 106-42-3
170 m-Xylene 108-38-3
171 Xylene (mixed isomers) 1330-20-7
172 Zinc 7440-66-6
Inorganic
Broad scan target analyte
Inorganic
Broad scan target analyte
Broad scan target analyte
Inorganic
MoJ. wt. too low for SMV detn.
Thermolabile, polar
Inorganic
Inorganic
Inorganic
Broad scan target analyte
No available reference mass spectrum
Broad scan target analyte
No available reference mass spectrum
Thermolabile (c)
Broad scan target analyte
Broad scan target analyte (c)
Broad scan target analyte
Broad Scan target analyte
Broad Scan target analyte
Moi. wt. too low for SMV detn.
Inorganic
Boiling pt too low for VOA detn.
Boiling pt too low for VOA detn.
Boiling pt too low for VOA detn.
Broad scan target analyte
Broad scan target analyte
Broad scan target analyte
Broad scan target analyte
Inorganic
Notes:
a. Compounds with boiling points lower than ca. 40ฐ C were not detectable in VOA composites.
b. Compounds with molecular weight less than 110 amu were not detectable in SMV
composites.
c. "GC/MS Suitability Testing of RCRA Appendix VIII and Michigan List Analytes", EPA/600/4-
87/024 Aug. 1987
d. Previously quantitated as part of the Broad Scan Study (Stanley 1986a, b, c, d)
32
-------
E. Target Compound Analysis
Execution of the target compound analysis proceeded in four steps:
1. Creation of TCA quantitation libraries.
2. Application of TCA procedure to FY82 data.
3. Manual review of TCA output.
4. Transfer of TCA results to a database.
As previously stated, the TCA procedure required that the RRT and
reference mass spectrum be placed in a special quantitation library which the
TCA procedure uses in the search routine. For this study, two separate
libraries were constructed; one each for the volatile and semi volatile TCA
analytes, respectively. In addition to the information above, other param-
eters used to control the searching routine were entered into the quantitation
libraries at this time, including search window half-widths and minimum FIT
thresholds. Based on the standard deviation of error calculated for the RRT
vs. boiling point regression plots, a search window half-width of 45 s and
60 s was initially used for the volatiles and semivolatiles, respectively.
This provided sufficiently broad windows such that any errors in RRT predic-
tion would not result in a compound being missed by the searching procedure.
If a compound was identified in a sample during the course of analysis, the
search window half-width was reduced to 20 s around the retention time from
the predicted observed RRT for all subsequent analyses to reduce the search
time of the TCA program. A minimum FIT of 750 and 900 (based on a weighted
comparison to the reference mass spectrum and ranging from 0 for no similarity
between spectra to 1000 for a perfect match between spectra) was used for the
VOA and SMV analytes, respectively.
The data set used in this study consisted of composited human
adipose tissue specimens prepared from the NHATS repository and were orig-
inaHy analyzed as part of a broad scan study. The composite samples were
originally analyzed by HRGC/MS for volatiles and semivolatiles during the
period from April 1984 to July 1984 (Stanley 1986a, Stanley 1986b). The
resulting HRGC/MS datafiles were generated from the analysis of 46 volatiles,
44 semivolatiles from the 6% Florisil cleanup fraction, and 46 semivolatiles
from the 15/5055 cleanup fraction. Within each of these categories, there were
12, 15, and 17 samples in the 0-14, 15-44, and 45+ age groups for the 6% semi-
volatiles, and 12, 17, and 17 samples in the 0-14, 15-44 and 45+ age groups
for the volatiles and 15/50% semivolatiles, respectively.
In addition to the samples above, six semivolatile method blanks,
six Florisil blanks (corresponding to three of each type for the 6% and 15/50%
Florisil fractions, respectively), and 11 volatile purge vessel blanks were
also analyzed using the same procedure.
Application of the TCA procedure to the FY82 data was performed on a
Finnigan/MAT Incos data system using the AutoQuan TCA software provided. At
the end of each TCA analysis, two documents were generated by the TCA program:
33
-------
a search summary report containing information about the success of the search
procedure, and a quantitation report containing the semiquantitative results
of the search. Results of each TCA analysis were manually reviewed to verify
the accuracy of the data. The manual review consisted of verifying each com-
pound identification via manual comparison of the unknown mass spectrum to the
reference spectrum. The TCA search summary provided the FIT values associated
with each positive identification. However, the use of FIT as the primary
criterion for identification often did not provide sufficient selectivity when
the target compound was searched within a retention window containing large
nontarget peaks. As a result, many false positive identifications were made
by TCA. This was especially true for targets which did not have distinctive
mass spectra. The difficulty of identifying target compounds with non-
distinctive mass spectra is discussed in Section V.
Compound identifications were also checked against the summary
reports generated in the original unidentified peaks study. This check proved
useful in identifying persistent misidentifications by TCA due to interference
by nontarget peaks as described above. For example, the TCA procedure con-
sistently identified the compound acetonitrile in most of the volatile com-
posites, but a check of the associated unidentified peaks summary report
indicated that the same peak was consistently identified as pentanal in the
original study. Comparison of the two reference mass spectra revealed that
these compounds exhibit many of the same ion masses, which resulted in the
false positive identification of acetonitrile whenever pentanal was present.
A TCA target identification was not rejected solely on the basis of a peak's
previous identification in the unidentified peaks study. However, prior
identification of a peak was seen as an indicator for the need for additional
checking in the form of more extensive mass spectral enhancement and back-
ground subtraction techniques.
As indicated previously, a few compounds could not be analyzed using
the automated TCA procedure because no retention information could be found.
These compounds were analyzed by examining the mass chromatograms of the three
major ions for each compound for possible occurrences based on relative
abundance measurements of observed peaks. Only one compound, bis(ethylhexyl)-
adipate, was found using this method.
The results of all TCA analyses were transferred to an Apple
Macintosh and were imported into a database (Fourth Dimension, Acius, Inc.)
for final processing and report generation.
F. GC/MS Analysis of Authentic Standards
After compiling the target compound analysis results into lists of
tentatively identified compounds, authentic compound material was procured and
composite standard solutions were prepared. All of the tentatively identified
compounds were obtained from commercial sources, with the exception of pentyl
benzaldehyde, which was not delivered in time to be included in this portion
of the study. A set of authentic compound solutions ranging from 10 to
400 ppm was prepared for each of the three fraction types: volatiles,
6% semivolatiles, and 15/50% semivolatiles. Gas chromatograph and mass
34
-------
spectrometer parameters were adjusted to match those used in the original
analysis as closely as possible, with the following exceptions:
A mass scanning range of 45 to 400 amu was used for the
semivolatile analysis;
A 15-m DB5 megabore FSCC column was used in place of the 30-m
DBS narrow bore for the volatile analysis;
A Finnigan/MAT 312 magnetic sector mass spectrometer was used
instead of the Finnigan 4500 mass spectrometer for the volatile
analysis; and
No heated vessel was used in the sample introduction setup for
the volatile analysis. This portion of the setup was only used
to purge the adipose of the volatiles, which then passed
through an unheated purge tower filled with 1 to 5 ml of
water. In the analysis of the volatile authentic standards,
the appropriate amount of volatile standard solution was
injected into a 5-mL syringe of volatile-free water, which was
immediately transferred directly into the unheated purge tower.
GC program parameters were adjusted so that the retention times of
the authentic standards would match the retention times of the original
analysis as closely as possible. In order to accomplish this, composite
solutions containing some of the original broad scan target analytes were run
and compared with their original retention times. Table 9 shows the compari-
son between the RRTs of selected broad scan target analytes as seen in both
the original 1984 analysis and this analysis (1989). Fairly close agreement
was achieved for the volatile compounds, with a percent relative difference
ranging from -1% to 4%. Agreement was not as good as for the semi volatiles,
although there did appear to be a trend in the percent relative RRT differ-
ences, with 1989 RRTs being higher than 1984 RRTs at the low end of the
retention range and lower than the 1984 RRTs at the high end of the retention
range. A linear regression of the 1984 vs. 1989 semivolatile data was then
plotted and later used to adjust the RRT values of the authentic standards of
tentatively identified compounds so that they would more closely approximate
the RRTs that they would have had under 1984 conditions.
When GC parameters had been optimized to match the original analysis
RRTs, the authentic standard solutions were analyzed. Two standards corre-
sponding to 100 and 400 ng of each authentic compound were analyzed for each
of the three standard sets. Average relative response factor (RRf) and RRT
values were determined from these authentic standards analyses. The semi-
volatile RRT values were then adjusted to match 1984 conditions using the 1984
vs. 1989 broad scan RRT regression analysis, as previously described. The
volatile RRT values were not adjusted since there was already good agreement
between the 1989 RRTs and the 1984 RRTs.
35
-------
Table 9
RRT Comparison of Selected Broad Scan Target Analytes
1984 Analysis vs 1989 Analysis
Volatlles
Compound Name
Bromochloromethane
1,1,1-Trichloroethane
Benzene
Tetrach lo roethene
Dibromochloromethane
1,1 ,2-Trichloroethane
Toluene
Chlorobenzene
Ethylbenzene
Bromoform
1 ,1 ,2,2-Tetrachloroethane
RRTa
.(1984)
.408
.462
.498
1.256
1.162
.996
.949
1.531
1.653
1.823
2.061
RRTa
.(1989)
.404
.481
.512
1.232
1.126
.986
.961
1.509
1.649
1.814
2.081
A RRT
(%)
-1
4
3
2
-3
-1
1
-1
0
0
1
RRf b
.(1989)
.423
.368
1.148
.379
.361
.275
1.045
.821
.410
.272
.473
Semlvolatilos
Compound Name
1 ,4-Dichlorobenzene
Naphthalene
Fluorene
Hexachlorobenzene
Fluoranthene
Butyl benzyl phthalate
Chrysene
Bis(2-ethylhexyi) phthalate
Dibenz(a,h)anthracene
RRTa
.(1984)
0.35
0.49
0.84
0.94
1.19
1.36
1.43
1.46
1.84
RRTa
.(1989)
0.4
0.54
0.87
0.96
1.18
1.32
1.39
1.41
1.8
A RRT
(%)
14
11
3
2
-1
-3
-3
-4
-2
RRfb
.(1989)
1.184
1.731
.938
.264
1.200
.513
.905
.782
.568
Notes:
a. RRT values calculated vs 2-Bromo-1-chloropropane for volatile compounds and
d 10-Anthracene for semivolatile compounds.
b. RRf values calculated vs 2-Bromo-1-chloropropane for volatile compounds and
d 10-Anthracene for semivolatile compounds.
36
-------
The authentic compound RRT values were compared to the respective
tentatively identified peak RRTs. If the RRT of the authentic standard com-
pound fell within the range of the RRTs observed in the composites, and if the
mass spectra of the authentic and tentatively identified peaks were identical,
the compound was considered positively identified. Some exceptions were made
if a compound fell slightly outside the RRT range of observed hits if there
was a compelling reason to do so, such as a very high mass spectral similarity
between the authentic and observed spectra, or if the authentic RRT was only
slightly outside the range of RRTs observed in the adipose composites. This
was done to compensate for both the rather broad variation of RRTs which were
actually observed in the original analysis and for the unavoidable minor
differences in GC conditions between the original analysis and the authentic
standards analysis.
IV. RESULTS
Application of the target compound analysis procedure to the FY82
composites as described above resulted in the following tables of results.
Tables 10 through 12 present the target compounds identified in the volatile,
6% semivolatile Florisil, and 15/50% semivolatile Florisil samples, respec-
tively. Each table consists of the following information in columnar form.
The first column shows an index number, which is simply a sequential numbering
of the compounds listed in the table. The index number is not related to any
other numbering order in previous reports. The compound name and CAS Registry
No. columns are derived from the compound's respective source listing. In
cases where a compound name was reported differently in the source listings,
the naming precedence is Title III > Title 110 > ECAD. The remaining columns
show the frequency of occurrence of the listed compounds within the three
tested age groups.
Tables 13 and 14 show the lists of compounds which were searched in
the FY82 composites but which were not observed in the volatile and semi-
volatile sample fractions, respectively.
Additional tables detailing the the occurrences of compounds
identified in the FY82 data and their relative responses are presented in
Appendices A through G. Appendices A through C show the quantitative results
for each identified compound in the volatile, 6% and 15/50% semivolatile
fractions, respectively. Appendices D through F show occurrences of target
compounds as a function of census region and census division for the volatile,
6% and 15/50% semivolatile fractions, respectively. Appendix G presents
representative hardcopies of library mass spectral comparisons for each target
compound identified in the FY82 data.
37
-------
Table 10
SARA/EGAD Compounds Identified in FY82 Adipose Composites
VGA Fraction
Frequency of Occurrence
No.
1
2
3
4
5
6
7
8
9
10
1 1
12
13
Name
2-Amyl furan
Bromoheptane
Bromopentane
Butyraldehyde
Ethyl isovalerate
1-lodopentane
Isobutyraldehyde
Limonene
Nonenes (1-Nonene)
3-Octen-2-one
Pentyl Alcohol
Pentyl cyclohexane
Trichloroethylene
CAS No.
3777-69-3
629-04-9
110-53-2
123-72-8
108-64-5
628-17-1
78-84-2
138-86-3
124-11-8
1669-44-9
123-51-3
4292-92-6
79-01-6
Total a
46
4
3
45
44
35
43
46
46
45
38
10
20
0-14b 1
12
2
2
11
11
9
1 1
12
12
12
7
1
3
I 5-44
18
1
1
17
17
14
16
18
17
18
15
5
8
45+ Blanks c
16
1
0
17
16
12
16
1 6
1 7
15
16
4
9
1
0
0
0
0
0
0
0
6
0
0
0
0
Notes:
a.
b.
c.
Frequency determined from a total of 46 composite samples.
0-14 = Samples collected from persons between the ages of 0-14 years.
15-44 = Samples collected from persons between the ages of 15-44 years.
45+ = Samples collected from persons above 45 years of age.
A total of 11 vessel blanks were analyzed for volatile compounds.
38
-------
Table 11
SARA/EC AD Compounds Identified in FY82 Adipose Composites
6% SMV Fraction
Frequency of Occurrence
No.
1
2
3
4
5
6
7
8
9
Name
Anthracene
Biphenyl
Cymene (isopropyltoluene)
Dibenzofuran
Diphenyl ether
Limonene
Safrole
(1 ,1'-Oxybisbenzene)
1 ,2,4-Trimethylbenzene
2,6-Xylidine
CAS No.
120-12-7
92-52-4
99-87-6
132-64-9
101-84-8
138-86-3
94-59-7
95-63-6
87-62-7
Total S
1
9
41
3
40
41
4
42
1 1
0-14b '
0
2
11
1
11
11
0
11
0
15-44
1
2
15
2
14
15
1
15
1
45+ Blanks0
0
5
15
0
15
15
3
16
10
0
0
0
0
0
0
0
4
0
^Frequency determined from a total of 44 composite samples.
"0-14 = Samples collected from persons between the ages of 0-14 years.
15-44 = Samples collected from persons between the ages of 15-44 years.
45+ = Samples collected from persons above 45 years of age.
CA total of six blanks were analyzed for 6% semi volatile compounds.
39
-------
Table 12
SARA/ECAD Compounds Identified in FY82 Adipose Composites
15/50% SMV Fraction
Frequency of Occurrence
No.
1
2
3
4
5
6
7
8
9
10
Name
Bis(2-ethylhexyl)adipate
Butyl glycol butyl phthalate
Carbaryl
o-Cresol (o-methylphenol)
m.p-Cresol (m,p-methylphenol)
Di-(2-ethylhexyl)phthalate (DEHP)
2,4-Diaminotoiuene
2-Ethoxy benzaldehyde
4-Pentyl benzaldehyde d
2-Phenyl phenol (o-Phenol phenol)
CAS No.
103-23-1
85-70-1
63-25-2
95-48-7
106-44-5
117-81-7
95-80-7
613-69-4
6853-57-2
90-43-7
Total a
8
8
1
38
43
42
20
6
9
22
0-14b
1
0
0
10
11
10
1
4
5
5
15-44
4
4
0
14
16
15
9
1
1
6
45+
3
4
1
14
16
17
10
1
3
1 1
Blanks0
0
0
0
0
0
4
0
0
0
0
^Frequency determined from a total of 46 composite samples.
Samples collected from persons between the ages of 0-14 years.
"0-14
15-44
Samples collected from persons between the ages of 15-44 years.
45+ = Samples collected from persons above 45 years of age.
^A total of six blanks were analyzed for 15/50% semivolatile compounds.
Identification of this compound was not confirmed by GC/MS analysis of authentic standard
material.
40
-------
Table 13
Volatile Compounds Not Detected in FY82 Adipose Composites
No
Comoound Name
CAS No.
No.
Compound Name
CAS No.
1 Acetone 67-64-1
2 Acetonitrile 75-05-8
3 Acrolein 107-02-8
4 Acrylic Acid 79-10-7
5 Acrylonitrile 107-13-1
6 Allyl Chloride 107-05-1
7 Butyl Acrylate 141-32-2
8 n-Butyl alcohol 71-36-3
9 tert-Butyl alcohol 75-65-0
10 sec-Butyl alcohol 78-92-2
11 1,2-Butylene oxide 106-88-7
12 Carbon disulfide 75-15-0
13 Carbon tetrachloride 56-23-5
14 Chloroprene 126-99-8
15 Cyclohexane 110-82-7
16 Diallate 2303-16-4
17 1,2-Dibromoethane (Ethylene bromide) 106-93-4
18 1,2-Dichloroethane 107-06-2
19 1,1-Dichloroethane 75-34-3
20 1,2-Dichloroethylene 540-59-0
21 1,2-Dichloropropane 78-87-5
22 1,3-Dichloropropylene 542-75-6
23 1,4-Dioxane 123-91-1
24 Epichlorohydrin 106-89-8
25 2-Ethoxyethanol 110-80-5
26 Ethyl acrylate 140-88-5
27 Ethyl chloroformate 541-41-3
28 Ethyleneimine (Aziridine) 151-56-4
29 Freon 113 76-13-1
30 1-Hexene 592-41-6
31 Isopropyl alcohol 67-63-0
32 2-Methoxyethanol 109-86-4
33 Methyl acrylate 96-33-3
34 Methyl ethyl ketone 78-93-3
35 Methyl iodide 74-88-4
36 Methyl isobutyl ketone 108-10-1
37 Methyl methacrylate 80-62-6
38 Methyl tert-butyl ether 1634-04-4
39 Methylene bromide 74-95-3
40 N-Nitroso-N-ethylurea 759-73-9
41 2-Nitropropane 79-46-9
42 p-Nitrosodiphenylamine 156-10-5
43 Propionaldehyde 123-38-6
44 B-Propiolactone 57-57-8
45 Propyleneimine 75-55-8
46 Pyridine 110-86-1
47 Quinone 106-51-4
48 Vinyl acetate 108-05-4
41
-------
Table 14
Semivolatile Compounds Not Detected in FY82 Adipose Composites
No. Compound Nam*
CAS No.
No. Compound Name
CAS No.
1 2-Acetylaminofluorene 53-96-3
2 1-Ammo-2-melhylanlhraquinone 82-28-0
3 2-Aminoanthraquinone 117-79-3
4 4-Aminoazobenzene 60-09-3
5 4-Aminobiphenyl 92-67-1
6 o-Anisidine 90-04-0
7 p-Anisidine 104-94-9
a Benzal chloride 98-87-3
9 Benzamide 55-21-0
10 Benzidine 92-87-5
11 Benzo(a)amhracene 56-55-3
12 Benzo(b)fluoranlhene 205-99-2
13 Benzo(a)pyrene 50-32-8
14 Benzole acid 65-85-0
15 Benzole trichloride 98-07-7
16 Benzoyl chloride 98-88-4
17 Benzyl chloride 100-44-7
18 Bis(2-chloro-1-methylethyl)elher 108-60-1
19 Bis(2-chloroethyl)elher 111 -44-4
20 Bromoheptane 629-04-9
21 Captan 133-06-2
22 Catechol 120-80-9
23 Chloramben 133-90-4
24 p-Chloro-m-cresol 59-50-7
25 2-Chloroacetophenone (Tear gas) 532-27-4
26 Chlorobenzilate 510-15-6
27 Chlorothalonil 1897-45-6
28 p-Cresidine 120-71-8
29 m-Cresol 108-39-4
30 Cumene 98-82-8
31 Cumene hydroperoxide 80-15-9
32 2,4-D 94-75-7
33 Decabromodiphenyt oxide 1163-19-5
34 2,4-Diaminoanisole 615-05-4
35 4,4<-Diaminodiphenyl ether 101-80-4
36 Ofeenz(a,tr)anthracene 53-70-3
37 1,2-Dibromo-3-chloropropane 96-12-8
38 3,3'-Oichlorobenzidine 91-94-1
39 Oichlorvos 62-73-7
40 Oicofol 115-32-2
41 Oiethyl sullate 64-67-5
42 3,3'-Dimethoxybenzidine 119-90-4
43 2,4-Dlmethyl phenol 105-67-9
44 Dimethyl sullale 77-78-1
45 4-Oimethylaminoazobenzene 60-11-7
46 3,3'-Dimethylbenzidine 119-93-7
47 Dimethylcarbamyl chloride 79-44-7
48 4,6-Dinitro-o-cresol 534-52-1
49 2.4-Dinitrophenol 51-28-5
50 2.4-Dinitrotoluene 121-14-2
51 2,6-Oinitrotoluene 606-20-2
52 Fluometuron 2164-
53 Hexachloro~1.3-butadiene 87-
54 Hexachtorocydopentadtene 77-
55 Hexachloroethane 67-
56 Hexamethylphosphoramide 680
57 Hydroquinone 123
58 lndeno(1,2,3-cd)pyrene 193
59 Isophorone 78
60 4,4'-lsopropylidenediphenol 80-
61 LJndane 58
62 Maneb 12427
63 Melamine 108
64 Methoxychlor 72
65 4,4'-Methylenebis(2-chloroaniline) 101
66 4,4'-Methylenebis(N,N-dimethyl)benzenamine 101
67 4,4'-Methylenedianiline 101
68 Michler's ketone 90-
69 N.N-Oimethylaniline 121
70 N-Nitrosodi-n-butylamine 924
71 N-Nilrosodi-n-propylamine 621
72 N-Nitrosodiphenylamine 86
73 N-Nitrosomorpholine 59
74 N-Nitrosopiperidine 100
75 a-Naphthylarnine 134
76 B-Naphthylamine 91
77 5-Nitro-o-anisidine 99
78 Nitrobenzene 98'
79 4-Nitrobiphenyl 92
80 Nitrofen 1836
81 2-Nitrophenol 88
82 4-Nitrophenol 100
83 Octachtoronaphthatene 2234
84 Parathion 56
85 p-Phenylenediamine 106
86 Phlhalic anhydride 85
87 Picric acid 88
88 Propane sultone 1120
89 Propoxur 114
90 Quinoiine 91
91 Quintozene (Pentachloronitrobenzene) 82
92 Styrene oxide 96
93 Terephthalic acid 100
94 Tetrachlorvinphos 961
95 4,4'-Thiodianiline 139
96 Toluene-2,4-diisocyanate 584
97 o-Toluidine 95
98 o-Toluidine hydro<:hloride 636
99 Trifluralin 1582
100 Tris(2,3-dibromopropyl) phosphate 126
101 Zineb 12122
17-2
68-3
47-4
72-1
31-9
31-9
39-5
59-1
05-7
89-9
38-2
78-1
43-5
14-4
61-1
77-9
94-8
69-7
16-3
64-7
30-6
89-2
75-4
32-7
59-8
59-2
95-3
93-3
75-5
75-5
02-7
13-1
38-2
50-3
44-9
89-1
-71-4
26-1
22-5
68-8
09-3
21-0
11-5
65-1
84-9
53-4
21-5
-09-8
72-7
-67-7
42
-------
V. DISCUSSION
A. Limitations of the FY82 Data
Several limitations of the FY82 data files posed problems for this
analysis. These limitations are the same as those described detail in the
original unidentified peaks report (Onstot 1986a). In summary, most of the
major problems revolved around the extremely complex sample matrix encountered
in most of the samples, a mass scanning range used in the semivolatile
analysis (m/z 100-700 amu) that was inappropriate for the proper identifica-
tion of many compounds, and somewhat erratic retention times observed in the
semivolatile composites which sometimes made identification of specific
isomers difficult and unreliable.
The higher than normal mass scanning range was originally chosen to
allow detection of polybrominated biphenyls and was thus appropriate for its
intended purpose. Similarly, the erratic retention time values were not a
problem in the broad scan study because standards were run daily and slight
corrections could be made to the broad scan target compound RRTs. However,
the lack of daily target analyte standards specific for the current study and
associated retention information made RRT corrections slightly less reliable
in this study. Corrections were primarily based on observed changes to the
elution times of internal standards and surrogate compounds. This proved
adequate for the volatiles which contained four standard compounds, and for
the 6% semivolatiles, which contained seven standard compounds; but was
marginally adequate for the 15/50% semivolatiles, which contained only one
standard compound.
B. Retention Prediction
The relative retention time scheme proved generally successful, with
most identified compounds having been observed well within the predicted
retention window. However, the accuracy of prediction using this approach is
known to be affected by a number of chemical and physical parameters. Inter-
-actions between the compounds of interest and the GC stationary phase can
result in different retention characteristics between polar and nonpolar com-
pounds. Thus, if the retention regression is based on a set of nonpolar
compounds, predictions for polar compounds based on the nonpolar regression
curve may be inaccurate (Kovats 1965). Interaction between sample components
in the GC column can also influence elution times. This effect may sometimes
be observed when a trace component is eluted on the back edge of a major com-
ponent; the major component will take part in the separation process, thus
acting as a "dynamic stationary phase" (Deans 1971). Since a large number of
major components were present in the FY82 data, this phenomenon may have been
responsible for some inaccuracies in observed retentions. Reproducibility of
various GC operating conditions such as column temperature programming,
carrier gas flow rate and injector temperature may also affect retention char-
acteristics (Schomburg 1973 Ettre 1984). Changes in retentive properties of a
column stationary phase may affect retention indices over time and are
probably due to oxidiative degradation of the phase.
43
-------
In spite of the limitations described above, prediction of retention
values proved to generally successful for most compounds because the search
window was set wide enough that minor errors in retention could be tolerated.
The method was less successful in identifying closely eluting isomers with
similar mass spectra, such as cumene and trimethylbenzene (C9H12).
C. Additional Problems Associated with VOA Analysis
The most persistent problem encountered during the TCA analysis of
the VOA composites was associated with the nonspecificity of some target mass
spectra, i.e., the mass spectra of many target compounds were not distinctive
enough to distinguish them from the many large nontarget peaks observed
throughout the chromatogram. A listing of compounds which were judged to have
nonspecific mass spectra is shown in Table 15. It should be noted that non-
specificity is related not only to the mass spectrum itself but may also be
associated with the sample matrix. As a result, trichloroethylene, which
coeluted with the major constituent pentanal was relatively easy to positively
identify because no interfering compounds with similar spectra were observed
within its retention window. On the other hand, the presence of acetone was
difficult to verify due the presence of a nontarget coeluting compound with
common fragment ions and their mass spectra could not be separated by enhance-
ment or subtraction routines. As a result, acetone was considered not
detected although its presence is suggested in many of the composites.
D. Additional Problems Associated with SMV Analysis
Some compounds in the semivolatile target group were difficult to
positively identify because of the nonspecificity of their mass spectra,
similar to that described for the volatile target compounds. For the semi-
volatile analytes; however, this problem was exascerbated by the high mass
scanning range, as described previously. For example, very little fragmenta-
tion was observable for the cresols because the mass spectrometer did not
collect data below 100 amu, and as a result, only the molecular ion and M-l
ton (fli/z 108 and 107) are visible in the mass spectrum. However, the M/M-1
ratio for cresol is relatively distinctive, and in some instances three
responses corresponding to the cresol elution pattern were observed. These
two factors led to the decision to report the identification of the cresol
isomers. It should be emphasized, however, that the identification of cresols
is based on extremely limited mass spectral information. Other semivolatile
compounds which presented problems due to limited mass spectral specificity
are shown in Table 16.
E. Comparison of Authentic Standards to Observed Targets
All of the compounds tentatively identified in the TCA analysis
portion of this study were verified via GC/MS analysis of authentic standard
material, with the exception of pentyl benzaldehyde, which could not be
obtained in time for the authentic standard analysis portion of this study.
The results of the authentic standard comparison are shown in Table 17.
44
-------
Table 15
Volatile Compounds with Non-Specific Mass Spectra
Carbon Disulfide
Ethyleneimine (Aziridine)
1,2-Butylene oxide
Vinyl acetate
Acetonitrile
Methyl ethyl ketone
Isopropyl alcohol
Ethyl acrylate
Acrolein
Propylamineimine
t-Butyl alcohol
sec-Butanol
Ethyl acrylate
Nitropropane
Acrylic acid
Table 16
Semivolatile Compounds with Non-Specific Mass Spectra
Cumene
Dimethylcarbamyl chloride
1,2,4-Trimethyl benzene
Cymeme
Propane Sulfone
Bis(2-chloroethyl) ether
Dimethyl sulfate
Styrene oxide
Benzoyl chloride
o-Cresol
m-Cresol
p-Cresol
N-Nitrosomorpholine
Nitrobenzene
Isophorone
N-Nitrosopiperidine
o-Toluidine hydrochloride
Hydroquinone
Catechol
Phenyienediamine
Michler's ketone
45
-------
Table 17
Comparison of Authentic Standards vs Observed Targets
Volatlles
Compound Name
Isobutyraldehyde
Butyraldehyde
Trichloroethene
1-Bromopentane
1-Pentanol
1-Nonene
Ethyl isovalerate
1 -lodopentane
2-Pentyl furan
Limonene
1-Bromoheptane
Pentyl cyclohexane
3-Octen-2-one
6% Semivolatlles
Compound Name
Cumene
1 ,2,4-Trimethylbenzene
Cymene
Limonene
2,6-Xylidene
Safrole
Biphenyl
Diphenyl -ether
Dibenzofuran
Anthracene
75/50% Semivolatlles
Compound Name
o-Cresol
m-Cresol
p-Cresol
2-Ethoxy benzaldehyde
Diaminotoluene
2-Phenyl phenol
Carbaryl
Average
Observed RRT
.332
.372
.606
1.508
1.127
1.911
1.705
2.188
2.742
2.966
3.093
3.532
3.124
Average
Observed RRT
.267
.292
.321
.324
.460
.582
.666
.686
.789
1.002
Average
Observed RRT
.347
.369
.380
.617
.660
.784
1.081
Butyl phthalate butyl glycolate 1.330
Bis(2-ethylhexyl) adipate
Bis(2-ethyihexyl) phthalate
1.371
1.455
Authentic
Std. RRT
.309
.358
.639
1.421
1.004
V.933
1.628
2.144
2.768
3.060
3.137
3.642
3.151
Authentic Std.
Adjusted RRT
.222
.291
.324
.328
.468
.588
.671
.695
.791
1.002
Authentic Std.
Adjusted RRT
.345
.367
.367
.600
.673
.784
.776
1.304
1.347
1.427
A RRT
(%)
-7.4
-3.9
5.2
-6.1
-12.3
1.1
-4.7
-2.1
.9
3.1
1.4
3.0
.9
A RRT
(%)
-20.3
-.3
.9
1.2
1.7
1.0
.7
1.3
.3
.0
A RRT
(%)
-.6
-.5
-3.5
-2.8
1.9
.0
-39.3
-2.0
-1.8
-2.0
RRT Range Observed
in Composites
.311 - .350
.353- .390
.593- .623
1.494- 1.529
1.067- 1.205
1.820- 2.084
1.630- 1.803
2.066- 2.376
2.573- 3.012
2.771 - 3.269
3.011 - 3.168
3.403 - 3.908
2.876- 3.824
RRT Range Observed
in Composites
.217- .344
.247- .323
.277- .348
.281 - .352
.437- .479
.572- .593
.656- .674
.671 - .781
.786- .793
1.002- 1.002
RRT Range Observed
in Composites
.291 - .398
.346- .412
.332- .428
.611 - .623
.645- .785
.777- .790
1.081 - 1.081
1.326- 1.335
1.360- 1.379
1.442- 1.465
Authentic
RRf
.070
.040
.335
.660
.020
.210
.315
.115
.170
.110
.220
.160
.010
Authentic
RRf
1.173
1.220
1.620
.150
.811
.478
1.286
.658
1.272
1.439
Authentic
RRf
.651
.638
.638
.031
.581
.333
.212
.053
.733
.898
46
-------
As can be seen in Table 17, most of the relative retention times of the
authentic standards agree very well with the average RRT values of the
tentatively identified compounds, with 23 compounds (out of a total of 33)
having a percent relative difference of 3% or less.
One compound, m-cresol, was removed from the list of identified
compounds because it was found to actually coelute with the para isomer (three
distinct isomers of cresol were thought to have been observed in the actual
samples). Since the actual identification of p- vs. m-cresol isomers could
not be determined from the data, the identified peaks are referred to as
"m,p-cresol" to signify that the peak could be either meta, para, or a
combination of the two.
One compound, carbaryl, was found to elute much earlier than was
observed in the original analysis. However, carbaryl was not removed from the
list of identified compounds because the mass spectrum of carbaryl still
showed a very high similarity to the spectrum observed in the composite.
One compound, cumene, was rejected because its actual RRT was
significantly different from the tentatively identified peak RRT. However,
unlike carbaryl, the mass spectral similarity of cumene to the respective
tentatively identified peaks was not a sufficiently compelling reason to
retain it on the list of identified compounds.
Several compounds were retained on the list of identified compounds
even though the RRT of the authentic standards did not fall within the range
of their respective tentatively identified peaks. In these cases, the dis-
crepancy is suspected to be caused by differences between the two analyses
which could not be entirely eliminated through normalization. In all these
cases, the high similarity of the reference mass spectra to the tentatively
identified peak mass spectra was a critical factor.
One compound was actually added to the list of identified compounds
as a result of the authentic standards analysis. Diphenyl ether was added to
the list when it was found that it bore a close resemblance to the mass
spectra originally assigned to 2-phenyl phenol in the 6% semivolatile frac-
tion.- These two compounds both have the same empirical formula, C12H100, and
very similar mass spectra. However, the RRTs of the peaks in the 6% fraction
were significantly different from those in the 15/50% fraction samples, even
though both analyses were performed using the same GC conditions. The iden-
tification of diphenyl ether was confirmed using an authentic standard for
comparison.
Positively identified compounds were quantitated in the adipose
composites using the response factors generated from the authentic standards
analysis. The quantitative results for each of the positively identified
compounds are presented in Appendices A through C. However, these results
should only be regarded as estimates, since the response factors may difer
significantly from what they might have been at the time of the original
analysis.
47
-------
F. Comparison of Frequency of Occurrence Results to Unidentified
Peaks Study
The 16 ECAO compounds selected from the original peaks study for
analysis were also identified in this study. However, the frequencies of
occurrence that were observed in this study usually differed somewhat from
those in the original study. These differences are due to the manner in which
the peaks were selected for identification in the unidentified peaks study and
to the inherent difference in selectivity between the two identification
methods. In the original study, only peaks which were distinguishable from
the total ion current baseline and which were reasonably separated from
coeluting peaks were selected for analysis. By using the TCA procedure in
this study, it was possible to identify compounds buried under high background
and coeluting peaks, which resulted in a higher number of identifications of
ECAD compounds than was observed in the original study. This difference is
illustrated in Table 18, which presents the frequencies of occurrence for ECAD
compounds from both the unidentified peaks study and the current study. In
fact, there were no cases where the TCA procedure failed to identify as many
occurrences of a compound as the unidentified peaks procedure, with the excep-
tion of hexene, which was not identified in the current task although it was
tentatively identified in the original unidentified peaks study. Examination
of the boiling point vs. retention time data from the original identification
indicated that the peak originally identified as hexene eluted much later than
would be expected and was probably an isomer of nonene.
Nonene itself was difficult to positively identify because several
peaks were often observed with mass spectra that were highly similar to the
nonene reference spectrum. These multiple peaks were assumed to be isomers of
the general formula C9H18. In these circumstances, peak areas for all peaks
passing the minimum FIT threshold were integrated and reported as "Nonenes."
If the hexene and nonene frequencies of occurrence from the original
unidentified peaks study are summed, the comparison of the frequency of
nonenes in that study to the current study becomes 47/46.
G. Possible Sources of Identified Compounds
A preliminary search to determine possible sources of the identified
compounds was conducted. All of the information below was found in the Merck
Index, 10th edition, unless otherwise noted.
48
-------
Table 18
Frequency of Occurrence of ECAD Analytes
in Original Unidentified Peaks Study and Current Study
Volatiles
Freq. of Occurrence Freq. of Occurrence
No. Compound Name Unidentified Peaks TCA Analysis
1
2
3
4
5
6
7
8
9
10
2-Amyl furan
Bromoheptane
Bromopentane
Ethyl isovalerate
Hexene
3-Octen-2-one
Limonene
Nonene
Pentyl alcohol
Pentyl cyclohexane
29
2
3
16
39
9
44
8
29
1
46
4
3
44
0
46
46
46
38
10
Semivolatiles
Freq. of Occurrence Freq. of Occurrence
No. Compound Name Unidentified Peaks (a) TCA Analysis (a)
1
2
3
4
5
6
Butyl glycol butyl phthalate
Cymene
2-Ethoxy benzaldehyde
4-Pentyl benzaldehyde
o-Phenyl Phenol (b)
Diphenyl ether (c)
6\0
7\0
0\4
0\1
0\18
35\0
0\8
41\0
0\6
0\9
0\22
40\0
Notes:
a. Frequencies of occurrence are shown for 6% and 15/50% Florisil fractions, respectively.
b. Identified as [1,1'-Biphenyl]-2-ol in Unidentified Peaks Study (Onstot, 1987).
c. Identified as 1,1'-Oxybis-benzene in Unidentified Peaks Study (Onstot, 1987).
49
-------
Volatiles
Ethyl isovalerate
Limonene
Pentyl alcohol
Trichloroethylene
Anthracene
Biphenyl
Diphenyl ether
Limonene
2-Phenyl phenol
Safrole
Xylidene
Bis(ethylhexyl) phthalate
Carbaryl
Cresol
Used in alcoholic solution for flavoring
confectionary and beverages.
Found in various ethereal oils, particularly oils
of lemon and orange. Lemon-like odor. Used as a
solvent in the manufacture of resins, and as a
wetting and dispersing agent.
Solvent.
Solvent for fats, waxes, resins, etc. Used for
solvent extraction in many industries. Also used
as a degreasing agent in dry cleaning.
Semivolatiles
Combustion product; found in fossil fuels. Used
as an intermediate in production of dyes (IARC
Monograph).
'Used as a heat transfer agent,, fungistat for
oranges (applied to inside of shipping container
or wrappers).
Used as a heat transfer medium and in perfuming
soaps.
See volatiles.
Oowicide 1; used as germicide and fungicide.
Active ingredient in Lysol. This compound is
suspected to be a contaminant from the adipose
collection procedure.
Topical antiseptic; used in the manufacture of
heliotropin. Listed as EPA carcinogen.
Used in the manufacture of dyes.
Plasticizer, vacuum pump oil.
Contact insecticide.
Used as local antiseptic, parasiticide,
disinfectant, in photographic developing
solutions, in manufacture of explosives.
50
-------
VI. REFERENCES
Stanley, JS. 1986a. Broad Scan Analysis of Human Adipose Tissue, Volume I:
Executive Summary. Washington, DC, U.S. Environmental Protection Agency,
Office of Toxic Substances. EPA 560/5-86-036.
Stanley, JS. 1986b. Broad Scan Analysis of Human Adipose Tissue,
Volume II: Volatile Organic Compounds. Washington, DC, U.S. Environmental
Protection Agency, Office of Toxic Substances. EPA 560/5-86-036.
Stanley, JS. 1986c. Broad Scan Analysis of Human Adipose Tissue,
Volume III: Semivolatile Organic Compounds. Washington, DC, U.S. Environ-
mental Protection Agency, Office of Toxic Substances. EPA 560/ 5-86-036.
Stanley, JS. 1986d. Broad Scan Analysis of Human Adipose Tissue, Volume
IV: Polychlorinated Dibenzo-p-dioxins (PCDD) and Polychlorinated
Dibenzofurans (PCDF). Washington, DC, U.S. Environmental Protection Agency,
Office of Toxic Substances. EPA 560/5-86-036.
Lucas RM, Rierson, SA, Myers DL, Handy RW. 1981. RTI. National Human
Adipose Tissue Survey Quality Assurance Program Plan. Preliminary draft.
RTI/1984/21-11.
Mack GA, Stanley J. 1984. Preliminary Strategy on the National Human Adipose
Tissue Survey. Washington, DC, U.S. Environmental Protection Agency, Office
of Toxic Substances. Contracts 68-01-6721 (Task 21) and 68-02-3938 (Work
Assignment 8).
Onstot JD, Ayling RE, Stanley JS. 1987. Characterization of HRGC/MS
Unidentified Peaks from the Analysis of Human Adipose Tissue, Volume I:
Technical Approach. Washington, DC, U.S. Environmental Protection Agency,
Office of Toxic Substances. Contract 68-02-4252 (Task 23). EPA 560/
5-87-002A.
Onstot JD, Ayling RE, Stanley JS. 1987. Characterization of HRGC/MS
Unidentified Peaks from the Analysis of Human Adipose Tissue, Volume II:
Appendices. Washington, DC, U.S. Environmental Protection Agency, Office of
Toxic Substances. Contract 68-02-4252 (Task 23). EPA 560/5-87-002B.
Heller, SR, Milne. GWA. EPA/NIH Mass Spectral Data Base, Publication
No. NSRDS-NBS 63, Volumes 1-5. National Bureau of Standards, Department of
Commerce, Washington, DC.
Lucas SV, Kornfeld RA. GC/MS Suitability Testing of RCRA Appendix VIII and
Michigan List Analytes. Cincinnati, OH, U.S. Environmental Protection Agency,
Environmental Monitoring and Support Laboratory. Contract 68-03-3224
(Task 1-04).
Federal Register, Volume 53, No. 30, pp 4500-4554, February 16, 1988. U.S.
Code 40 CFR Part 372. Toxic Chemical Release Reporting, Community Right-to-
Know. Final Rule.
51
-------
Federal Hegister, Volume 52, No. 74, pp. 12966-12870, April 17, 1987. Notice
of the first priority list of hazardous substances that will be the subject of
toxicological profiles.
Price MG. Results of ranking task for NHMP Workgroup. Internal memorandum,
December 14, 1987. Washington, DC, U.S. Environmental Protection Agency,
Office of Toxic Substances.
IARC Monograph. Polynuclear Aromatic Compounds, Volume 32, p. 95. 1983.
World Health Organization, International Agency for Research on Cancer.
Deans DR. Anal. Chem. 43, 2026 (1971).
Ettre LS. Chromatographia 18, 243 (1984).
Schomburg G. and Guiochon, G. Anal. Chem. 45, 1188 (1973).
Kovats E. In Advances in Chromatography, Volume 1 (J. C. Giddings and
R. A. Keller, eds.). Marcel Dekker, New York, 1965, p. 229
52
-------
APPENDIX A
VOLATILE COMPOSITE SUMMARY REPORTS
A-l
-------
Appendix A-1
FY82 VOA Adipose Composite Summary
Data Report -
MR I Sample
Number
82-301
82-302
82-303
82-304
82-305
82-306
82-307
82-308
82-309
82-310
82-311
82-312
82-313
82-314
82-315
82-316
82-317
82-318
82-319
82-320
82-321
82-322
82-323
82-324
82-325
82-326
82-327
82-328
82-329
82-330
82-331
82-332
82-333
82-334
82-335
82-336
82-337
82-338
82-339
82-340
82-341
82-342
82-343
82-344
82-345
82-346
2-Amyl
furan
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
3 -
3 -
3 -
3 -
4 -
4 -
PA
PA
PA
N=
N=
NE
MA
MA
MA
BJ
B4
BJ
W\l
WN
V\N
SA
SA
SA
ES
ES
ES
WS
WS
WS
MO
MD
MO
MA
MA
MA
EN
EN
EN
WN
SA
SA
SA
ES
ES
WS
EN
EN
SA
SA
SA
SA
-VD
-VD
-VD
-VD
-VD
-VO
-VD
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VD
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VD
-VO
-VO
-VO
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 45+
- 0-14
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 15-44
- 45 +
- 15-44
- 45+
- 15-44
- 45+
Tissue Wt
(9)
15.0
17.4
20.7
20.0
23.6
25.5
20.3
25.0
15.5
12.7
20.8
18.6
18.9
21.6
21.6
12.6
22.2
15.4
25.6
19.0
20.6
6.0
22.4
22.0
5.1
18.8
22.4
18.1
25.3
17.8
17.3
21.1
22.6
18.3
16.7
18.7
23.2
24.3
19.3
21.9
19.6
21.4
10.1
13.8
17.8
11.6
RRT
2.811
2.712
2.699
2.684
2.667
2.650
2.780
2.752
2.774
2.785
2.714
2.632
2.789
2.716
2.722
2.837
2.937
2.893
2.772
2.905
2.859
2.844
2.724
2.738
2.910
2.824
2.987
2.835
2.866
3.012
2.751
2.604
ND
2.664
2.573
2.628
2.650
2.600
2.636
2.592
2.582
2.598
2.649
2.698
2.642
2.720
CAS No.:
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
92.416
32.468
33.199
246.867
571.778
786.271
47.423
190.777
153.481
94.927
73.326
37.386
261.608
9.084
3.219
564.965
42.548
52.164
71.659
62.282
98.328
264.880
480.778
255.697
68.353
176.056
328.794
98.021
183.018
178.199
72.512
33.620
ND
9.482
426.676
167.508
30.274
14.449
64.277
74.050
18.030
64.955
83.036
73.627
95.552
25.318
6.161
1.865
1.603
12.343
24.227
30.834
2.336
7.631
9.902
7.474
3.525
2.010
13.841
.420
.149
44.838
1.916
3.387
2.799
3.278
4.773
44.146
21.463
11.622
13.402
9.364
14.678
5.415
7.233
10.011
4.191
1.593
ND
.518
25.549
8.957
1.304
.594
3.330
3.381
.919
3.035
8.221
5.335
5.368
2.182
" 3777-69-3
VOA
0.170
Analysis
Date
6/19/84
6/20/84
6/20/84
6/20/84
6/21/84
6/26/84
6/27/84
6/27/84
6/27/84
6/28/84
6/28/84
6/28/84
6/29/84
6/29/84
7/2/84
7/3/84
7/3/84
7/3/84
7/9/84
7/9/84
7/9/84
7/11/84
7/11/84
7/11/84
7/1 1/84
7/12/84
7/12/84
7/12/84
7/13/84
7/13/84
7/13/84
7/16/84
7/16/84
7/1 6/84
7/17/84
7/17/84
7/17/84
7/18/84
7/20/84
7/18/84
7/18/84
7/18/84
7/20/84
7/20/84
7/20/84
7/20/84
A-2
-------
Appendix A-2
FY82 VOA Adipose Composite Summary
Data Report -
MRI Sample
Number
82-301
82-302
82-303
82-304
82-305
82-306
82-307
82-308
82-30?
82-310
82-311
82-312
82-313
82-314
82-315
82-316
82-317
82-318
82-319
82-320
82-321
82-322
82-323
82-324
82-325
82-326
82-327
82-328
82-329
82-330
82-331
82-332
82-333
82-334
82-335
82-336
82-337
82-338
82-339
82-340
82-341
82-342
82-343
82-344
82-345
82-346
Bromoheptane
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
3 -
3 -
3 -
3 -
4 -
4 -
PA
PA
PA
NE
NE
NE
MA
MA
MA
W
ai
ai
WN
WN
V\N
SA
SA
SA
es
ES
E5
W3
WS
WS
MD
MD
MD
MA
MA
MA
W
Rl
BJ
WM
SA
SA
SA
ES
ES
WS
EN
EN
SA
SA
SA
SA
-VD
-VO
-VO
-VD
-VD
-VD
-VO
-VD
-VO
-VO
-VD
-VO
-VO
-VO
-VD
-VO
-VD
-VD
-VD
-VO
-VO
-VD
-VD
-VO
-VO
-VO
-VD
-VO
-VD
-VD
-VO
-VD
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VD
-VD
-VD
-VD
-VO
-VD
-VD
- 0-14
- 15-44
- 45+
- 0-14
- 15-4'4
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 45+
- 0-14
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 45+
Tissue Wt
(g)
15.0
17.4
20.7
20.0
23.6
25.5
20.3
25.0
15.5
12.7
20.8
18.6
18.9
21.6
21.6
12.6
22.2
15.4
25.6
19.0
20.6
6.0
22.4
22.0
5.1
18.8
22.4
18.1
25.3
17.8
17.3
21.1
22.6
18.3
16.7
18.7
23.2
24.3
19.3
21.9
19.6
21.4
10.1
13.8
17.8
11.6
RRT
3.117
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
3.074
ND
ND
ND
ND
ND
ND
ND
3.168
ND
3.011
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
Amount
(Total ug)
.247
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
2.256
ND
ND
ND
ND
ND
ND
ND
.378
ND
1.553
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
CAS No.:-
Fraction:
RRf:
Concentration
(ug/g)
.016
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.119
ND
ND
ND
ND
ND
ND
ND
.018
ND
.069
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
629-04-9
VOA
0.220
Analysis
Date
6/19/84
6/20/84
6/20/84
6/20/84
6/21/84
6/26/84
6/27/84
6/27/84
6/27/84
6/28/84
6/28/84
6/28/84
6/29/84
6/29/84
7/2/84
7/3/84
7/3/84
7/3/84
7/9/84
7/9/84
7/9/84
7/1 1/84
7/1 1 /84
7/1 1 /84
7/1 1 /84
7/12/84
7/12/84
7/12/84
7/13/84
7/13/84
7/13/84
7/16/84
7/1 6/84
7/16/84
7/17/84
7/17/84
7/17/84
7/18/84
7/20/84
7/18/84
7/18/84
7/18/84
7/20/84
7/20/84
7/20/84
7/20/84
A-3
-------
Appendix A-3
FY82 VOA Adipose Composite Summary
Data Report -
MRI Sample
Number
82-301
82-302
82-303
82-304
82-305
82-306
82-307
82-308
82-309
82-310
82-311
82-312
82-313
82-314
82-315
82-316
82-317
82-318
82-319
82-320
82-321
82-322
82-323
82-324
82-325
82-326
82-327
82-328
82-329
82-330
82-331
82-332
82-333
82-334
82-335
82-336
82-337
82-338
82-339
82-340
82-341
82-342
82-343
82-344
82-345
82-346
Bromopentane
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
3 -
3 -
3 -
3 -
4 -
4 -
PA
PA
PA
r
NE
N=
MA
MA
MA
BJ
BY
BY
VW
WSI
VW
SA
SA
SA
ES
E3
ES
W3
WS
WS
MD
MD
MD
MA
MA
MA
BM
BY
BY
WY
SA
SA
SA
ES
ES
WS
BY
BY
SA
SA
SA
SA
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 45+
- 0-14
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 15-44
- 45 +
- 15-44
- 45+
- 15-44
- 45+
Tissue Wt
(9)
15.0
17.4
20.7
20.0
23.6
25.5
20.3
25.0
15.5
12.7
20.8
18.6
18.9
21.6
21.6
12.6
22.2
15.4
25.6
19.0
20.6
6.0
22.4
22.0
5.1
18.8
22.4
18.1
25.3
17.8
17.3
21.1
22.6
18.3
16.7
18.7
23.2
24.3
19.3
21.9
19.6
21.4
10.1
13.8
17.8
11.6
RRT
1.529
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
1.500
ND
ND
ND
ND
ND
ND
ND
ND
ND
1.494
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
CAS No.:
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
.021
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.072
ND
ND
ND
ND
ND
ND
ND
ND
ND
.031
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
NO
.001
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.003
ND
ND
ND
ND
ND
ND
ND
ND
ND
.001
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
110-53-J
VO/
0.66C
Analysis
Date
6/1 9/84
6/20/84
6/20/84
6/20/84
6/21/84
6/26/84
6/27/84
6/27/84
6/27/84
6/28/84
6/28/84
6/28/84
6/29/84
6/29/84
7/2/84
7/3/84
7/3/84
7/3/84
7/9/84
7/9/84
7/9/84
7/1 1/84
7/1 1/84
7/1 1/84
7/1 1/84
7/1 2/84
7/12/84
7/12/84
7/1 3/84
7/13/84
7/1 3/84
7/1 6/84
7/1 6/84
7/1 6/84
7/17/84
7/1 7/84
7/1 7/84
7/18/84
7/20/84
7/1 8/84
7/18/84
7/1 8/84
7/20/84
7/20/84
7/20/84
7/20/84
A-4
-------
Appendix A-4
FY82 VOA Adipose Composite Summary
Data Report -
MRI Sample
Number
82-301
82-302
82-303
82-304
82-305
82-306
82-307
82-308
82-309
82-310
82-311
82-312
82-313
82-314
82-315
82-316
82-317
82-318
82-319
82-320
82-321
82-322
82-323
82-324
82-325
82-326
82-327
82-328
82-329
82-330
82-331
82-332
82-333
82-334
82-335
82-336
82-337
82-338
82-339
82-340
82-341
82-342
82-343
82-344
82-345
82-346
Butyraldehyde
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2-
2 -
2 -
2 -
2 -
2 -
3 -
3 -
3 -
3 -
4 -
4 -
PA
PA
PA
N=
NE
N=
MA
MA
MA
Rl
W
34
V\M
V\N
V\N
SA
SA
SA
ES
es
ES
VMS
WS
WS
MD
MD
MD
MA
MA
MA
Rl
ai
ai
WN
SA
SA
SA
E3
ES
WS
EN
BJ
SA
SA
SA
SA
-VO
-VD
-VD
-VO
-VO
-VD
-VD
-VO
-VD
-VD
-VD
-VD
-VO
-VD
-VD
-VD
-VD
-VO
-VO
-VO
-VO
-VO
-VD
-VO
-VD
-VD
-VO
-VO
-VO
-VD
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VD
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 45 +
- 0-14
- 15-44
- 45 +
- 15-44
- 45+
- 15-44
- 15-44
- 45 +
- 15-44
- 45+
- 15-44
- 45+
Tissue Wt
(9)
15.0
17.4
20.7
20.0
23.6
25.5
20.3
25.0
15.5
12.7
20.8
18.6
18.9
21.6
21.6
12.6
22.2
15.4
25.6
19.0
20.6
6.0
22.4
22.0
5.1
18.8
22.4
18.1
25.3
17.8
17.3
21.1
22.6
18.3
16.7
18.7
23.2
24.3
19.3
21.9
19.6
21.4
10.1
13.8
17.8
11.6
RRT
.372
.367
.372
.360
.361
.356
.372
.366
.365
.378
.353
.363
.367
.375
.378
.369
.390
.383
.372
.382
.385
ND
.360
.365
.384
.374
.388
.377
.380
.388
.364
.366
.369
.380
.359
.368
.367
.366
.370
.367
.367
.369
.372
.375
.372
.384
CAS No. :^
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
14.
42.
12.
62.
34.
184.
17.
35.
21.
24.
31.
28.
12.
48.
14.
47.
23.
13.
36.
15.
35.
139.
71.
4.
21.
34.
20.
25.
20.
39.
47.
23.
20.
75.
77.
67.
16.
14.
24.
21.
18.
25.
22.
38.
32.
785
384
620
288
594
550
077
145
672
404
908
191
477
676
990
197
713
047
927
982
807
ND
731
595
257
889
830
272
477
999
694
979
045
570
867
784
073
633
297
659
165
583
306
985
072
029
2
3
1
7
1
1
1
1
1
2
3
1
1
1
6
3
1
1
1
1
1
2
2
1
1
4
4
2
1
1
2
1
2
2
.985
.435
.609
.114
.465
.237
.841
.405
.398
.921
.534
.515
.660
.253
.693
.745
.068
.847
.442
.841
.738
ND
.238
.254
.834
.164
.554
.120
.007
.179
.294
.273
.019
.124
.542
.159
.891
.684
.740
.125
.079
.868
.505
.665
.138
.761
123-72-8
VOA
0.040
Analysis
Date
6/19/84
6/20/84
6/20/84
6/20/84
6/21/84
6/26/84
6/27/84
6/27/84
6/27/84
6/28/84
6/28/84
6/28/84
6/29/84
6/29/84
7/2/84
7/3/84
7/3/84
7/3/84
7/9/84
7/9/84
7/9/84
7/1 1 /84
7/1 1/84
7/1 1 /84
7/1 1/84
7/12/84
7/12/84
7/12/84
7/13/84
7/13/84
7/13/84
7/16/84
7/1 6/84
7/16/84
7/17/84
7/17/84
7/17/84
7/18/84
7/20/84
7/18/84
7/18/84
7/18/84
7/20/84
7/20/84
7/20/84
7/20/84
A-5
-------
Appendix A-5
FY82 VOA Adipose Composite Summary
Data Report -
MRI Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
Ethyl isovalerate
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2-
2 -
2 -
3 -
3 -
3 -
3 -
4 -
4 -
PA
PA
PA
NE
NE
NE
MA
MA
MA
Rl
a*
BJ
WN
WN
WN
SA
SA
SA
ES
ES
ES
WS
WS
WS
MD
MD
MD
MA
MA
MA
EN
EN
EN
WN
SA
SA
SA
ES
ES
WS
EN
EN
SA
SA
SA
SA
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
- VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 45 +
- 0-14
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 45+
Tissue Wt
(9)
15.0
17.4
20.7
20.0
23.6
25.5
20.3
25.0
15.5
12.7
20.8
18.6
18.9
21.6
21.6
12.6
22.2
15.4
25.6
19.0
20.6
6.0
22.4
22.0
5.1
18.8
22.4
18.1
25.3
17.8
17.3
21.1
22.6
18.3
16.7
18.7
23.2
24.3
19.3
21.9
19.6
21.4
10.1
13.8
17.8
11.6
RRT
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
.756
.719
.710
.702
.690
.691
.721
.702
.715
.722
.718
.683
.718
.701
.702
.734
.775
.759
.725
.769
ND
ND
.697
.703
.753
.729
.789
.738
.753
.803
.705
.654
.652
.682
.630
.660
.669
.654
.665
.650
.646
.652
.667
.684
.667
.713
CAS No.:
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
4.177
6.959
8.590
18.173
7.618
2.419
.554
6.432
3.227
33.380
53.504
15.441
5.497
8.572
6.998
.341
13.665
15.850
.918
13.562
ND
ND
35.999
34.945
.190
2.752
11.199
2.832
.397
4.105
8.890
4.434
7.117
5.371
1.175
39.797
10.221
1 .828
7.430
31.811
18.212
14.874
12.585
7.178
6.470
11.502
.278
.399
.414
.908
.322
.094
.027
.257
.208
2.628
2.572
.830
.290
.396
.324
.027
.615
1.029
.035
.713
ND
ND
1.607
1.588
.037
.146
.499
.156
.015
.230
.513
.210
.314
.293
.070
2.128
.440
.075
.385
1.452
.929
.695
1.246
.520
.363
.991
108-64-!
VCv
0.31!
Analysis
Date
6/19/84
6/20/84
6/20/84
6/20/84
6/21/84
6/26/84
6/27/84
6/27/84
6/27/84
6/28/84
6/28/84
6/28/84
6/29/84
6/29/84
7/2/84
7/3/84
7/3/84
7/3/84
7/9/84
7/9/84
7/9/84
7/1 1/84
7/1 1/84
7/1 1/84
7/1 1/84
7/12/84
7/12/84
7/12/84
7/1 3/84
7/13/84
7/13/84
7/16/84
7/16/84
7/16/84
7/17/84
7/17/84
7/17/84
7/18/84
7/20/84
7/18/84
7/18/84
7/18/84
7/20/84
7/20/84
7/20/84
7/20/84
A-6
-------
Appendix A-6
FY82 VOA Adipose Composite Summary
Data Report -
MRI Sample
Number
82-301
82-302
82-303
82-304
82-305
82-306
82-307
82-308
82-309
82-310
82-311
82-312
82-313
82-314
82-315
82-316
82-317
82-318
82-319
82-320
82-321
82-322
82-323
82-324
82-325
82-326
82-327
82-328
82-329
82-330
82-331
82-332
82-333
82-334
82-335
82-336
82-337
82-338
82-339
82-340
82-341
82-342
82-343
82-344
82-345
82-346
1 -lodopentane
Sample Composite
Number
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
4
4
- PA
- PA
- PA
- NE
- NE
- NE
- MA
- MA
- MA
- BJ
- W
- BJ
- WN
- WN
- WN
- SA
- SA
- SA
- ES
. ES
. ES
- WS
- WS
- WS
- MD
- MD
- MD
- MA
- MA
- MA
- BJ
- BJ
- B*
- WN
- SA
- SA
- SA
- ES
- ES
- WS
- EN
- BM
- SA
- SA
- SA
- SA
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-'VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
. 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 45+
- 0-14
- 15-44
- 45 +
- 15-44
- 45+
- 15-44
- 15-44
- 45+
- 15-44
- 45+
- 15-44
- 45+
Tissue
(g)
15.
17.
20.
20.
23.
25.
20.
25.
15.
12.
20.
18.
18.
21.
21.
12.
22.
15.
25.
19.
20.
6.
22.
22.
5.
18.
22.
18.
25.
17.
17.
21.
22.
18.
16.
18.
23.
24.
19.
21.
19.
21.
10.
13.
17.
11.
Wt
0
4
7
0
6
5
3
0
5
7
8
6
9
6
6
6
2
4
6
0
6
0
4
0
1
8
4
1
3
8
3
1
6
3
7
7
2
3
3
9
6
4
1
8
8
6
RRT
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
250
189
176
167
143
139
ND
200
217
218
ND
ND
218
183
181
ND
ND
297
223
ND
285
272
172
188
283
250
ND
ND
283
376
193
107
ND
147
066
115
127
107
127
092
089
ND
127
ND
ND
192
CAS No.:,
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
.996
.246
.871
.328
4.147
26.769
ND
.674
.436
.131
ND
ND
1.094
.194
.186
ND
ND
.153
.258
MD
.643
1.292
.894
1.532
.510
3.220
ND
ND
.477
.420
.120
.643
ND
.090
.355
.803
.159
1.108
.470
.535
.171
ND
.972
ND
ND
.568
.066
.014
.042
.016
.175
1.049
ND
.026
.028
.010
ND
ND
.057
.008
.008
ND
ND
.009
.010
ND
.031
.215
.039
.069
.100
.171
ND
ND
.018
.023
.006
.030
ND
.004
.021
.042
.006
.045
.024
.024
.008
ND
.096
ND
ND
.048
628-17-1
VOA
0.115
Analysis
Date
6/19/84
6/20/84
6/20/84
6/20/84
6/21/84
6/26/84
6/27/84
6/27/84
6/27/84
6/28/84
6/28/84
6/28/84
6/29/84
6/29/84
7/2/84
7/3/84
7/3/84
7/3/84
7/9/84
7/9/84
7/9/84
7/1 1/84
7/1 1/84
7/1 1/84
7/1 1/84
7/12/84
7/12/84
7/12/84
7/13/84
7/13/84
7/13/84
7/16/84
7/1 6/84
7/16/84
7/17/84
7/17/84
7/17/84
7/18/84
7/20/84
7/18/84
7/18/84
7/18/84
7/20/84
7/20/84
7/20/84
7/20/84
A-7
-------
Appendix A-7
FY82 VOA Adipose Composite Summary
Data Report -
MR! Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
Isobutyraldehyde
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
3 -
3 -
3 -
3 -
4 -
4 -
PA
PA
PA
N=
N=
N=
MA
MA
MA
W
W
B4
V\N
VW
V\M
SA
SA
SA
ES
E5
E5
WS
WS
W5
MD
MO
MO
MA
MA
MA
ai
B4
Bi
WN
SA
SA
SA
ES
ES
WS
EN
EN
SA
SA
SA
SA
-VO
-VO
-VD
-VD
-VO
-VD
-VO
VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VD
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VD
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VD
-VO
-VO
-VO
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 45 +
- 0-14
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 45 +
Tissue Wt
(9)
15.0
17.4
20.7
20.0
23.6
25.5
20.3
25.0
15.5
12.7
20.8
18.6
18.9
21.6
21.6
12.6
22.2
15.4
25.6
19.0
20.6
6.0
22.4
22.0
5.1
18.8
22.4
18.1
25.3
17.8
17.3
21.1
22.6
18.3
16.7
18.7
23.2
24.3
19.3
21.9
19.6
21.4
10.1
13.8
17.8
11.6
RRT
.333
.325
.338
.323
.324
.319
.333
.328
.326
.332
.311
.319
.328
.329
.335
.333
.348
.342
.333
ND
.341
ND
.318
.326
.344
.334
.350
.337
.340
.350
.325
.327
.329
.339
.320
.328
ND
.327
.334
.328
.328
.329
.332
.338
.332
.343
CAS No.:
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
1
4
5
2
17
5
6
4
1
7
1
1
2
1
2
2
1
3
1
8
5
4
3
4
3
2
2
4
2
2
3
4
3
3
2
2
1
5
3
2
2
.441
.136
.153
.088
.277
.770
.503
.358
.285
.350
.107
.908
.918
.104
.542
.877
.138
.843
.362
ND
.956
ND
.935
.447
.484
.093
.759
.476
.589
.905
.351
.691
.303
.396
.127
.241
ND
.578
.044
.536
.214
.534
.021
.124
.340
.042
.096
.237
.007
.254
.096
.696
.271
.254
.276
.106
.341
.102
.101
.097
.071
.228
.096
.119
.131
ND
.094
ND
.398
.247
.094
.217
.167
.247
.141
.163
.135
.222
.101
.130
.187
.226
ND
.147
.157
.115
.112
.071
.497
.226
.131
.176
78-84-2
VOA
0.070
Analysis
Date
6/19/84
6/20/84
6/20/84
6/20/84
6/21/84
6/26/84
6/27/84
6/27/84
6/27/84
6/28/84
6/28/84
6/28/84
6/29/84
6/29/84
7/2/84
7/3/84
7/3/84
7/3/84
7/9/84
7/9/84
7/9/84
7/1 1/84
7/1 1/84
7/1 1/84
7/1 1/84
7/12/84
7/12/84
7/12/84
7/13/84
7/13/84
7/13/84
7/16/84
7/16/84
7/16/84
7/17/84
7/17/84
7/1 7/84
7/18/84
7/20/84
7/18/84
7/18/84
7/18/84
7/20/84
7/20/84
7/20/84
7/20/84
A-8
-------
Appendix A-8
FY82 VOA Adipose Composite Summary
Data Report -
MRI Sample
Number
82-301
82-302
82-303
82-304
82-305
82-306
82-307
82-308
82-309
82-310
82-311
82-312
'82-313
82-314
82-315
82-316
82-317
82-318
82-319
82-320
82-321
82-322
82-323
82-324
82-325
82-326
82-327
82-328
82-329
82-330
82-331
82-332
82-333
82-334
82-335
82-336
82-337
82-338
82-339
82-340
82-341
82-342
82-343
82-344
82-345
82-346
Umonene
Sample Composite
Number
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
4
4
- PA
- PA
- PA
- N=
- N=
- NE
- MA
- MA
- MA
- B4
- Bl
- m
- WN
- WN
- WN
- SA
- SA
- SA
- ES
- E3
- ES
- WS
- WS
- WS
- MD
- MD
- MD
- MA
- MA
- MA
- BJ
- Bi
- B4
WN
- SA
- SA
- SA
- E3
- ES
- WS
- B^
- B*
- SA
- SA
- SA
- SA
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VO
-VD
-VO
-VD
-VD
-VD
-VD
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 45+
- 0-14
- 15-44
- 45+
- 15-44
- 45 +
- 15-44
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 45 +
Tissue Wt
(9)
15.0
17.4
20.7
20.0
23.6
25.5
20.3
25.0
15.5
12.7
20.8
18.6
18.9
21.6
21.6
12.6
22.2
15.4
25.6
19.0
20.6
6.0
22.4
22.0
5.1
18.8
22.4
18.1
25.3
17.8
17.3
21.1
22.6
18.3
16.7
18.7
23.2
24.3
19.3
21.9
19.6
21.4
10.1
13.8
17.8
11.6
RRT
3.
2.
2.
2.
2.
2.
3.
2.
3.
3.
2.
2.
3.
2.
2.
3.
3.
3.
3.
3.
3.
3.
2.
2.
3.
3.
3.
3.
3.
3.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
047
931
921
903
874
856
011
984
003
007
931
852
007
946
953
055
186
138
003
152
092
068
942
961
129
055
227
072
105
269
976
816
ND
885
771
844
861
809
850
796
792
810
861
918
861
947
CAS No.:,
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
57.
5.
17.
2.
15.
20.
1.
36.
21.
10.
9.
5.
34.
3.
4.
8.
12.
22.
5.
14.
9.
4.
10.
13.
2.
4.
7.
3.
6.
10.
2.
27.
7.
41.
70.
9.
7.
20.
16.
5.
12.
14.
15.
13.
3.
455
285
318
140
899
240
659
724
251
162
109
983
420
859
281
043
525
899
419
718
877
449
351
796
123
348
511
621
170
112
026
491
ND
126
443
908
395
265
211
058
198
947
836
842
753
285
3.830
.303
.836
.107
.673
.793
.081
1.468
1.371
.800
.437
.321
1.821
.178
.198
.638
.564
1.486
.211
.774
.479
.741
.462
.627
.416
.231
.335
.200
.243
.568
.117
1.302
ND
.389
2.481
3.791
.404
.298
1.047
.733
.265
.605
1.468
1.148
.772
.283
138-86-3
VOA
0.110
Analysis
Date
6/19/84
6/20/84
6/20/84
6/20/84
6/21 /84
6/26/84
6/27/84
6/27/84
6/27/84
6/28/84
6/28/84
6/28/84
6/29/84
6/29/84
7/2/84
7/3/84
7/3/84
7/3/84
7/9/84
7/9/84
7/9/84
7/1 1/84
7/1 1/84
7/1 1 /84
7/1 1/84
7/12/84
7/12/84
7/12/84
7/13/84
7/13/84
7/13/84
7/16/84
7/1 6/84
7/16/84
7/17/84
7/17/84
7/17/84
7/18/84
7/20/84
7/18/84
7/18/84
7/18/84
7/20/84
7/20/84
7/20/84
7/20/84
A-9
-------
Appendix A-9
FY82 VOA Adipose Composite Summary
Data Report -
MRI Sample
Number
82-301
82-302
82-303
82-304
82-305
82-306
82-307
82-308
82-309
82-310
82-311
82-312
82-313
82-314
82-315
82-316
82-317
82-318
82-319
82-320
82-321
82-322
82-323
82-324
82-325
82-326
82-327
82-328
82-329
82-330
82-331
82-332
82-333
82-334
82-335
82-336
82-337
82-338
82-339
82-340
82-341
82-342
82-343
82-344
82-345
82-346
Nonenes (1-Nonene)
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
3 -
3 -
3 -
3 -
4 -
4 -
PA
PA
PA
N=
N=
N=
MA
MA
MA
Bl
Bl
BSI
WN
WN
WN
SA
SA
SA
ES
E3
ES
WS
WS
WS
MD
MD
MD
MA
MA
MA
EM
B4
EN
V\M
SA
SA
SA
ES
ES
WS
EN
BJ
SA
SA
SA
SA
-VO
-VD
-VO
-VD
-VD
-VD
-VD
-VD
-VO
-VD
-VO
-VO
-VO
-VO
-VO
-VD
-VD
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VD
-VD
-VO
-VO
-VO
-VD
-VO
-VO
-VD
-VD
-VO
-VD
-VO
-VO
-VO
-VO
-VO
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 45 +
- 0-14
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 45+
Tissue Wt
(9)
15.0
17.4
20.7
20.0
23.6
25.5
20.3
25.0
15.5
12.7
20.8
18.6
18.9
21.6
21.6
12.6
22.2
15.4
25.6
19.0
20.6
6.0
22.4
22.0
5.1
18.8
22.4
18.1
25.3
17.8
17.3
21.1
22.6
18.3
16.7
18.7
23.2
24.3
19.3
21.9
19.6
21.4
10.1
13.8
17.8
11.6
RRT
1.945
1.901
1.894
1.910
1.863
1.878
1.909
1.895
1.910
1.917
1.904
1.860
1.910
1.877
1.857
1.944
2.020
2.004
1.960
2.016
1.979
1.984
1.900
1.907
1.995
1.968
2.084
1.943
2.008
2.081
1.926
1.852
1.824
1.867
1.820
1.851
1.865
1.838
1.847
1.828
1.821
1.831
1.854
1.899
1.854
1.924
CAS No.: "
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
275.
240.
335.
160.
381.
219.
205.
177.
213.
62.
109.
94.
163.
137.
91.
555.
291.
360.
977.
495.
410.
544.
215.
229.
23.
417.
138.
145.
281.
209.
282.
171.
162.
166.
241.
543.
332.
190.
223.
104.
145.
270.
231.
812.
617.
169.
371
382
653
121
242
628
781
356
251
186
071
078
745
709
438
272
532
057
277
604
324
895
792
972
191
887
810
961
974
512
243
198
628
119
669
256
522
270
354
246
024
228
211
598
080
950
18.
13.
16.
8.
16.
8.
10.
7.
13.
4.
5.
5.
8.
6.
4.
44.
13.
358
815
215
006
154
612
137
094
758
896
243
058
663
375
233
069
132
23.380
38.
26.
19.
90.
9.
10.
4.
22.
6.
8.
11.
11.
16.
8.
7.
9.
14.
29.
14.
7.
11.
4.
7.
12.
22.
58.
34.
14.
174
084
918
815
633
453
547
228
196
064
145
770
314
113
195
077
471
051
332
830
572
760
399
627
892
883
667
650
124-11-
VC
0.21
Analysis
Date
6/19/84
6/20/84
6/20/84
6/20/84
6/21/84
6/26/84
6/27/84
6/27/84
6/27/84
6/28/84
6/28/84
6/28/84
6/29/84
6/29/84
7/2/84
7/3/84
7/3/84
7/3/84
7/9/84
7/9/84
7/9/84
7/1 1/84
7/1 1/84
7/1 1/84
7/1 1/84
7/12/84
7/1 2/84
7/1 2/84
7/13/84
7/13/84
7/1 3/84
7/1 6/84
7/1 6/84
7/1 6/84
7/1 7/84
7/1 7/84
7/1 7/84
7/18/84
7/20/84
7/1 8/84
7/1 8/84
7/1 8/84
7/20/84
7/20/84
7/20/84
7/20/84
A-10
-------
Appendix A-10
FY82 VOA Adipose Composite Summary
Data Report -
MRI Sample
Number
82-301
82-302
32-303
32-304
32-305
32-306
32-307
32-308
82-309
82-310
32-311
32-312
32-313
32-314
82-315
82-316
82-317
82-318
82-319
82-320
82-321
82-322
82-323
82-324
82-325
82-326
82-327
82-328
82-329
82-330
82-331
82-332
82-333
82-334
82-335
82-336
82-337
82-338
82-339
82-340
82-341
82-342
82-343
82-344
82-345
82-346
3-Octen-2-one
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2-
2-
2 -
2-
2-
2 -
2 -
2-
2-
2 -
2 -
2-
2 -
3 -
3 -
3 -
3 -
4 -
4 -
PA
PA
PA
N=
NE
NE
MA
MA
MA
&J
RJ
ai
\AM
V\M
WN
SA
SA
SA
ES
EB
GS
WS
WS
WS
MD
MD
MD
MA
MA
MA
Bvl
9t
ai
V\M
SA
SA
SA
ES
ES
WS
EN
EN
SA
SA
SA
SA
-VD
-VD
-VD
-VD
-VD
-VD
-VD
VD
-VO
-VD
-VD
-VD
-VO
-VD
-VD
-VO
-VO
-VO
-VO
-VO
-VD
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VD
-VD
-VO
-VO
-VO
-VO
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 45 +
- 0-14
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 15-44
- 45 +
- 15-44
- 45+
- 15-44
- 45 +
Tissue Wt
(g)
15.0
17.4
20.7
20.0
23.6
25.5
20.3
25.0
15.5
12.7
20.8
18.6
18.9
21.6
21.6
12.6
22.2
15.4
25.6
19.0
20.6
6.0
22.4
22.0
5.1
18.8
22.4
18.1
25.3
17.8
17.3
21.1
22.6
18.3
16.7
18.7
23.2
24.3
19.3
21.9
19.6
21.4
10.1
13.8
17.8
11.6
RRT
3.160
3.030
3.018
3.000
2.977
2.963
3.113
3.081
3.108
3.824
3.722
2.948
3.824
3.057
ND
3.170
3.315
3.257
3.121
3.279
3.208
3.188
3.049
3.065
3.263
3.191
3.367
3.180
3.238
3.423
3.089
2.917
ND
2.988
2.876
2.942
2.960
2.910
2.952
2.892
2.889
2.906
2.967
3.018
2.959
3.056
Amount
(Total ug)
296
104
29
265
479
424
33
116
170
141
104
117
132
27
1022
182
138
184
126
121
865
548
196
155
270
504
73
154
166
208
67
31
758
399
65
77
85
50
70
141
252
219
399
133
.474
.800
.316
.657
.644
.655
.322
.204
.634
.092
.098
.966
.310
.014
NO
.786
.773
.485
.541
.598
.924
.808
.157
.100
.395
.497
.488
.088
.011
.130
.795
.476
ND
.665
.123
.827
.396
.709
.373
.793
.602
.031
.322
.589
.743
.775
CAS No.:
Fraction:
RRf:
Concentration
(ug/g)
19.
6.
1.
13.
20.
16.
1.
4.
11.
11.
5.
6.
7.
1.
81.
8.
8.
7.
6.
5.
144.
24.
8.
30.
14.
22.
4.
6.
9.
12.
3.
1.
45.
21.
2.
3.
4.
2.
3.
6.
24.
15.
22.
11.
764
023
416
282
323
653
641
648
008
109
004
342
000
250
ND
173
233
992
208
663
918
301
471
913
469
388
521
038
087
333
069
197
ND
730
396
381
818
197
423
319
602
590
982
912
457
532
1669-44-9
VOA
0.010
Analysis
Date
6/19/84
6/20/84
6/20/84
6/20/84
6/21/84
6/26/84
6/27/84
6/27/84
6/27/84
6/28/84
6/28/84
6/28/84
6/29/84
6/29/84
7/2/84
7/3/84
7/3/84
7/3/84
7/9/84
7/9/84
7/9/84
7/1 1/84
7/1 1/84
7/11/84
7/1 1/84
7/12/84
7/12/84
7/12/84
7/13/84
7/13/84
7/13/84
7/16/84
7/1 6/84
7/16/84
7/17/84
7/17/84
7/17/84
7/18/84
7/20/84
7/18/84
7/18/84
7/18/84
7/20/84
7/20/84
7/20/84
7/20/84
A-11
-------
Appendix A-11
FY82 VOA Adipose Composite Summary
Data Report -
MRI Sample
Number
82-301
82-302
82-303
82-304
82-305
82-306
82-307
82-308
82-309
82-310
82-311
82-312
82-313
82-314
82-315
82-316
82-317
82-318
82-319
82-320
82-321
82-322
82-323
82-324
82-325
82-326
82-327
82-328
82-329
82-330
82-331
82-332
82-333
82-334
82-335
82-336
82-337
82-338
82-339
82-340
82-341
82-342
82-343
82-344
82-345
82-346
Pentyl Alcohol (3-methyl-1-butanol)
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2-
2 -
3 -
3 -
3 -
3 -
4 -
4 -
PA
PA
PA
N=
N5
N=
MA
MA
MA
BJ
34
EN
V\M
WN
V\M
SA
SA
SA
ES
ES
ES
WS
WS
WS
MD
MD
MD
MA
MA
MA
EN
EN
EN
WN
SA
SA
SA
ES
ES
WS
EN
EN
SA
SA
SA
SA
-VO
-VO
-VO
-VD
-VD
-VD
-VO
-VD
-VD
-VD
-VD
-VD
-VO
-VO
-VD
-VD
-VO
-VO
-VO
-VD
-VO
-VD
-VO
-VO
-VO
-VO
-VO
-VD
-VO
-VO
-VO
-VD
-VD
-VD
-VO
-VO
-VO
-VO
-VD
-VO
-VO
-VO
-VO
-VO
-VO
-VO
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 45 +
- 0-14
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 45 +
Tissue Wt
(9)
15.0
17.4
20.7
20.0
23.6
25.5
20.3
25.0
15.5
12.7
20.8
18.6
18.9
21.6
21.6
12.6
22.2
15.4
25.6
19.0
20.6
6.0
22.4
22.0
5.1
18.8
22.4
18.1
25.3
17.8
17.3
21.1
22.6
18.3
16.7
18.7
23.2
24.3
19.3
21.9
19.6
21.4
10.1
13.8
17.8
11.6
RRT
1.117
1.125
1.067
ND
1.110
ND
1.094
1.111
1.120
1.093
1.117
ND
1.121
1.095
1.146
ND
1.190
1.195
1.145
1.205
1.100
ND
ND
1.126
ND
ND
1.177
1.088
1.190
1.179
1.139
1.140
1.114
1.121
ND
1.122
1.116
1.118
1.127
1.121
1.100
1.100
1.109
1.100
1.127
1.128
CAS No.:
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
128
81
40
349
35
37
44
41
35
31
63
7
92
73
237
150
63
236
320
145
237
199
95
59
131
67
222
142
68
37
44
92
89
86
140
180
93
.485
.837
.998
ND
.769
ND
.650
.860
.780
.198
.474
ND
.864
.990
.648
ND
.669
.039
.386
.415
.423
ND'
ND'
.147
ND
ND'
.029
.772
.444
.842
.985
.177
.009
.062
ND
.237
.719
.954
.503
.403
.235
.607
.0511
.745
.280
.730
8
4
1
14
1
1
2
3
1
1
2
4
4
9
7
3
10
14
.565
.703
.980
ND
.820
ND
.756
.514
.889
.243
.705
ND
.685
.962
.354
ND
.174
.742
.272
.916
.078
ND
ND
.733
ND
ND
.287
8.053
9
11
5
2
5
3
11
6
2
1
2
4
4
8
10
10
8
.385
.227
.548
.804
.796
.664
ND
.884
.151
.837
.943
.027
.705
.187
.519
.198
.128
.080
123-51-3
VOA
0.02C
Analysis
Date
6/19/84
6/20/84
6/20/84
6/20/84
6/21/84
6/26/84
6/27/84
6/27/84
6/27/84
6/28/84
6/28/84
6/28/84
6/29/84
6/29/84
7/2/84
7/3/84
7/3/84
7/3/84
7/9/84
7/9/84
7/9/84
7/1 1/84
7/1 1/84
7/1 1/84
7/1 1/84
7/12/84
7/12/84
7/1 2/84
7/1 3/84
7/13/84
7/1 3/84
7/1 6/84
7/1 6/84
7/16/84
7/1 7/84
7/17/84
7/1 7/84
7/18/84
7/20/84
7/1 8/84
7/18/84
7/18/84
7/20/84
7/20/84
7/20/84
7/20/84
A-12
-------
Appendix A-12
FY82 VOA Adipose Composite Summary
Data Report -
MRI Sample
Number
82-301
82-302
82-303
82-304
82-305
82-306
82-307
82-308
82-309
82-310
82-311
82-312
82-313
82-314
82-315
82-316
82-317
82-318
82-319
82-320
82-321
82-322
82-323
82-324
82-325
82-326
82-327
82-328
82-329
82-330
82-331
82-332
82-333
82-334
82-335
82-336
82-337
82-338
82-339
82-340
82-341
82-342
82-343
82-344
82-345
82-346
Pentyl cyclohexane
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
3 -
3 -
3 -
3 -
4 -
4 -
PA
PA
PA
NE
NE
NE
MA
MA
MA
BM
Rl
BJ
VW
V\N
\AM
SA
SA
SA
ES
EB
ES
WS
WS
WS
MO
MD
MD
MA
MA
MA
EN
EN
EN
\AM
SA
SA
SA
ES
ES
WS
EN
EN
SA
SA
SA
SA
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VO
-VO
-VD
-VO
-VO
-VD
-VD
-VD
-VD
-VO
-VD
-VO
-VO
-VO
-VO
-VD
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VO
-VD
-VO
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45+
- 0-14
- 15-44
- 45 +
- 45+
- 0-14
- 15-44
- 45+
- 15-44
- 45+
- 15-44
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 45+
Tissue Wt
(9)
15.0
17.4
20.7
20.0
23.6
25.5
20.3
25.0
15.5
12.7
20.8
18.6
18.9
21.6
21.6
12.6
22.2
15.4
25.6
19.0 '
20.6
6.0
22.4
22.0
5.1
18.8
22.4
18.1
25.3
17.8
17.3
21.1
22.6
18.3
16.7
18.7
23.2
24.3
19.3
21.9
19.6
21.4
10.1
13.8
17.8
11.6
RRT
ND
ND
to
ND
ND
3.485
ND
ND
ND
3.679
ND
ND
ND
ND
ND
ND
3.908
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
3.480
3.428
ND
3.403
ND
3.422
3.485
3.546
3.481
ND
CAS No.:,
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
ND
ND
ND
ND
ND
7.216
ND
ND
ND
1.383
ND
ND
ND
ND
ND
ND
1.257
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
2.144
.588
ND
1.615
ND
.423
2.040
2.434
2.521
ND
ND
ND
ND
ND
ND
.282
ND
ND
ND
.108
ND
ND
ND
ND
ND
ND
.056
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.092
.024
ND
.073
ND
.019
.202
.176
.141
ND
4292-92-6
VOA
0.160
Analysis
Date
6/19/84
6/20/84
6/20/84
6/20/84
6/21/84
6/26/84
6/27/84
6/27/84
6/27/84
6/28/84
6/28/84
6/28/84
6/29/84
6/29/84
7/2/84
7/3/84
7/3/84
7/3/84
7/9/84
7/9/84
7/9/84
7/1 1 /84
7/1 1/84
7/1 1/84
7/1 1 /84
7/12/84
7/12/84
7/12/84
7/13/84
7/13/84
7/13/84
7/16/84
7/16/84
7/16/84
7/17/84
7/17/84
7/17/84
7/18/84
7/20/84
7/18/84
7/18/84
7/18/84
7/20/84
7/20/84
7/20/84
7/20/84
A-13
-------
Appendix A-13
FY82 VOA Adipose Composite Summary
Data Report -
MRI Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
301
302
303
304
305
306
307
308
309
310
31 1
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
Trichloroethylene
{Trichloroethene}
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2-
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
2 -
3 -
3 -
3 -
3 -
4 -
4 -
PA
PA
PA
N=
N=
NE
MA
MA
MA
EN
EN
EN
WN
WN
WN
SA
SA
SA
ES
ES
ES
WS
WS
WS
MO
MD
MO
MA
MA
MA
EN
EN
EN
WN
SA
SA
SA
ES
ES
WS
EN
EN
SA
SA
SA
SA
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
- VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
-VD
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 0-14
- 15-44
- 45 +
- 45 +
- 0-14
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 15-44
- 45 +
- 15-44
- 45 +
- 15-44
- 45 +
Tissue
(9)
15.
17.
20.
20.
23.
25.
20.
25.
15.
12.
20.
18.
18.
21.
21.
12.
22.
15.
25.
19.
20.
6.
22.
22.
5.
18.
22.
18.
25.
17.
17.
21.
22.
18.
16.
18.
23.
24.
19.
21.
19.
21.
10.
13.
17.
11.
Wt
0
4
7
0
6
5
3
0
5
7
8
6
9
6
6
6
2
4
6
0
6
0
4
0
1
8
4
1
3
8
3
1
6
3
7
7
2
3
3
9
6
4
1
8
8
6
CAS No.:
Fraction:
RRf:
Amount Concentration
RRT (Total ug) (ug/g)
ND
.602
.605
.602
ND
ND
ND
.602
.603
.605
ND
.599
ND
ND
.610
ND
ND
.612
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.623
ND
.593
.607
.602
.612
ND
ND
ND
.607
.607
.603
.607
.609
.605
ND
ND
ND
ND
.031
.135
.113
ND
ND
ND
.171
.032
.046
ND
.191
ND
ND
.020
ND
ND
.070
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.095
ND
.098
.176
.161
.099
ND
ND
ND
.088
.115
.082
.054
.099
.044
ND
ND
ND
ND
.001
.006
.005
ND
ND
ND
.006
.002
.003
ND
.010
ND
ND
<.001
ND
ND
.004
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.003
ND
.005
.008
.007
.005
ND
ND
ND
.003
.006
.003
.002
.004
.004
ND
ND
ND
79-01-6
VOA
0.335
Analysis
Date
6/19/84
6/20/84
6/20/84
6/20/84
6/21/84
6/26/84
6/27/84
6/27/84
6/27/84
6/28/84
6/28/84
6/28/84
6/29/84
6/29/84
7/2/84
7/3/84
7/3/84
7/3/84
7/9/84
7/9/84
7/9/84
7/1 1/84
7/1 1/84
7/1 1/84
7/1 1/84
7/1 2/84
7/1 2/84
7/12/84
7/1 3/84
7/13/84
7/13/84
7/1 6/84
7/1 6/84
7/1 6/84
7/1 7/84
7/1 7/84
7/1 7/84
7/18/84
7/20/84
7/18/84
7/18/84
7/18/84
7/20/84
7/20/84
7/20/84
7/20/84
A-14
-------
APPENDIX B
6% FLORISIL FRACTION SEMIVOLATILE COMPOSITE
SUMMARY REPORTS
B-l
-------
Appendix B-1
FY82 6% SMV Adipose Composite Summary
Data Report -
MRI Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
36
55
46
63
82
67
77
70
58
52
42
49
43
50
64
53
83
85
71
56
78
59
61
73
75
37
68
69
65
84
79
41
51
72
60
66
62
81
74
76
54
44
48
57
Anthracene
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
1 -
1 -
1 -
1 -
1 -
2 -
1 -
2 -
2 -
1 -
1 -
2-
3 -
3 -
4 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
3 -
2 -
3 -
4 -
2 -
1 -
1 -
1 -
MD
Q4
PA
WN
WS
SA
ES
SA
BJ
MA
N=
MA
NE
MA
WN
MA
WS
WS
SA
B4
ES
ai
BI
SA
SA
MD
SA
SA
WN
WS
ES
MD
MA
SA
BJ
WN
B4
ES
SA
SA
MA
N=
PA
EN
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45 +
- 45 +
- 45 +
- 45+
- 45+
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
Tissue
(9)
9.
18.
19.
23.
11.
20.
28.
19.
21.
20.
19.
23.
21.
25.
20.
26.
22.
21.
19.
21.
19.
21.
20.
17.
18.
18.
26.
20.
22.
22.
20.
21.
16.
26.
26.
21.
23.
21.
18.
17.
18.
26.
22.
19.
Wt
0
1
7
4
1
7
1
1"
2
2
1
0
9
2
6
1
7
9
5
6
9
4
2
9
2
3
4
0
5
4
7
0
2
1
2
4
2
1
0
6
1
7
0
8
RRT
ND
ND
ND
ND
ND
ND
ND
ND
ND
MD
ND
ND
ND
ND
ND
ND
1.002
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
CAS No.:
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.005
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
<.001
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
120-12->
6% SMV
1.43S
Analysis
Date
4/19/84
4/1 9/84
4/1 9/84
5/7/84
5/8/84
5/1 1/84
6/1/84
6/5/84
6/5/84
6/13/84
4/6/84
4/6/84
4/5/84
4/5/84
5/4/84
6/12/84
5/4/84
6/18/84
6/18/84
4/20/84
5/1 0/84
6/4/84
6/5/84
6/5/84
6/6/84
4/1 9/84
4/20/84
4/20/84
5/7/84
5/7/84
5/1 0/84
5/1 0/84
6/1 /84
6/4/84
6/4/84
6/5/84
6/6/84
6/6/84
6/1 2/84
6/12/84
6/1 2/84
4/15/84
4/1 9/84
4/20/84
B-2
-------
Appendix B-2
FY82 6% SMV Adipose Composite Summary
Data Report -
MRI Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
'82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
36
55
46
63
82
67
77
70
58
52
42
49
43
50
64
53
83
85
71
56
78
59
61
73
75
37
68
69
65
84
79
41
51
72
60
66
62
81
74
76
54
44
48
57
Biphenyl
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
1 -
1 -
1 -
1 -
1 -
2 -
1 -
2 -
2 -
1 -
1 -
2 -
3 -
3 -
4 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
3 -
2 -
3 -
4 -
2 -
1 -
1 -
1 -
MD
BJ
PA
WN
WS
SA
ES
SA
BJ
MA
NE
MA
NE
MA
WN
MA
WS
WS
SA
ai
ES
W
BJ
SA
SA
MD
SA
SA
WN
WS
ES
MD
MA
SA
BM
WN
BM
ES
SA
SA
MA
NE
PA
BM
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
- 45+
- 45+
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
Tissue
(g)
9.
18.
19.
23.
11.
20.
28.
19.
21.
20.
19.
23.
21.
25.
20.
26.
22.
21.
19.
21.
19.
21.
20.
17.
18.
18.
26.
20.
22.
22.
20.
21.
16.
26.
26.
21.
23.
21.
18.
17.
18.
26.
22.
19.
Wt
0
1
7
4
1
7
1
1
2
2
1
0
9
2
6
1
7
9
5
6
9
4
2
9
2
3
4
0
5
4
7
0
2
1
2
4
2
1
0
6
1
7
0
8
RRT
ND
ND
ND
.665
ND
.665
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.662
ND
ND
ND
.674
ND
ND
ND
ND
ND
ND
.667
.667
ND
ND
.662
ND
ND
ND
ND
ND
.656
ND
ND
ND
ND
.672
ND
CAS No.:-
Fraction:
RRf:
Amount Concentration
(Total ug) ("9/9)
ND
ND
ND .
.009
ND
.026
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.014
ND
ND
ND
.012
ND
ND
ND
ND
ND
ND
.017
.014
ND
ND
.014
ND
ND
ND
ND
ND
.022
ND
ND
ND
ND
.009
ND
ND
ND
ND
<.001
ND
.001
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
<.001
ND
ND
ND
<.001
ND
ND
ro
ND
ND
ND
<.001
<.001
ND
ND
<.001
ND
ND
ND
ND
ND
.001
ND
ND
ND
ND
<.001
ND
92-52-4
6% SMV
1.286
Analysis
Date
4/19/84
4/19/84
4/19/84
5/7/84
5/8/84
5/1 1 /84
6/1/84
6/5/84
6/5/84
6/13/84
4/6/84
4/6/84
4/5/84
4/5/84
5/4/84
6/12/84
5/4/84
6/18/84
6/18/84
4/20/84
5/10/84
6/4/84
6/5/84
6/5/84
6/6/84
4/1 9/84
4/20/84
4/20/84
5/7/84
5/7/84
5/10/84
5/10/84
6/1/84
6/4/84
6/4/84
6/5/84
6/6/84
6/6/84
6/12/84
6/12/84
6/12/84
4/15/84
4/1 9/84
4/20/84
B-3
-------
Appendix B-3
FY82 6% SMV Adipose Composite Summary
Data Report -
MR1 Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
36
55
46
63
82
67
77
70
58
52
42
49
43
50
64
53
83
85
71
56
78
59
61
73
75
37
68
69
65
84
79
41
51
72
60
66
62
81
74
76
54
44
48
57
Cymene
(isopropyltoluene)
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
1 -
1 -
1 -
1 -
1 -
2 -
1 -
2 -
2 -
1 -
1 -
2 -
3 -
3 -
4 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
3 -
2 -
3 -
4 -
2 -
1 -
1 -
1 -
MD
BJ
PA
V\M
WS
SA
ES
SA
at
MA
N=
MA
NE
MA
WN
MA
WS
WS
SA
Bl
ES
EN
EN
SA
SA
MO
SA
SA
WN
WS
ES
MD
MA
SA
EN
WN
EN
ES
SA
SA
MA
NE
PA
EN
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45 +
- 45 +
- 45+
- 45+
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
- 45 +
- 45 +
- 45+
- 45 +
- 45 +
- 45 +
Tissue
(g)
9
18
19
23
11
20
28
19
21
20
19
23
21
25
20
26
22
21
19
21
19
21
20
17
18
18
26
20
22
22
20
21
16
26
26
21
23
21
18
17
18
26
22
19
Wt
.0
.1
.7
.4
.1
.7
.1
.1
.2
.2
.1
.0
.9
.2
.6
.1
.7
.9
.5
.6
.9
.4
.2
.9
.2
.3
.4
.0
.5
.4
.7
.0
.2
.1
.2
.4
.2
.1
.0
.6
.1
.7
.0
.8
CAS No.:
Fraction:
RRf:
Amount Concentration
RRT (Total ug) (ug/g)
.342
.344
.344
.331
.327
.330
.292
.293
ND
.325
.292
.332
.328
.331
.345
.329
.325
.317
.322
.342
.347
.295
.295
.277
.281
.338
.344
.342
.331
.345
ND
.331
.316
.338
.282
.293
.286
.288
.311
ND
.317
.327
.348
.344
.005
.008
.011
.016
.010
.080
.034
.034
ND
.002
.001
.002
.014
.011
.018
.007
.029
.006
.046
.018
.026
.007
.018
.101
.051
.009
.087
.067
.017
.027
to
.018
.009
.053
.041
.009
.027
.058
.031
ND
.027
.009
.011
.017
<.001
<.001
<.001
<.001
<.001
.003
.001
.001
ND
<.001
<.001
<.001
<.001
<.001
<.001
<.001
.001
<.001
.002
<.001
.001
<.001
<.001
.005
.002
<.001
.003
.003
<.001
.001
ND
<.001
<.001
.002
.001
<.001
.001
.002
.001
ND
.001
<.001
<.001
<.001
2P-87-6
6% SMV
1.620
Analysis
Date
4/19/84
4/19/84
4/19/84
5/7/84
5/8/84
5/1 1/84
6/1/84
6/5/84
6/5/84
6/13/84
4/6/84
4/6/84
4/5/84
4/5/84
5/4/84
6/12/84
5/4/84
6/18/84
6/18/84
4/20/84
5/10/84
6/4/84
6/5/84
6/5/84
6/6/84
4/19/84
4/20/84
4/20/84
5/7/84
5/7/84
5/10/84
5/1 0/84
6/1/84
6/4/84
6/4/84
6/5/84
6/6/84
6/6/84
6/12/84
6/12/84
6/12/84
4/15/84
4/19/84
4/20/84
B-4
-------
Appendix B-4
FY82 6% SMV Adipose Composite Summary
Data Report -
MRI Sample
Number
82-36
82-55
82-46
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
63
82
67
77
70
58
52
42
49
43
50
64
53
83
85
71
56
78
59
61
73
75
37
68
69
65
84
79
41
51
72
60
66
62
81
74
76
54
44
48
57
Dibenzofuran
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
1 -
1 -
1 -
1 -
1 -
2 -
1 -
2 -
2 -
1 -
1 -
2 -
3 -
3 -
4 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
3 -
2 -
3 -
4 -
2 -
1 -
1 -
1 -
MD
Bi
PA
V\M
VWS
SA
E5
SA
m
MA
NE
MA
NE
MA
WN
MA
WS
W5
SA
W
ES
ftl
Bt
SA
SA
MD
SA
SA
V\N
WS
ES
MD
MA
SA
Rl
V\N
Rl
ES
SA
SA
MA
NE
PA
EN
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45 +
- 45 +
- 45+
- 45 +
- 45+
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
- 45 +
- 45 +
- 45+
Tissue
(9)
9
18
19
23
11
20
28
19
21
20
19
23
21
25
20
26
22
21
19
21
19
21
20
17
18
18
26
20
22
22
20
21
16
26
26
21
23
21
18
17
18
26
22
19.
Wt
.0
.1
.7
.4
.1
.7
.1
.1
.2
.2
.1
.0
.9
.2
.6
.1
.7
.9
.5
.6
.9
.4
.2
.9
.2
.3
.4
.0
.5
.4
.7
.0
.2
.1
.2
.4
.2
.1
.0
.6
.1
.7
.0
,8
RRT
ND
ND
ND
ND
ND
.786
ND
ND
ND
ND
ND
ND
ND
.793
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.788
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
CAS No.:,
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
ND
ND
ND
ND
ND
.011
ND
ND
ND
ND
ND
ND
ND
.014
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.023
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
c.001
ND
ND
ND
ND
ND
ND
ND
<.001
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
<.001
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
132-64-9
6% SMV
1.272
Analysis
Date
4/19/84
4/19/84
4/19/84
5/7/84
5/8/84
5/1 1 /84
6/1/84
6/5/84
6/5/84
6/13/84
4/6/84
4/6/84
4/5/84
4/5/84
5/4/84
6/12/84
5/4/84
6/18/84
6/18/84
4/20/84
5/10/84
6/4/84
6/5/84
6/5/84
6/6/84
4/1 9/84
4/20/84
4/20/84
5/7/84
5/7/84
5/10/84
5/10/84
6/1 /84
6/4/84
6/4/84
6/5/84
6/6/84
6/6/84
6/12/84
6/12/84
6/12/84
4/15/84
4/1 9/84
4/20/84
B-5
-------
Appendix B-5
FY82 6% SMV Adipose Composite Summary
Data Report -
MR! Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
36
55
46
63
82
67
77
70
58
52
42
49
43
50
64
53
83
85
71
56
78
59
61
73
75
37
68
69
65
84
79
41
51
72
60
66
62
81
74
76
54
44
48
57
Diphenyl ether (1,1'-Oxybisbenzene)
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2-
2 -
1 -
1 -
1 -
1 -
1 -
2 -
1 -
2 -
2 -
1 -
1 -
2 -
3 -
3 -
4 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
3 -
2 -
3 -
4 -
2 -
1 -
1 -
1 -
MD
BJ
PA
WN
WS
SA
ES
SA
Bi
MA
NE
MA
ME
MA
WN
MA
WS
WS
SA
ai
ES
at
Bi
SA
SA
MD
SA
SA
WN
WS
ES
MO
MA
SA
EN
WN
EM
ES
SA
SA
MA
N=
PA
EN
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
- 45 +
Tissue
(g)
9.
18.
19.
23.
11.
20.
28.
19.
21.
20.
19.
23.
21.
25.
20.
26.
22.
21.
19.
21.
19.
21.
20.
17.
18.
18.
26.
20.
22.
22.
20.
21.
16.
26.
26.
21.
23.
21.
18.
17.
18.
26.
22.
19.
Wt
0
1
7
4
1
7
1
1
2
2
1
0
9
2
6
1
7
9
5
6
9
4
2
9
2
3
4
0
5
4
7
0
2
1
2
4
2
1
0
6
1
7
0
8
RRT
MD
.689
.688
.684
.683
.684
.678
.678
.682
.683
.679
.696
.693
.695
.693
.684
.681
.674
.680
.689
.693
.678
.680
MD
.677
.687
.688
.686
.686
.692
ND
.781
MD
.671
.675
.677
.676
.676
.675
.674
.678
.694
.690
.689
Amount
(Total ug)
MD
.021
.053
.064
.059
.941
.480
.111
.030
.048
.004
.085
.079
.252
.540
.334
.236
.188
.373
.208
.326
.034
.073
MD
.208
.239
1.214
.594
.538
.718
MD
.139
MD
.607
.260
.124
.286
.171
.075
.049
.117
.097
.134
.212
CAS No.:
Fraction:
RRf:
Concentration
(ug/g)
MD
.001
.002
.002
.005
.045
.017
.005
.001
.002
<.001
.003
.003
.010
.026
.012
.010
.008
.019
.009
.016
.001
.003
MD
.011
.013
.045
.029
.023
.032
MD
.006
MD
.023
.009
.005
.012
.008
.004
.002
.006
.003
.006
.010
101-84-f
6% SMV
0.651
Analysis
Date
4/19/84
4/19/84
4/1 9/84
5/7/84
5/8/84
5/1 1/84
6/1/84
6/5/84
6/5/84
6/13/84
4/6/84
4/6/84
4/5/84
4/5/84
5/4/84
6/12/84
5/4/84
6/18/84
6/18/84
4/20/84
5/10/84
6/4/84
6/5/84
6/5/84
6/6/84
4/19/84
4/20/84
4/20/84
5/7/84
5/7/84
5/10/84
5/10/84
6/1/84
6/4/84
6/4/84
6/5/84
6/6/84
6/6/84
6/12/84
6/12/84
6/12/84
4/15/84
4/1 9/84
4/20/84
B-6
-------
Appendix B-6
FY82 6% SMV Adipose Composite Summary
Data Report -
MRI Sample
Number
82-36
82-55
82-46
82-63
82-82
82-67
82-77
82-70
82-58
82-52
82-42
82-49
82-43
82-50
82-64
82-53
82-83
82-85
82-71
82-56
82-78
82-59
82-61
82-73
82-75
82-37
82-68
82-69
82-65
82-84
82-79
82-41
82-51
82-72
82-60
82-66
82-62
82-81
82-74
82-76
82-54
82-44
82-48
82-57
Limonene
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
1 -
1 -
1 -
1 -
1 -
2 -
1 -
2 -
2-
1 -
1 -
2 -
3 -
3 -
4 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
3 -
2 -
3 -
4 -
2 -
1 -
1 -
1 -
MD
ai
PA
V\N
WS
SA
ES
SA
EN
MA
N=
MA
NE
MA
V\N
MA
WS
WS
SA
Rl
ES
m
ai
SA
SA
MD
SA
SA
\AM
WS
ES
MD
MA
SA
B4
WN
BM
GS
SA
SA
MA
NE
PA
ai
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45+
- 45+
- 45+
- 45+
- 45+
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
- 45+
- 45 +
Tissue Wt
(g)
9.0
18.1
19.7
23.4
11.1
20.7
28.1
19.1
21.2
20.2
19.1
23.0
21.9
25.2
20.6
26.1
22.7
21.9
19.5
21.6
19.9
21.4
20.2
17.9
18.2
18.3
26.4
20.0
22.5
22.4
20.7
21.0
16.2
26.1
26.2
21.4
23.2
21:1
18.0
17.6
18.1
26.7
22.0
19.8
RRT
.346
.348
.347
.335
.331
.334
.296
.297
ND
.327
.296
.337
.333
.336
.349
.333
.329
.319
.326
.346
.351
.299
.298
.281
.285
.342
.348
.345
.335
.349
ND
.335
.320
ND
.286
.297
.289
.292
.315
.314
.321
.331
.352
.347
CAS No.:
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
.178
.084
.806
.353
.077
.250
.382
.331
ND
.027
.007
.023
.184
.410
.385
.126
.272
.146
.962
.235
.392
.106
.222
.555
.398
.067
.423
.957
.299
.382
ND
.146
.313
ND
.477
.154
.266
.984
.306
.271
.716
.149
.347
.276
.019
.004
.040
.015
.006
.012
.013
.017
to
.001
<.001
.001
.008
.016
.018
.004
.012
.006
.049
.010
.019
.004
.010
.031
.021
.003
.016
.047
.013
.017
ND
.006
.019
ND
.018
.007
.011
.046
.017
.015
.039
.005
.015
.013
138-86-3
6% SMV
0.150
Analysis
Date
4/19/84
4/19/84
4/19/84
5/7/84
5/8/84
5/1 1/84
6/1/84
6/5/84
6/5/84
6/13/84
4/6/84
4/6/84
4/5/84
4/5/84
5/4/84
6/12/84
5/4/84
6/18/84
6/18/84
4/20/84
5/10/84
6/4/84
6/5/84
6/5/84
6/6/84
4/19/84
4/20/84
4/20/84
5/7/84
5/7/84
5/10/84
5/10/84
6/1/84
6/4/84
6/4/84
6/5/84
6/6/84
6/6/84
6/12/84
6/12/84
6/12/84
4/15/84
4/19/84
4/20/84
B-7
-------
Appendix B-7
FY82 6% SMV Adipose Composite Summary
Data Report -
MRI Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
36
55
46
63
82
67
77
70
58
52
42
49
43
50
64
53
83
85
71
56
78
59
61
73
75
37
68
69
65
84
79
41
51
72
60
66
62
81
74
76
54
44
48
57
Safrole
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
1 -
1 -
1 -
1 -
1 -
2 -
1 -
2 -
2 -
1 -
1 -
2 -
3 -
3 -
4 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
3 -
2-
3 -
4 -
2 -
1 -
1 -
1 -
MD
BJ
PA
Wsl
W3
SA
ES
SA
BJ
MA
NE
MA
NE
MA
WN
MA
WS
WS
SA
RJ
ES
EN
EN
SA
SA
MO
SA
SA
WN
WS
ES
MO
MA
SA
EN
WN
EN
ES
SA
SA
MA
NE
PA
EN
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
Tissue
(9)
9.
18.
19.
23.
11.
20.
28.
19.
21.
20.
19.
23.
21.
25.
20.
26.
22.
21.
19.
21.
19.
21.
20.
17.
18.
18.
26.
20.
22.
22.
20.
21.
16.
26.
26.
21.
23.
21.
18.
17.
18.
26.
22.
19.
Wt
0
1
7
4
1
7
1
1
2
2
1
0
9
2
6
1
7
9
5
6
9
4
2
9
2
3
4
0
5
4
7
0
2
1
2
4
2
1
0
6
1
7
0
8
RRT
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.593
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.572
ND
ND
ND
ND
ND
ND
ND
.572
.590
ND
ND
CAS No.:
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.011
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.033
ND
ND
ND
ND
ND
ND
ND
1.150
.102
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
<.001
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.002
ND
ND
ND
ND
ND
ND
ND
.063
.003
ND
ND
94-59-7
6% SMV
0.478
Analysis
Date
4/19/84
4/19/84
4/19/84
5/7/84
5/8/84
5/1 1/84
6/1/84
6/5/84
6/5/84
6/13/84
4/6/84
4/6/84
4/5/84
4/5/84
5/4/84
6/12/84
5/4/84
6/18/84
6/18/84
4/20/84
5/1 0/84
6/4/84
6/5/84
6/5/84
6/6/84
4/1 9/84
4/20/84
4/20/84
5/7/84
5/7/84
5/1 0/84
5/1 0/84
6/1 /84
6/4/84
6/4/84
6/5/84
6/6/84
6/6/84
6/12/84
6/1 2/84
6/12/84
4/1 5/84
4/1 9/84
4/20/84
B-8
-------
Appendix B-8
FY82 6% SMV Adipose Composite Summary
Data Report -
MR! Sample
Number
82-36
82-55
82-46
52-63
82-82
32-67
32-77
82-70
82-58
82-52
82-42
82-49
82-43
82-50
82-64
82-53
82-83
82-85
82-71
82-56
82-78
82-59
82-61
82-73
82-75
82-37
82-68
82-69
82-65
82-84
82-79
82-41
82-51
82-72
82-60
82-66
82-62
82-81
82-74
82-76
82-54
82-44
82-48
82-57
1 ,2,4-Trimethylbenzene
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2-
2 -
2 -
1 -
1 -
1 -
1 -
1 -
2 -
1 -
2 -
2 -
1 -
1 -
2 -
3 -
3 -
4 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
3 -
2 -
3 -
4 -
2 -
1 -
1 -
1 -
MD
Rl
PA
WM
WS
SA
ES
SA
Bi
MA
NE
MA
NE
MA
WM
MA
WS
WS
SA
BJ
ES
EN
EN
SA
SA
MD
SA
SA
UN
WS
ES
MD
MA
SA
EN
\AW
EN
ES
SA
SA
MA
NE
PA
EN
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45-1-
- 45i-
- 45+
- 45+
- 45+
- 45+
- 45+
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
Tissue Wt
(9)
9.0
18.1
19.7
23.4
11.1
20.7
28.1
19.1
21.2
20.2
19.1
23.0
21.9
25.2
20.6
26.1
22.7
21.9
19.5
21.6
19.9
21.4
20.2
17.9
18.2
18.3
26.4
20.0
22.5
22.4
20.7
21.0
16.2
26.1
26.2
21.4
23.2
21.1
18.0
17.6
18.1
26.7
22.0
19.8
RRT
.315
.320
.316
.305
.300
.305
.263
.262
ND
.297
.261
.301
.298
.303
.318
.302
.300
.289
.296
.316
.321
.263
.265
.247
.251
.312
.320
.317
.304
.319
ND
.304
.289
.273
.250
.263
.256
.261
.282
.283
.289
.297
.323
.318
CAS No.: -
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
.051
.037
.105
.026
.047
1.080
.084
.115
ND
.028
.016
.037
.045
.040
.039
.057
.058
.010
.541
.068
.060
.010
.037
.764
.409
.024
.787
.618
.093
.070
ND
.054
.040
.132
.051
.015
.073
.023
.306
.031
.062
.052
.030
.062
.005
.002
.005
.001
.004
.052
.003
.006
ND
.001
<.001
.001
.002
.001
.001
.002
.002
<.001
.027
.003
.003
<.001
.001
.042
.022
.001
.029
.030
.004
.003
ND
.002
.002
.005
.001
<.001
.003
.001
.017
.001
.003
.001
.001
.003
95-63-6
6% SMV
1.220
Analysis
Date
4/19/84
4/1 9/84
4/19/84
5/7/84
5/8/84
5/1 1/84
6/1/84
6/5/84
6/5/84
6/13/84
4/6/84
4/6/84
4/5/84
4/5/84
5/4/84
6/12/84
5/4/84
6/18/84
6/18/84
4/20/84
5/10/84
6/4/84
6/5/84
6/5/84
6/6/84
4/19/84
4/20/84
4/20/84
5/7/84
5/7/84
5/10/84
5/10/84
6/1/84
6/4/84
6/4/84
6/5/84
6/6/84
6/6/84
6/12/84
6/12/84
6/12/84
4/15/84
4/1 9/84
4/20/84
B-9
-------
Appendix B-9
FY82 6% SMV Adipose Composite Summary
Data Report -
MRI Sample
Number
82-36
82-55
82-46
82-63
82-82
82-67
82-77
82-70
82-58
82-52
82-42
82-49
82-43
82-50
82-64
82-53
82-83
82-85
82-71
82-56
82-78
82-59
82-61
82-73
82-75
82-37
82-68
82-69
82-65
82-84
82-79
82-41
82-51
82-72
82-60
82-66
82-62
82-81
82-74
82-76
82-54
82-44
82-48
82-57
2,6-Xylidine
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2-
1 -
1 -
1 -
1 -
1 -
2 -
1 -
2 -
2 -
1 -
1 -
2-
3 -
3 -
4 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
3 -
2 -
3 -
4 -
2 -
1 -
1 -
1 -
MD
BJ
PA
WN
WS
SA
ES
SA
BJ
MA
N=
MA
N=
MA
WN
MA
WS
WS
SA
BM
ES
ai
Bl
SA
SA
MD
SA
SA
WN
WS
ES
MD
MA
SA
EN
WN
EN
ES
SA
SA
MA
N=
PA
EN
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45+
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
- 45 +
Tissue Wt
(9)
9.0
18.1
19.7
23.4
11.1
20.7
28.1
19.1
21.2
20.2
19.1
23.0
21.9
25.2
20.6
26.1
22.7
21.9
19.5
21.6
19.9
21.4
20.2
17.9
18.2
18.3
26.4
20.0
22.5
22.4
20.7
21.0
16.2
26.1
26.2
21.4
23.2
21.1
18.0
17.6
18.1
26.7
22.0
19.8
CAS No.:
Fraction:
RRf:
Amount Concentration
RRT (Total ug) (ug/g)
MD
ND
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
.479
MD
MD
MD
MD
MD
MD
.471
.467
MD
MD
.464
MD
MD
.437
MD
.440
.442
MD
.450
.456
MD
.479
.475
MD
MD
MD
MD
MD
MD
MD
to
ND
MD
to
MD
MD
ND
MD
MD
MD
MD
MD
M)
.014
M)
M)
M)
MD
MD
MD
.005
.291
MD
MD
.422
ND
ND
.198
ND
.328
.036
ND
.318
.008
ND
.207
.050
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
ND
MD
MD
MD
MD
MD
MD
<.001
MD
MD
MD
MD
MD
MD
<.001
.012
MD
MD
.020
MD
MD
.007
MD
.014
.001
MD
.018
<.001
MD
.009
.002
87-62-7
6% SMV
0.811
Analysis
Date
4/19/84
4/19/84
4/19/84
5/7/84
5/8/84
5/1 1/84
6/1 /84
6/5/84
6/5/84
6/13/84
4/6/84
4/6/84
4/5/84
4/5/84
5/4/84
6/12/84
5/4/84
6/1 8/84
6/1 8/84
4/20/84
5/10/84
6/4/84
6/5/84
6/5/84
6/6/84
4/1 9/84
4/20/84
4/20/84
5/7/84
5/7/84
5/1 0/84
5/10/84
6/1/84
6/4/84
6/4/84
6/5/84
6/6/84
6/6/84
6/12/84
6/12/84
6/12/84
4/15/84
4/19/84
4/20/84
B-10
-------
APPENDIX C
15/50% FLORISIL FRACTION SEMIVOLATILE COMPOSITE
SUMMARY REPORTS
C-l
-------
Appendix C-1
FY82 15/50% SMV Adipose Composite Summary
Data Report -
MRI Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
67
82
46
36
42
49
55
63
77
52
70
58
43
50
80
47
61
75
73
71
53
83
85
59
37
64
56
78
68
51
76
81
48
57
44
74
62
66
60
41
79
69
65
54
72
84
Bis(2-ethylhexyi)adipate
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
1 -
1 -
2 -
1 -
3 -
4 -
3 -
2 -
2 -
1 -
2 -
2-
1 -
1 -
1 -
1 -
1 -
1 -
4 -
2 -
1 -
1 -
1 -
3 -
3 -
2 -
2 -
1 -
1 -
1 -
1 -
2 -
2 -
1 -
SA
WS
PA
MO
NE
MA
BJ
WN
ES
MA
SA
eu
NE
MA
ES
PA
BJ
SA
SA
SA
MA
WS
WS
BJ
MD
WN
BJ
ES
SA
MA
SA
ES
PA
EN
NE
SA
EN
WN
EN
MO
ES
SA
WN
MA
SA
WS
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
Tissue
(9)
20.
11.
19.
9.
19.
23.
18.
23.
28.
20.
19.
21.
21.
25.
25.
21.
20.
18.
17.
19.
26.
22.
21.
21.
18.
20.
21.
19.
26.
16.
17.
21.
22.
19.
26.
18.
23.
21.
26.
21.
20.
20.
22.
18.
26.
22.
Wt
7
1
7
0
1
0
1
4
1
2
1
2
9
2
7
6
2
2
9
5
1
7
9
4
3
6
6
9
4
2
6
1
0
8
7
0
2
4
2
0
7
0
5
1
1
4
RRT
1.363
ID
tO
ND
ND
ND
NO
ND
to
tO
ND
ND
to
to
to
to
ND
ND
to
1.379
1.379
ND
1.379
ND
to
to
1.360
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
to
1.373
1.364
ND
ND
1.370
ND
CAS No.:
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
.124
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.551
1.987
ND
2.840
ND
ND
ND
.053
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
3.426
.085
ND
ND'
.864
ND
.006
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.028
.076
ND
.129
ND
ND
ND
.002
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.165
.004
ND
ND
.033
ND
103-23-1
15/50% SMV
0.732
Analysis
Date
4/26/84
5/14/84
4/24/84
4/24/84
4/23/84
4/23/84
4/25/84
5/10/84
5/14/84
6/13/84
6/1 4/84
6/14/84
4/1 5/84
4/12/84
6/1 5/84
4/27/84
6/18/84
6/1 8/84
6/1 6/84
6/13/84
6/13/84
5/9/84
6/15/84
6/14/84
4/25/84
5/1 1/84
4/26/84
5/14/84
4/24/84
4/24/84
6/1 8/84
6/1 6/84
4/25/84
4/26/84
4/23/84
6/1 6/84
6/1 6/84
6/1 5/84
6/1 4/84
5/1 4/84
5/1 4/84
4/24/84
5/1 0/84
6/13/84
6/1 4/84
5/10/84
C-2
-------
Appendix C-2
FY82 15/50% SMV Adipose Composite Summary
Data Report -
MR! Sample
Number
82-67
82-82
82-46
82-36
82-42
82-49
82-55
82-63
82-77
82-52
82-70
82-58
82-43
82-50
82-80
82-47
82-61
82-75
82-73
82-71
82-53
82-83
82-85
82-59
82-37
82-64
82-56
82-78
82-68
82-51
82-76
82-81
82-48
82-57
82-44
82-74
82-62
82-66
82-60
82-41
82-79
82-69
82-65
82-54
82-72
82-84
Butyl glycol
butyl
phthalate
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
1 -
1 -
2 -
1 -
3 -
4 -
3 -
2 -
2 -
1 -
2 -
2 -
1 -
1 -
1 -
1 -
1 -
1 -
4 -
2 -
1 -
1 -
1 -
3 -
3 -
2 -
2 -
1 -
1 -
1 -
1 -
2 -
2 -
1 -
SA
VYS
PA
MD
NE
MA
BJ
V\N
EB
MA
SA
Ri
NE
MA
ES
PA
EN
SA
SA
SA
MA
WS
V\S
EN
MD
V\N
EN
ES
SA
MA
SA
ES
PA
EN
N=
SA
EN
V\N
EN
MO
ES
SA
V\M
MA
SA
WS
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
Tissue Wt
(9)
20.7
11.1
19.7
9.0
19.1
23.0
18.1
23.4
28.1
20.2
19.1
21.2
21.9
25.2
25.7
21.6
20.2
18.2
17.9
19.5
26.1
22.7
21.9
21.4
18.3
20.6
21.6
19.9
26.4
16.2
17.6
21.1
22.0
19.8
26.7
18.0
23.2
21.4
26.2
21.0
20.7
20.0
22.5
18.1
26.1
22.4
RRT
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
1.333
ND
ND
1.335
ND
ND
ND
ND
ND
1.326
ND
ND
1.326
ND
ND
ND
ND
ND
ND
ND
1.335
ND
1.329
ND
ND
ND
1.326
ND
1.328
ND
CAS No.:,
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.053
ND
ND
1.281
ND
ND
ND
ND
ND
1.873
ND
ND
.736
ND
ND
ND
ND
ND
ND
ND
.267
ND
.037
ND
ND
ND
.247
ND
.120
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.002
ND
ND
.065
ND
ND
ND
ND
ND
.090
ND
ND
.027
ND
ND
ND
ND
ND
ND
ND
.011
ND
.001
ND
ND
ND
.011
ND
.004
ND
85-70-1
15/50% SMV
1.330
Analysis
Date
4/26/84
5/14/84
4/24/84
4/24/84
4/23/84
4/23/84
4/25/84
5/1 0/84
5/14/84
6/13/84
6/14/84
6/14/84
4/15/84
4/12/84
6/15/84
4/27/84
6/18/84
6/18/84
6/16/84
6/13/84
6/13/84
5/9/84
6/15/84
6/14/84
4/25/84
5/1 1 /84
4/26/84
5/14/84
4/24/84
4/24/84
6/18/84
6/16/84
4/25/84
4/26/84
4/23/84
6/1 6/84
6/16/84
6/15/84
6/14/84
5/14/84
5/14/84
4/24/84
5/1 0/84
6/13/84
6/14/84
5/1 0/84
C-3
-------
Appendix C-3
FY82 15/50% SMV Adipose Composite Summary
Data Report -
MR! Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
67
82
46
36
42
49
55
63
77
52
70
58
43
50
80
47
61
75
73
71
53
83
85
59
37
64
56
78
68
51
76
81
48
57
44
74
62
66
60
41
79
69
65
54
72
84
Carbaryl
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
1 -
1 -
2 -
1 -
3 -
4 -
3 -
2 -
2 -
1 -
2 -
2 -
1 -
1 -
1 -
1 -
1 -
1 -
4 -
2 -
1 -
1 -
1 -
3 -
3 -
2 -
2 -
1 -
1 -
1 -
1 -
2 -
2 -
1 -
SA
WS
PA
MD
NE
MA
ai
WN
ES
MA
SA
Bl
NE
MA
ES
PA
EN
SA
SA
SA
MA
WS
WS
EN
MO
WN
EN
ES
SA
MA
SA
ES
PA
EN
NE
SA
EN
WN
EN
MD
ES
SA
WN
MA
SA
WS
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
- 45 +
- 45+
- 45+
- 45+
- 45+
- 45+
Tissue
(g)
20
11
19
9
19
23
18
23
28
20
19
21
21
25
25
21
20
18
17
19
26
22
21
21
18
20
21
19
26
16
17
21
22
19
26
18
23
21
26
21
20
20
22
18
26
22
Wt
.7
.1
.7
.0
.1
.0
.1
.4
.1
.2
.1
.2
.9
.2
.7
.6
.2
.2
.9
.5
.1
.7
.9
.4
.3
.6
.6
.9
.4
.2
.6
.1
.0
.8
.7
.0
.2
.4
.2
.0
.7
.0
.5
.1
.1
.4
RRT
ND
ro
ISO
ro
MD
IO
NO
ND
ND
ND
ND
ND
ro
ro
10
ro
to
10
to
ND
ro
ro
IO
ro
ND
ro
10
ND
ND
ND
ro
ro
IO
ro
ND
ND
ro
IO
ro
ro
ND
1.081
IO
IO
IO
to
CAS No.:
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
IO
IO
IO
ro
IO
IO
10
10
ro
IO
10
IO
ro
ND
ND
IO
IO
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ro
46.501
NO
IO
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
IO
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
2.325
ND
ND
ND
ND
63-25-2
15/50% SMV
0.212
Analysis
Date
4/26/84
5/14/84
4/24/84
4/24/84
4/23/84
4/23/84
4/25/84
5/10/84
5/14/84
6/13/84
6/14/84
6/14/84
4/15/84
4/12/84
6/15/84
4/27/84
6/18/84
6/18/84
6/16/84
6/13/84
6/13/84
5/9/84
6/1 5/84
6/14/84
4/25/84
5/1 1/84
4/26/84
5/14/84
4/24/84
4/24/84
6/18/84
6/1 6/84
4/25/84
4/26/84
4/23/84
6/16/84
6/16/84
6/15/84
6/14/84
5/14/84
5/14/84
4/24/84
5/1 0/84
6/13/84
6/14/84
5/10/84
C-4
-------
Appendix C-4
FY82 15/50% SMV Adipose Composite Summary
Data Report -
MRI Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
67
82
46
36
42
49
55
63
77
52
70
58
43
50
80
47
61
75
73
71
53
83
85
59
37
64
56
78
68
51
76
81
48
57
44
74
62
66
60
41
79
69
65
54
72
84
o-Cresol (o-methylphenol)
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2-
2-
1 -
1 -
2 -
1 -
3 -
4 -
3 -
2 -
2 -
1 -
2 -
2 -
1 -
1 -
1 -
1 -
1 -
1 -
4 -
2 -
1 -
1 -
1 -
3 -
3 -
2 -
2 -
1 -
1 -
1 -
1 -
2 -
2 -
1 -
SA
WS
PA
MD
NE
MA
BN
WN
ES
MA
SA
Bsl
NE
MA
ES
PA
EN
SA
SA
SA
MA
WS
WS
EN
MD
WN
BM
ES
SA
MA
SA
ES
PA
EN
NE
SA
EN
WN
BM
MD
ES
SA
WN
MA
SA
WS
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45+
- 45 +
- 45+
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
- 45 +
- 45+
- 45 +
- 45+
- 45+
Tissue
(9)
20.
11.
19.
9.
19.
23.
18.
23.
28.
20.
19.
21.
21.
25.
25.
21.
20.
18.
17.
19.
26.
22.
21.
21.
18.
20.
21.
19.
26.
16.
17.
21.
22.
19.
26.
18.
23.
21.
26.
21.
20.
20.
22.
18.
26.
22.
Wt
7
1
7
0
1
0
1
4
1
2
1
2
9
2
7
6
2
2
9
5
1
7
9 '
4
3
6
6
9
4
2
6
1
0
8
7
0
2
4
2
0
7
0
5
1
1
4
RRT
.373
ND
.369
.364
.365
ND
.360
.373
.353
.335
.338
.341
.340
.336
ND
ND
ND
.327
.296
.341
.329
.374
.330
.339
.354
.359
.368
.346
.356
.348
ND
.297
ND
.366
ND
.291
.291
.335
.345
.351
.371
.361
.375
.333
.398
.375
CAS No.:,
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
.954
ND
.329
.471
.117
ND
.240
.235
1.255
5.870
1.155
1.799
.316
.262
ND
ND
ND
.150
.049
.348
3.374
.615
1.313
.682
.474
.970
.295
.894
.319
.296
ND
.002
ND
.112
ND
.044
.059
2.478
.285
.720
.906
.272
.329
1.329
.580
.226
.046
ND
.016
.052
.006
ND
.013
.010
.044
.290
.060
.084
.014
.010
ND
ND
ND
.008
.002
.017
.129
.027
.059
.031
.025
.047
.013
.044
.012
.018
ND
<.001
ND
.005
ND
.002
.002
.115
.010
.034
.043
.013
.014
.073
.022
.010
95-48-7
15/50% SMV
0.651
Analysis
Date
4/26/84
5/14/84
4/24/84
4/24/84
4/23/84
4/23/84
4/25/84
5/10/84
5/14/84
6/13/84
6/14/84
6/14/84
4/15/84
4/12/84
6/15/84
4/27/84
6/18/84
6/18/84
6/16/84
6/13/84
6/13/84
5/9/84
6/15/84
6/14/84
4/25/84
5/1 1/84
4/26/84
5/14/84
4/24/84
4/24/84
6/18/84
6/16/84
4/25/84
4/26/84
4/23/84
6/16/84
6/16/84
6/15/84
6/14/84
5/14/84
5/14/84
4/24/84
5/10/84
6/13/84
6/14/84
5/10/84
C-5
-------
Appendix C-5
FY82 15/50% SMV Adipose Composite Summary
Data Report -
MRI Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
67
82
46
36
42
49
55
63
77
52
70
58
43
50
80
47
61
75
73
71
53
83
85
59
37
64
56
78
68
51
76
81
48
57
44
74
62
66
60
41
79
69
65
54
72
84
m,p-Cresol
(m.p-methylphenol)
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2-
2 -
1 -
1 -
2 -
1 -
3 -
4 -
3 -
2 -
2 -
1 -
2 -
2 -
1 -
1 -
1 -
1 -
1 -
1 -
4 -
2 -
1 -
1 -
1 -
3 -
3 -
2 -
2 -
1 -
1 -
1 -
1 -
2 -
2 -
1 -
SA
WS
PA
MO
N=
MA
m
WN
ES
MA
SA
BJ
N=
MA
ES
PA
EN
SA
SA
SA
MA
WS
WS
EN
MD
WN
EN
ES
SA
MA
SA
ES
PA
B4
N=
SA
BJ
WN
a*
MO
ES
SA
WN
MA
SA
WS
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
Tissue
(g)
20.
11.
19.
9.
19.
23.
18.
23.
28.
20.
19.
21.
21.
25.
25.
21.
20.
18.
17.
19.
26.
22.
21.
21.
18.
20.
21.
19.
26.
16.
17.
21.
22.
19.
26.
18.
23.
21.
26.
21.
20.
20.
22.
18.
26.
22.
Wt
7
1
7
0
1
0
1
4
1
2
1
2
9
2
7
6
2
2
9
5
1
7
9
4
3
6
6
9
4
2
6
1
0
8
7
0
2
4
2
0
7
0
5
1
1
4
RRT
.403
.397
ND
.396
.391
.384
.392
.401
.382
.371
.374
.376
.375
.373
ND
.382
.371
.365
.338
.378
.366
.400
.366
.373
.386
.379
.401
.378
.385
.381
.361
.336
.386
.398
ND
.332
.332
.368
.380
.385
.399
.393
.400
.367
.428
.402
CAS No.:
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
.181
2.504
ND
.077
.096
.133
.090
.301
1.017
1.719
.982 .
.995
.279
.155
ND
.491
.138
.104
.026
.199
2.689
.261
2.098
.404
.113
1.618
.419
2.566
.369
.191
.304
.004
.412
.422
ND
.571
.382
9.356
.449
1.615
.457
.158
.352
.792
1.114
.117
.008
.225
ND
.008
.005
.005
.004
.012
.036
.085
.051
.046
.012
.006
ND
.022
.006
.005
.001
.010
.103
.01 1
.095
.018
.006
.078
.019
.128
.013
.011
.017
<.001
.018
.021
ND
.031
.016
.437
.017
.076
.022
.007
.015
.043
.042
.005
" 106-44-5
15/50% SMV
0.638
Analysis
Date
4/26/84
5/14/84
4/24/84
4/24/84
4/23/84
4/23/84
4/25/84
5/10/84
5/14/84
6/13/84
6/14/84
6/14/84
4/15/84
4/12/84
6/1 5/84
4/27/84
6/1 8/84
6/1 8/84
6/16/84
6/1 3/84
6/13/84
5/9/84
6/1 5/84
6/1 4/84
4/25/84
5/1 1 /84
4/26/84
5/1 4/84
4/24/84
4/24/84
6/1 8/84
6/1 6/84
4/25/84
4/26/84
4/23/84
6/1 6/84
6/1 6/84
6/1 5/84
6/14/84
5/1 4/84
5/1 4/84
4/24/84
5/1 0/84
6/1 3/84
6/14/84
5/1 0/84
C-6
-------
Appendix C-6
FY82 15/50% SMV Adipose Composite Summary
Data Report -
MRI Sample
Number
82-67
82-82
82-46
82-36
82-42
82-49
82-55
82-63
82-77
82-52
82-70
82-58
82-43
82-50
82-80
82-47
82-61
82-75
82-73
82-71
82-53
82-83
82-85
82-59
82-37
82-64
82-56
82-78
82-68
82-51
82-76
82-81
82-48
82-57
82-44
82-74
82-62
82-66
82-60
82-41
82-79
82-69
82-65
82-54
82-72
82-84
Di-(2-ethylhexyl)phthaiate (DEHP)
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
1 -
1 -
2 -
1 -
3 -
4 -
3 -
2 -
2 -
1 -
2 -
2 -
1 -
1 -
1 -
1 -
1 -
1 -
4 -
2 -
1 -
1 -
1 -
3 -
3 -
2 -
2 -
1 -
1 -
1 -
1 -
2 -
2 -
1 -
SA
WS
PA
MO
NE
MA
EN
WJ
ES
MA
SA
EN
NE
MA
ES
PA
Rl
SA
SA
SA
MA
V\S
WS
EN
MO
V\N
EN
ES
SA
MA
SA
ES
PA
Bl
NE
SA
BSI
V\M
BJ
MO
ES
SA
VAN
MA
SA
WS
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45+
- 45 +
- 45+
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
- 45+
Tissue Wt
(g)
20.7
11.1
19.7
9.0
19.1
23.0
18.1
23.4
28.1
20.2
19.1
21.2
21.9
25.2
25.7
21.6
20.2
18.2
17.9
19.5
26.1
22.7
21.9
21.4
18.3
20.6
21.6
19.9
26.4
16.2
17.6
21.1
22.0
19.8
26.7
18.0
23.2
21.4
26.2
21.0
20.7
20.0
22.5
18.1
26.1
22.4
RRT
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
.445
.457
.445
.448
.449
ND
.449
.452
ND
.464
.457
.464
ND
.442
.461
.452
.460
.465
.465
.464
.465
.450
ND
.465
.454
.453
.443
.456
.451
.453
.463
.459
.451
.446
.451
.464
.464
.462
.459
.457
.456
.447
.453
.464
.455
.456
CAS No.-:
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
3
4
1
2
3
19
1
4
17
4
2
2
1
5
2
2
2
4
2
8
1
3
3
5
.549
.738
.830
.391
.141
ND
.246
.989
ND
.740
.244
.963
ND
.325
.222
.221
.297
.305
.292
.917
.965
.905
ND
.807
.369
.569
.337
.228
.939
.076
.053
.012
.835
.445
.050
.445
.654
.493
.871
.424
.009
.081
.278
.822
.187
.700
.171
.426
.042
.043
.007
ND
.013
.085
ND
.135
.169
.941
ND
.012
.008
.056
.014
.016
.016
.252
.688
.216
ND
.131
.129
.076
.015
.262
.111
.004
.003
<.001
.128
.022
.001
.024
.028
.116
.185
.115
.386
.054
.145
.211
.198
.031
117-81-7
15/50% SMV
0.898
Analysis
Date
4/26/84
5/14/84
4/24/84
4/24/84
4/23/84
4/23/84
4/25/84
5/10/84
5/14/84
6/13/84
6/14/84
6/14/84
4/15/84
4/12/84
6/1 5/84
4/27/84
6/18/84
6/18/84
6/16/84
6/13/84
6/13/84
5/9/84
6/15/84
6/14/84
4/25/84
5/1 1/84
4/26/84
5/14/84
4/24/84
4/24/84
6/18/84
6/1 6/84
4/25/84
4/26/84
4/23/84
6/1 6/84
6/1 6/84
6/1 5/84
6/1 4/84
5/1 4/84
5/1 4/84
4/24/84
5/1 0/84
6/1 3/84
6/14/84
5/1 0/84
C-7
-------
Appendix C-7
FY82 15/50% SMV Adipose Composite Summary
Data Report -
MRI Sample
Number
82-67
82-82
82-46
82-36
82-42
82-49
82-55
82-63
82-77
82-52
82-70
82-58
82-43
82-50
82-80
82-47
82-61
82-75
82-73
82-71
82-53
82-83
82-85
82-59
82-37
82-64
82-56
82-78
82-68
82-51
82-76
82-81
82-48
82-57
82-44
82-74
82-62
82-66
82-60
82-41
82-79
82-69
82-65
82-54
82-72
82-84
2,4-Diaminotoluene
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
1 -
1 -
2 -
1 -
3 -
4 -
3 -
2 -
2 -
1 -
2 -
2-
1 -
1 -
1 -
1 -
1 -
1 -
4 -
2 -
1 -
1 -
1 -
3 -
3 -
2 -
2 -
1 -
1 -
1 -
1 -
2 -
2 -
1 -
SA
WS
PA
MO
N=
MA
BJ
WN
ES
MA
SA
BJ
NE
MA
ES
PA
BJ
SA
SA
SA
MA
WS
WS
BJ
MD
WN
B4
ES
SA
MA
SA
ES
PA
EN
N=
SA
BJ
WN
EN
MD
ES
SA
WN
MA
SA
WS
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-1 4
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
Tissue Wt
(9)
20.7
11.1
19.7
9.0
19.1
23.0
18.1
23.4
28.1
20.2
19.1
21.2
21.9
25.2
25.7
21.6
20.2
18.2
17.9
19.5
26.1
22.7
21.9
21.4
18.3
20.6
21.6
19.9
26.4
16.2
17.6
21.1
22.0
19.8
26.7
18.0
23.2
21.4
26.2
21.0
20.7
20.0
22.5
18.1
26.1
22.4
RRT
MD
MD
MD
MD
MD
MD
MD
MD
MD
.658
MD
MD
MD
MD
MD
MD
MD
MD
.651
.658
.653
MD
.649
.653
MD
.651
.658
.651
.785
.646
MD
MD
.649
.657
ND
.645
MD
.653
.657
MD
MD
MD
.653
.654
.665
.657
CAS No.:
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
MD
MD
MD
MD
MD
MD
MD
MD
MD
3.261
MD
MD
MD
MD
MD
MD
MD
MD
.039
.630
3.593
MD
5.225
1.822
MD
1.277
.438
2.605
.527
.530
ND
ND
.153
.192
ND
.123
MD
2.470
.848
ND
ND
ND
1.630
2.114
3.480
1.134
MD
MD
MD
MD
MD
MD
MD
MD
MD
.161
MD
MD
MD
MD
MD
ND
MD
MD
.002
.032
.137
MD
.238
.085
MD
.062
.020
.130
.019
.032
MD
MD
.006
.009
MD
.006
MD
.115
.032
MD
MD
MD
.072
.116
.133
.050
95-80-:
15/50% SMV
0.581
Analysis
Date
4/26/84
5/14/84
4/24/84
4/24/84
4/23/84
4/23/84
4/25/84
5/1 0/84
5/14/84
6/13/84
6/14/84
6/14/84
4/15/84
4/12/84
6/15/84
4/27/84
6/18/84
6/18/84
6/1 6/84
6/13/84
6/13/84
5/9/84
6/1 5/84
6/14/84
4/25/84
5/1 1/84
4/26/84
5/1 4/84
4/24/84
4/24/84
6/1 8/84
6/1 6/84
4/25/84
4/26/84
4/23/84
6/1 6/84
6/1 6/84
6/15/84
6/1 4/84
5/1 4/84
5/14/84
4/24/84
5/1 0/84
6/13/84
6/14/84
5/1 0/84
C-8
-------
Appendix C-8
FY82 15/50% SMV Adipose Composite Summary
Data Report -
MRI Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
67
82
46
36
42
49
55
63
77
52
70
58
43
50
80
47
61
75
73
71
53
83
85
59
37
64
56
78
68
51
76
81
48
57
44
74
62
66
60
41
79
69
65
54
72
84
2-Ethoxy benzaldehyde
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
1 -
1 -
2 -
1 -
3 -
4 -
3 -
2 -
2 -
1 -
2 -
2 -
1 -
1 -
1 -
1 -
1 -
1 -
4 -
2 -
1 -
1 -
1 -
3 -
3 -
2 -
2 -
1 -
1 -
1 -
1 -
2 -
2 -
1 -
SA
WS
PA
MO
NE
MA
EN
WN
ES
MA
SA
EN
NE
MA
ES
PA
EN
SA
SA
SA
MA
WS
WS
EN
MO
WN
EN
ES
SA
MA
SA
ES
PA
EN
NE
SA
EN
WN
EN
MO
ES
SA
WN
MA
SA
WS
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45+
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
Tissue
(g)
20
11
19
9
19
23
18
23
28
20
19
21
21
25
25
21
20
18
17
19
26
22
21
21
18
20
21
19
26
16
17
21
22
19
26
18
23
21
26
21
20
20
22
18
26
22
Wt
.7
.1
.7
.0
.1
.0
.1
.4
.1
.2
.1
.2
.9
.2
.7
.6
.2
.2
.9
.5
.1
.7
.9
.4
.3
.6
.6
.9
.4
.2
.6
.1
.0
.8
.7
.0
.2
.4
.2
.0
.7
.0
.5
.1
.1
.4
RRT
.623
ND
.620
.616
ND
ND
ND
.615
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.611
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.617
ND
ND
ND
ND
CAS NO.:A
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
.139
ND
.036
.050
ND
ND
ND
.031
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.038
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.029
ND
ND
ND
ND
.006
ND
.001
.005
ND
ND
ND
.001
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.002
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.001
ND
ND
ND
ND
613-69-4
15/50% SMV
1.000
Analysis
Date
4/26/84
5/14/84
4/24/84
4/24/84
4/23/84
4/23/84
4/25/84
5/10/84
5/14/84
6/13/84
6/14/84
6/14/84
4/15/84
4/12/84
6/15/84
4/27/84
6/18/84
6/18/84
6/16/84
6/13/84
6/13/84
5/9/84
6/15/84
6/14/84
4/25/84
5/1 1 /84
4/26/84
5/14/84
4/24/84
4/24/84
6/18/84
6/16/84
4/25/84
4/26/84
4/23/84
6/16/84
6/16/84
6/1 5/84
6/14/84
5/14/84
5/14/84
4/24/84
5/10/84
6/13/84
6/14/84
5/10/84
C-9
-------
Appendix C-9
FY82 15/50% SMV Adipose Composite Summary
Data Report -
MR) Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
67
82
46
36
42
49
55
63
77
52
70
58
43
50
80
47
61
75
73
71
53
83
85
59
37
64
56
78
68
51
76
81
48
57
44
74
62
66
60
41
79
69
65
54
72
84
4-Pentyl
benzaldehyde
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
1 -
1 -
2 -
1 -
3 -
4 -
3 -
2 -
2 -
1 -
2 -
2 -
1 -
1 -
1 -
1 -
1 -
1 -
4 -
2 -
1 -
1 -
1 -
3 -
3 -
2 -
2 -
1 -
1 -
1 -
1 -
2 -
2 -
1 -
SA
WS
PA
MO
N=
MA
BJ
WN
ES
MA
SA
W
N=
MA
ES
PA
BJ
SA
SA
SA
MA
WS
WS
EN
MO
V\M
BJ
ES
SA
MA
SA
ES
PA
EN
N=
SA
EN
V\M
EN
MO
ES
SA
WN
MA
SA
WS
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
- 45 +
- 45+
- 45 +
- 45 +
- 45+
- 45+
- 45 +
- 45+
- 45 +
- 45 +
- 45 +
- 45 +
Tissue
(9)
20.
11.
19.
9.
19.
23.
18.
23.
28.
20.
19.
21.
21.
25.
25.
21.
20.
18.
17.
19.
26.
22.
21.
21.
18.
20.
21.
19.
26.
16.
17.
21.
22.
19.
26.
18.
23.
21.
26.
21.
20.
20.
22.
18.
26.
22.
Wt
7
1
7
0
1
0
1
4
1
2
1
2
9
2
7
6
2
2
9
5
1
7
9
4
3
6
6
9
4
2
6
1
0
8
7
0
2
4
2
0
7
0
5
1
1
4
CAS No.:
Fraction:
RRf:
Amount Concentration
RRT (Total ug) (ug/g)
.742
rO
ND
ND
.737
.737
ND
.738
.734
ND
ND
ND
hO
t>
ND
ND
M3
ND
to
M3
t>
ND
hO
hD
ND
ND
to
ND
.736
ND
ND
ND
ND
fO
ND
ND
ND
ND
ND
ND
.738
.739
N)
ND
ND
.739
.069
ND
ND
ND
.016
.015
ND
.067
.170
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
N)
ND
ND
ND
ND
ND
.024
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.138
.040
ND
ND
ND
.043
.003
ND
ND
ND
<.001
<.001
ND
.002
.006
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
<.001
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
.006
.002
ND
ND
ND
.001
" 6853-57-2
15/50% SMV
1.000
Analysis
Date
4/26/84
5/14/84
4/24/84
4/24/84
4/23/84
4/23/84
4/25/84
5/10/84
5/14/84
6/13/84
6/14/84
6/14/84
4/15/84
4/12/84
6/15/84
4/27/84
6/18/84
6/18/84
6/16/84
6/13/84
6/13/84
5/9/84
6/1 5/84
6/14/84
4/25/84
5/1 1/84
4/26/84
5/1 4/84
4/24/84
4/24/84
6/18/84
6/16/84
4/25/84
4/26/84
4/23/84
6/16/84
6/1 6/84
6/15/84
6/14/84
5/14/84
5/14/84
4/24/84
5/10/84
6/13/84
6/14/84
5/10/84
C-10
-------
Appendix C-10
FY82 15/50% SMV Adipose Composite Summary
Data Report -
MRl Sample
Number
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
82-
67
82
46
36
42
49
55
63
77
52
70
58
43
50
80
47
61
75
73
71
53
83
85
59
37
64
56
78
68
51
76
81
48
57
44
74
62
66
60
41
79
69
65
54
72
84
2-Phenyl phenol (o-Phenol phenol)
Sample Composite
Number
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
1 -
2 -
2 -
2 -
1 -
1 -
2 -
1 -
3 -
4 -
3 -
2 -
2 -
1 -
2 -
2 -
1 -
1 -
1 -
1 -
1 -
1 -
4 -
2 -
1 -
1 -
1 -
3 -
3 -
2 -
2 -
1 -
1 -
1 -
1 -
2 -
2 -
1 -
SA
W5
PA
MO
NE
MA
BJ
WN
ES
MA
SA
m
NE
MA
ES
PA
&l
SA
SA
SA
MA
WS
WS
Bi
MD
WN
W
ES
SA
MA
SA
E5
PA
EN
NE
SA
EN
\AM
EN
MD
ES
SA
WN
MA
SA
WS
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
-SV
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 0-14
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 15-44
- 45+
- 45 +
- 45+
- 45 +
- 45 +
- 45+
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45 +
- 45+
- 45+
- 45+
- 45 +
Tissue
(g)
20.
11.
19.
9.
19.
23.
18.
23.
28.
20.
19.
21.
21.
25.
25.
21.
20.
18.
17.
19.
26.
22.
21.
21.
18.
20.
21.
19.
26.
16.
17.
21.
22.
19.
26.
18.
-23.
21.
26.
21.
20.
20.
22.
18.
26.
22.
Wt
7
1
7
0
1
0
1
4
1
2
1
2
9
2
7
6
2
2
9
5
1
7
9
4
3
6
6
9
4
2
6
1
0
8
7
0
2
4
2
0
7
0
5
1
1
4
RRT
.790
.784
ND
ND
.785
ND
.787
ND
ND
ND
ND
.782
ND
.788
ND
.785
ND
ND
ND
ND
ND
.788
.779
.781
.785
ND
ND
ND
ND
.783
ND
ND
.785
.790
.784
ND
.777
ND
.783
.783
ND
.787
.786
ND
.787
.778
CAS No.:
Fraction:
RRf:
Amount Concentration
(Total ug) (ug/g)
.299
1.243
ND
ND
2.641
ND
1.867
ND
ND
ND
ND
1.121
ND
1.370
ND
.203
ND
ND
ND
ND
ND
5.808
7.155
.461
.900
ND
ND
ND
ND
1.244
ND
ND
.257
.286
9.366
ND
.361
ND
.443
23.087
ND
1.042
2.458
ND
1.018
.445
.014
.112
ND
ND
.138
ND
.103
ND
ND
ND
ND
.052
ND
.054
ND
.009
ND
ND
ND
ND
ND
.255
.326
.021
.049
ND
ND
ND
ND
.076
ND
ND
.011
.014
.350
ND
.015
ND
.016
1.099
ND
.052
.109
ND
.039
.019
90-43-7
15/50% SMV
0.333
Analysis
Date
4/26/84
5/14/84
4/24/84
4/24/84
4/23/84
4/23/84
4/25/84
5/10/84
5/14/84
6/13/84
6/14/84
6/14/84
4/15/84
4/12/84
6/15/84
4/27/84
6/18/84
6/18/84
6/1 6/84
6/13/84
6/13/84
5/9/84
6/15/84
6/14/84
4/25/84
5/1 1 /84
4/26/84
5/14/84
4/24/84
4/24/84
6/18/84
6/16/84
4/25/84
4/26/84
4/23/84
6/16/84
6/16/84
6/15/84
6/14/84
5/14/84
5/14/84
4/24/84
5/10/84
6/13/84
6/14/84
5/10/84
C-11
-------
APPENDIX D
INCIDENCE OF VOA SARA/ECAD TARGET ANALYTES IN FY82
ADIPOSE COMPOSITES
D-l
-------
Appendix D-1
Incidence of VOA SARA/ECAD Target Analytes in FY82 Adipose Composites
NORTH-CENTRAL
East North Central " West North Central
No. Compound Name CAS No 0-1 4 C 15-44 45+ 0-14 15-44 45+
1 2-Amyl furan 3777-69-3 + +d
2 Bromoheptane 629-04-9 - -
3 Bromopentane 110-53-2 - -
4 Butyraldehyde 123-72-8 + +
5 Ethyl isovalerate 108-64-5 + +
6 1-lodopentane 628-17-1 + +
7 Isobutyraldehyde 78-84-2 + +
8 LJmonene 138-86-3 + +
9 Nonenes (1-Nonene) 124-11-8 + +
10 3-Octen-2-one 1669-44-9 + +
11 Pentyl Alcohol (3-methyl-1-butanol) 123-51-3 + +
1 2 Pentyl cydohexane 4292-92-6 + -
13 Trichloroethylene {Trichloroethene} 79-01-6 + +
III
+ + I
*
+
I
Appendix D-2
Incidence of VOA SARA/ECAD Target Analytes in FY82 Adipose
NORTHEAST
New England b Middle Atlantic
No. Compound Name CAS No 0-14 C 15.44 45+ O.u -,5.44 45+
1 2-Amyl furan 3777-69-3 + d
2 Bromoheptane 629-04-9
3 Bromopentane 110-53-2
4 Butyraldehyde 123-72-8 +
5 ... Ethyl, isovalerate 108-64-5 +
6 1-lodopentane 628-17-1 +
7 Isobutyraldehyde 78-84-2 +
8 Limonene 138-86-3 +
9 Nonenes (1-Nonene) 124-11-8 +
10 3-Octen-2-one 1669-44-9 +
11 Pentyl Alcohol (3-methyl-1-butanol) 123-51-3
1 2 Pentyl cyclohexane 4292-92-6
13 Trichloroethylene {Trichloroethene} 79-01-6 +
|
\
\
\
|
Notes:
a. Census region
b. Census division
c. Age group from which the composite samples were collected.
d. Pluses and minuses correspond to the the number of composites analyzed within a given
census division. A "+" indicates that a compound was identified in a composite and a "-"
indicates that the compound was not detected in a composite.
D-2
-------
Appendix D-3
Incidence of VOA SARA/ECAD Target Analytes in FY82 Adipose
SOUTH a
South Atlantic ^ East S. Central
No. Compound Name CAS No 0-14C 15-44 45+ 0-14 15-44 45+
1 2-Amyl furan 3777-69-3 + +d
2 Bromoheptane 629-04-9 - -
3 Bromopentane 110-53-2 - -
4 Butyraldehyde 123-72-8 + +
5 Ethyl isovalerate 108-64-5 + +
6 1-lodopentane 628-17-1 - +
7 Isobutyraldehyde 78-84-2 + +
8 Limonene 138-86-3 + +
SMrvnonoc M.MnnanaX 1 24-1 1 -8 J- J.
INUMcileo \ 1 V>IUntjni3/ 1 t.*T" 1 t o T -T-
10 3-Octen-2-one 1669-44-9 + +
11 Pentyl Alcohol (3-methyl-1-butanol) 123-51-3 - -
1 2 Pentyl cyclohexane 4292-92-6 - -
13 Trichloroethylene {Trichloroethene} 79-01-6 - -
+ + + +
+ + + +
+ + + +
- + + -
+ + + +
+ + + +
+ + + +
+ + + +
+ - + +
+
+ + + +
+ + + +
+ + - +
+ - + +
+ + + +
+ + + +
+ + + +
- + + -
4- - - -
+
+
+
+
+
+
+
-
-
4- +
4 +
- +
- +
+ +
+ +
+ +
- +
- +
+ +
- 4
+ +
+ +
+ +
+ +
+ +
- -
- +
West S. Central
0-14 15-44 45+
+
-
-
-
+
-
+
+
-
-
-
+ +
+ -
+ 4-
+ 4-
+ +
+ 4
+ *
+ +
- +
- +
- +
*
-
+
+
+
+
+
+
+
-
-
Appendix D-4
Incidence of VOA SARA/ECAD Target Analytes in FY82 Adipose
No. Compound Name
WEST
CAS No
0-14C 15-44 45+
Pacific
0-14 15-44 45+
1 2-Amyl furan 3777-69-3 + d
2 Bromoheptane 629-04-9
3 Bromopentane 110-53-2
4 Butyraldehyde 123-72-8 +
5 Ethyl isovalerate 108-64-5 +
6 1-todoperrtane 628-17-1 +
7 Isobutyraldehyde 78-84-2 +
8 Limonene 138-86-3 +
9 Nonenes (1-Nonene) 124-11-8 +
10 3-Octen-2-one 1669-44-9 +
11 Pentyl Alcohol (3-methyl-1 -butanol) 123-51-3
1 2 Pentyl cyclohexane 4292-92-6
13 Trichloroethylene {Trichloroethene} 79-01-6
+
I
|
+
\
Notes:
a. Census region
b. Census division
c. Age group from which the composite samples were collected.
d. Pluses and minuses correspond to the the number of composites analyzed within a given
census division. A *+" indicates that a compound was identified in a composite and a "-"
indicates that the compound was not detected in a composite.
D-3
-------
APPENDIX E
INCIDENCE OF 6% SMV SARA/ECAD TARGET ANALYTES IN FY82
ADIPOSE
E-l
-------
Appendix E-1
Incidence of 6% SMV SARA/ECAD Target Analytes in FY82 Adipose
NORTH CENTRAL0
No. Compound Name
CAS No
East North Central
0-14C 15-44 45+
West North Central
0-14 15-44 45+
1 Anthracene 120-12-7 - -d
2 Biphenyl 92-52-4 - -
3 Cymene (isopropyltoluene) 99-87-6 + -
4 Dibenzofuran 132-64-9 - -
5 Diphenyl ether (1,1'-Oxybisbenzene) 101-84-8 + +
Limonens loo-oo-o +
7 Safrole 94-59-7 - -
8 1,2,4-Trimethylbenzene 95-63-6 + -
Q 1 C Vwliป4inฃi fl7.ft9.7 . .
::":
a. ฑ j.
X
Appendix E-2
Incidence of 6% SMV SARA/ECAD Target Analytes in FY82
No. Compound Name
NORTHEAST
CAS No
New England b Middle Atlantic
0-14 C 15-44 45+ Q-U 15.44 45-t
1 Anthracene 120-12-7 - d
2 Biphenyl 92-52-4
3 Cymene (isopropyltoluene) 99-87-6 +
4 Dibenzofuran 132-64-9
5 Diphenyl ether {1,1'-Oxybisbenzene) 101-84-8 +
6 Limonene 138-86-3 +
7 Safrole 94-59-7
8 1,2,4-Trimethylbenzene 95-63-6 +
9 2,6-Xylidine 87-62-7
I
+
*
*
*
Notes:
a. Census region
b. Census division
c. Age group from which the composite samples were collected.
d. Pluses and minuses correspond to the the number of composites analyzed within a given
census division. A "+" indicates that a compound was identified in a composite and a "-"
indicates that the compound was not detected in a composite.
E-2
-------
Appendix E-3
Incidence of 6% SMV SARA/ECAD Target Analytes in FY82 Adipose Composites
SOUTH
No. Compound Name
CAS No
South Atlantic D East S. Central West S. Central
0-14C 15-44 45+ 0-14 15-44 45+ 0-14 15-44 45+
1 Anthracene 120-12-7 d - -
2 Biphenyl 92-52-4 +
3 Cymene (isopropyltoluene) 99-87-6 + +
4 Dibenzofuran 132-64-9 +
5 Diphenyl ether (1,1'-Oxybisbenzene) 101-84-8 + +
6 Limonene 138-86-3 + +
Safrole 94-59-7
8 1 ,2,4-Trimethylbenzene 95-63-6 * +
9 2,6-Xylidine 87-62-7 '
+ + + +
+ + +
+ -+ +
+
*
+ -
*-
+
*
-
*
*
+ +
-
-
*
+
Appendix E-4
Incidence of 6% SMV SARA/ECAD Target Analytes in FY82 Adipose Composites
WEST3
No. Compound Name
CAS No
Mountain D Pacific
0-14C 15-44 45+ 0-14 15-44 45+
1 Anthracene 120-12-7 -d
2 Biphenyl 92-52-4
3 Cymene (isopropyltoluene) 99-87-6 +
4 Dibenzofuran 132-64-9
5 Diphenyl ether (1,1'-Oxybisbenzene) 101-84-8
6 Limonene 138-86-3 +
7 Safrole 94-59-7
8 1,2,4-Trimethylbenzene 95-63-6 +
9 2,6-Xylidine 87-62-7
*
f
*
-
*
Notes:
a. Census region
b. Census division
c. Age group from which the composite samples were collected.
d. Pluses and minuses correspond to the the number of composites analyzed within a given
census division. A "+" indicates that a compound was identified in a composite and a "-"
indicates that the compound was not detected in a composite.
E-3
-------
APPENDIX F
INCIDENCE OF 15/50% SMV SARA/ECAD TARGET ANALYTES IN FY82
COMPOSITES
F-l
-------
Appendix F-1
Incidence of 15/50% SMV SARA/ECAD Target Analytes in FY82 Adipose
NORTH CENTRAL'
East Nor|h Central ^
No. Compound Name CAS No 0-1 4 c 15-44 45+
1 Bis(2-ethylhexyl)adipate 103-23-1 - -d
2 Butyl glycol butyl phthalate 85-70-1 - -
3 Carbaryl 63-25-2 - -
4 o-Cresol (o-methylphenol) 95-48-7 + +
5 m,p-Cresol (m,p-methylphenol) 106-44-5 + +
6 Di-(2-ethylhexyl)phthalate (DEHP) 117-81-7 + +
7 2,4-Diaminotoluene 95-80-7 - -
8 2-Ethoxy benzaldehyde 613-69-4 - -
9 4-Pentyl benzaldehyde 6853-57-2 - -
10 2-Phenyl phenol (o-Phenol phenol) 90-43-7 + +
ir
West North Central
0-14 15-44 45+
*
f
*
Appendix F-2
Incidence of 15/50% SMV SARA/ECAD Target Analytes in FY82
NORTHEAST
No.
1
2
3
4
5
6
7
8
9
10
Compound Name
Bis(2-ethylhexyl)adipate
Butyl glycol butyl phthalate
Carbaryl
OTCrasol .(o-methylphenol)
m,p-Cresol (m,p-methylpnenol)
Di-(2-ethylhexyl)phthalate (DEHP)
2,4-Diaminotoluene
2-Ethoxy benzaldehyde
4-Pentyl benzaldehyde
2-Phenyl phenol (o-Phenol phenol)
Notes:
a. Census region
b. Census division
c. Age group from which the cmposite
New England b Middle Atlantic
CAS No 0-1 4 C 15-44 45+ 0-14 15-44 45+
103-23-1 -d
85-70-1
63-25-2
95-48-7 +
106-44-5 +
117-81-7 +
95-80-7
613-69-4
6853-57-2 +
90-43-7 +
-
-
-
+
+
-
-
-
-
-
-
-
-
-
+
-
-
-
+
-
-
-
+
+
+
+
-
+
+
-
-
+
+
+
+
-
-
+
-
-
-
+
+
+
+
-
-
+
sample were collected.
d. Pluses and minuses correspond to the number of composites anlayzed within a given
census division. A *+' indicates that a compound was Identified in a composite and a "-"
indicates that the compound was not detected in a composite.
F-2
-------
Append* F-3
Inctdenoeof 1560% SMVSARAyECADTa^AraVtes in FY82 Adipose Oxnposites
SOUTH
Na OorrpourdName
CASNa
South Atlantic
0-14^15-44 45+
East S. Central West S. Central
0-14 15-44 45+ 0-14 15-44 45+
1 B^-etnylhexyl)adipate 10353-1 d + '
2Di fell nk.u%rJ tw iKil nWK<*|.'rta flKJTWI -
OUty I gyCOl DUly I )ji v leUcttt (Sj-f1_DAnh/t ^>Aซ-i*ToirlAVซซ-tA ftQgQCT O 4. .
*t-rtHRyi uwitdpoenyoe ooix>-iป/-ฃ. +
1O O-Dhonwl nh^rvU /rt_PKor*-J rU^orWl QfVJt*a_7 x -
+ + --
+ .--
-
-
- -
+
- -
*
-
-
*
+
+
+ +
-
-
+
*
Appendix F-4
incidence of 15/50% SMV SARA/ECAD Target Analytes in FY82 Adipose Composites
No. Compound Name
WEST
Mountain
CAS No 0-14C 15-44 45+
Pacific
0-14 15-44 45+
1 Bis(2-ethylhexyl)adipate 103-23-1 -d
2 Butyl glycol butyl phthalate 85-70-1
3 Carbaryl 63-25-2
-4 o-Cresol ^o-methyiphenol) 95-48-7 +
5 m,p-Cresol (m,p-methylphenol) 106-44-5 +
6 Di-(2-ethylhexyl)phthalate (DEHP) 117-81-7 +
7 2,4-Diaminotoluene 95-80-7
8 2-Ethoxy benzaldehyde 613-69-4 +
9 4-Pentyl benzaldehyde 6853-57-2
1 0 2-Phenyl phenol (o-Phenol phenol) 90-43-7
|
*
:
;
*
Notes:
a.
b.
c.
d.
Census region
Census division
Age group from which the cmposlte sample were collected.
Pluses and minuses correspond to the number of composites anlayzed within a given
census division. A "+* indicates that a compound was identified in a composite and a "-*
indicates that the compound was not detected in a composite.
F-3
-------
APPENDIX G
COMPARISON PLOTS OF SAMPLE vs. REFERENCE MASS SPECTRA
FOR COMPOUNDS IDENTIFIED IN FY82 COMPOSITES
G-l
-------
. ฉ
oo
oo
co
LU
U1 O
<*
CO ป
r>- an
** s
iS 3 O1
N TI a>
in
ซ
U- IN
U_
O _J
01 -a:
f-- o
O CJ
UD
in
CM
e?
mo
oo
CJID
o a
-i.
+ $
* -ซr 12
- I LU
_ o ui .
OS CM
IS 3 =
i z: m
z in LU in
o i ca -
ui -. 00 UT
m cj LU
s_
LU
O_
loin
rm
-------
in -
TT
ซ}
TT
rvi
LU
ffj Q;
O> CO
cw
U"l
00
kฃ>
-t C'
CO
0
u> * jri
.. in uJ
t
O I -'
wป*'o
r cc> LU
Of v LU O
I -H _J Lfl ^
a: < d_ o
0)
c
re
4->
O.
O)
2
.0
I
C
o
s_
(O
CL
O
o
O
CD
O.
CM
I
C5
(5-3
-------
T' I
T I
in
in
rvi co
<.n o
-i
CCl f
CO CO
00
cn
^,* ฐ
3 -ป in
in 3 cn
>N cn fti
u. CM cn
r- o
s3
o o
01
<9
in
i in
i CO
i O
-- I UJ
LD S> CO
1 CO *
03Z2-
.. I S CD
i in *+ uj u~>
!_!'-< I "I
c^ co in
uj ^4 n ซ-'
LO tt I
o: x UJ o
-T cri _i cn =
' CD -Ct O S
_J S> U'l CJ UJ
a;
o
Q.
o
a
(U
-*->
ro
(9
CM
-S
03
ai
Q.
(O
o
O)
c
c
ai
a.
o
JD
c
o
to
s-
(T3
O
o
(O
4-J
o
0)
C-
01
(/I
(O
o
Oi
in
LJ
(U
s_
C7>
cn
ru
G-4
-------
rvป i
LU ..
1.0 O
aซ-ซ
coo:
L>"i
ซซ o
00 -ซ
LD
in
C")
* 01
*r
\StLts'
~ I S CD
I M- < LU in
o in i o ซ
Lt ซ. CO ID
.n
LU _ ir>
01 ซ i
v a
D- CO ซ LU
x- r,
LU
.s
B
CD
o
en
to
o
Q.
O
U
-------
CO <5-
CO CO
co
UJ ป
LC| O
CC t>
CD C*.
CM
in co
* a:
Sg g
co 3 en
U_ CM U1
en .
o
ฃ5! i
Q O
\.
LO
I
CO
CJ I
=> in
CM T U1
(O I Z
.. in uu
I LD t
Si*
i*^ OJ *T*
x rs! UJ in
IV ซ U^
^ in *^ oo *ji
LI i ซ-M CO ซ-< '^'
Ln * i
TT Q
5- CO ซ UJ
ซ cojins
Lt (N Q. Q ซ1
OQ X S Z Z
_J O U"l CJ UJ
CM
01
o
a.
o
o
a>
IT3
"o
oo
8
cs
CO
Q.
03
O
+->
CD
O UJ
6-6
-------
CD
Ol
ro on
s- o
rvi oo
UJ ซ
UT O
a ป-l
moe;
in
O
O-
o
(D
(t5
O
ซN
o> t
ir> ft:
*fc a:
* o
3 in
IO 3 O1
(x to ซy
u_
en _J
22
ซซ
s>
o <_, -,
u>
in
-* I
in
ss
re
O)
Q_
ro
O
OJ
c
c
QJ
Q-
O
oa
10
c
O
i.
CO
O.
(O
S-
*->
O
a>
D.
(O
ID
I
O)
CE>
m
to
fc-* CTSX")
3S _
cs s=aaa:ซB
G-7
-------
en
-* r-
CM
.. evi
IN
X
UJ >
(J'\ O
I
i"fi iv
CO Tl
'."N U?
U. CM
O .
cn
SZ
o
s
5!
ฃ
UTl
in
o i
U'l CO
ID
C-l 4- Z
.. U'J UJ
. -a- LTi ^
LO t
O I O
i$aS
Z CO UJ ITi
!_>ซ I O
n' .. LJi ii-i
..I u? (S CO Lrt
UJ -! CO -^ -w-
i.o at i
f Q
%- 00 UJ
a: x UJ . CJ
-x u? _) un z
ct: CM u. o
a
(T3
s_
3
.a
o
C OJ
o -u
-l-> ro
U i
OJ O
a. >
O)
S-
CD
Gป<0ซ
o can*-
'"SiUCl
OO*1"*
z t
M
6-8
-------
a-
ID en
CM
in
rvj CN
x CM
UJ
O
CD 1
r-- ro
cn 3 en
s5 8
O _l
.. tn
ซ-.
t _i
^r ^T ^2 ^?^
001-
LH
I-U)
uJin
O (N
in
CD ^
CO
^ซr ui
in z
.. t UJ
CM o ui o uj
O)
4-J
O
c.
o
a>
s>
Si
-LD
(O
cu
a.
c
a>
c
o
E
O
Q.
O
O
o.
en
CO
I
o
QJ
cn
G>
wi
G-9
-------
in LO
..2
HJ ~ซ
Jjj
m a:
cj LO
o LU
o _i =>
en ^-ซ
01 :
2-00 ซ - i
|V *s I I I I
'ฃ-ฃฃ
S^igฑ
_J C3 '/I CJ LU
!=!
G) LU
S"
-8
LU
CO
COCSLD CO
S ?^i ^
o
00
t
a:
cu
CL
01
-------
^r in
CM
^f*
i>i oo
=
UJ
22
00 iv
on in
fs-
o:
tXL
3 -ซ in
S^ S
C3 O LO
r?o LU
Q.
IJ'l
gg 2
CM
. I
tn i
-co
s.
IT) S> I/I -^
I U> t
O I <5>
"*" -'2
>s> o: CM
^LP = CD
arcM LU in
LU i- co v^
>- 00 ซ LU
ฃฃ \ LU -O
ซ: co _itri z
: o z
I O LU
QJ
to
o
D.
o
o
QJ
(O
o
.8
-ง
.8
-8
GJ
Q.
re
O
QJ
O
I
CM
I
0
O
I
C
O
en
ฃ
-------
(N ซ
ซ r^-
^ป
m
-. hป
rvi
X
LU
(.n o
*T *< '
NJL *^
CD CC
r
w^
Si CO h-
o oc.
yff CtC
* o
f\l
is < in
3 en
^vi ^.rf ribl
IN ซ~* ISf
u. CM tn
U. LU
%74 ="
OT -Z
'-ฐ s!
.. ซ CO
T* - - -
^ 1 1 ^M
t _J .ซ
ป
in "^c ^^^^"^
1-3
g
i ui
O LU Z
ZLU
\r> i en <^v
r- t
1 1 O
+ in o
o z
O iT> IN
o ae z>
s m
CS) LU LU lO
O CEi ^i -<
u; .. en in
--i oo en 05 tn __
t 1 1 *4 lป4 w^ -~S
O1 H- I _ ^^_
T Q
ฃk! X LU . IU
)
4->
(U
E
i
CVJ
ฎ 'o
Fซfc_ r
r^ป Jta
o
a
.
i *
c
a>
CL
14-
.g ฐ .
C OJ
O 4->
l/l !
^ (/I
s- o
ro Q_
Q_ P=
*-?- C
e o
O 0
o
(U
fO '^-
.S S- -M
~u7 ^_> 03
O i
a> o
c. >
CO
-------
co in
oo r-
CO
.. CM
ru
ui
ui o
in CM
en
CO
3 ;
CM i
CJ
~* O Ul
ฉ _J 3>
I _l I
^Z ^1 ^s)
00
U5
CiS
t I
l/l CJ
CO
2 -
i z
C' i' z: co
a: in co ui iri
o in i &>
a: .. rs- in
- CO .. Ul
Cฃ 'V UJ O
I C*i ' U"i Z
or oo
-S
^f
o
fvl
o
a.
o
o
a>
(O
"o
03
>
u
c
a>
CL
o
I/)
Q.
O
U
TO
4->
U
cu
a.
to
ro
C>0
tI
o
O)
=3
CT
G-13
-------
(N
to
If)
CM
QIO
I.OCD
>-* CO
cun
I Z CO
r~ LU in
S I O
51 LO 00 LI
LU T O
IX CO .. .. LU
U1 x LU O
i-n i in ^
.IJ}
-------
CO
r>- co
UJ ซ
IT) CJ>
25
.. .. in
Gป
*?'
>- CO
ฃฃ x uj -co
cs>
co
CO
-g
en
CD UJ
ru
s-
o
oo
$- -r-
(C V>
o. o
e c.
O E
0 O
o
03 OJ
S- i
O (->
aj fa
O- r
o
O)
i
o
-------
in
ru
uj
iซ
co 5
CM co
in
r~ o uj _j
.. .. o ui
1 -CC
t _J O
u'i 2:
CN 1 -H
oo z:
.. I UJ
S T CO -3-
r_i CM I O ซ
CL .ซ ซ CD in
cc -a- o us
UJ CT| ป *
in rป- i
rr i
j CO
^^yunTM
gxtiS10
in
O 0)
O) -t->
Q. f-
(/>
tn ex
to g
(O O
LO
CD
O)
3
CT
G-16
-------
O CO
r- CM
co
ID
ru
x
LU
to o
^o ^^ CM
I 3E CO
rc u? co LU in
O CM I & *^
O^ ^^ Si
r^ in
uj en ซ ^~
to r^- i
* o
>- CO .. .. LU
m x E: 2 :c
ซ -a-
Q.
ro
o
o
O)
c
o
Q.
co O
co -f-
co E
ro O)
CNJ
co
i
iD
OJ
S-
3
cr
6-17
-------
LU
ui
o
LU
.
o'
c
o
(/I
s_
(C
Q.
(O
<_) a>
d) -M
Q- !-
00 ซ/)
o
CO Q.
w E
ฃ S
03
-------
3R
~8
?
MI ..
U1 O
&1
IN O
Q - o i
in o LU
m
CO
- -r>-
LD
-in
s>
tn
S-
o
VJD
CO
ซc
(O
QJ
o.
(O
o
o
Nl
c
OJ
_0
-o
n-
o
o
10 0)
to t/i
CL O
E Q.
O E
u o
fO 0)
(-> -1-
(_) 40
Ol CO
O-
-r-
oo E
co Ol
00
O)
3
en
o
ซป4
e>
^
6-19
-------
LO
Ill ป
t/i O
.. I UJ CQ
TOO IT<
UJ H CTl ^w
i.n r-. i
S I' LU " ง
O) <0
Q. r
to O
>
to >f-
to E
-ง
O
l/l
u>-
o irtnc
G-20
r*i
-------
ฃ8
en
F*^
fvl
111
coS
oo
CD C- UJ
CO CO _)
--ง3
ฃ3g&
cc t-
LCi LU (S>
"*" "^ *5 -ป-
Ci> ITj ^ ?5
Cv* ^^ ">
.. I S CCl
Z ซ CO LU JTi
O ซ I CO ป-i
a: ซ ITI
a IOOLD Ln
ซ* o
CO UJ
'ซ. LU O
a: -< d_ Q 'i
CD x rr z z
ซ LC-
f *J
s- -
re w
CL o
E ex
o E
o o
o
re 01
s
-t-> -i-
0 *->
a> re
Q-i
(/) O
in -r-
re ai
o
CM
I
OJ
en
6-21
-------
in
UJ ซ
too
ex. -+
*ซQC.
1 O
:esปuj
1O
(9
00
(9
s
G-22
-------
in en
co in
.. -a-
rvi ซ
X
UJ -
LO O
2ฃ
CD
* CO
CM
^fc
j*ฃ
CO
CL
Qi
ซl ซf
UJ ซ
UJ
(T> ^ O >
r*w f, ^ uj <^j
.. .. o m
ซ ซ
i _! o
o tn
i
om
_. _ ^*
=> N
Cf 2
) CD
Z
*""_
= ^
t -: ui i
1^1 f^* ^ฃt
"*" rC r^ z
GD ij ^^ rN
CD G? ?T
* i LL! fy^
Z V Q? If5
O CM 1 S> ___
^r ^^ f^ ^ft i n
LU - m < Z^-
Tf Q
;- OD ซ uj
^- ^* --J ^-Tj ซC ^ ^^
^rt T^ ^" ^3 ^*^
in ซ o z
_j s> in o uj
L
BENZENE
J
3
Zul
"i
o:
1 i
' CN
^^
^M
^i^HM*
^
1 *B^B
- ft.
1
CO
ง
s
~
CD
in
fp
~-
1
-S
^"^
-I
f
CC
^
C
*""
re
CD
Q.
re
O
c
CD
tM
C
QJ
JD
^
E
r-
S-
^_1
I O
i O.
I*- O
0 0
C CD
O
s- re
re i
n. o
E >
81
cu
f I/I
re
^J *^^
o to
0) <-
CL S-
to O
to u-
to
re &ซ
y to
C\J
CNJ
ci
CD
=3
CT>
ฐ"
S cnoin *CMCป
2 u, r^2Sฎ S
uj r>i>-o>ป* m
Qs 5
^ 2
ป ic^ hJ
Si*! =
G-23
-------
in
en
.. co
ru
iii ..
in o
m cc
ID fO
CO
r- i
ฃ r;1
O CK
1
O
CD Cu
.. .. p ui
ป " ^- o
3 -CC UJ
O O ~J U"!
CSi
I
: en
UJ I
fy *^i
--' U5
"S-CO
o in
- CO
U-i Q
O -CC
ui ss:
in i
W UJ H-
1^1 ff^i <^i
.ซ I UJ CO
i en co in
Of) I CO ซ
ft' mm 4"^ CS
^Z ^C* CSi U5 Lfl
UJ Ti >^-
>- CO UJ
o: x uj . o
cc co _i in 3:
Ct: -* CL. Q -CC
ฃ2^isi
_J O U'l C_i UJ
e-
o
O UJ
_.g
cs>
CO
si
O
VO
oo
ra
o>
Q.
O
-M
>
X
ป* CM
CO Ol
il -i-
s. i
ป-> -i
o +->
O) IB
Q.I
CO O
CO T
co E
CM
G-24
-------
O"l -^H
CM cn
S
.. ^>
ru
z:
UJ ..
I r* / \
V 1 ^K1
4t
^~
Q; ^ซ
ซ- o:
^4 ^J" s**>
UJ O
IS* -_J O
ITi ซ 0 H-
TN- O
2-aci LU
"o1"
=.m
CM ^
**
V
50
"" s>
_J *-
=!co
"S
4- 1
in o
ft- U>
งi
irico
i i
CTi ITi
LUCCl
! O
*><
-. -cc
r^R^E:
CM O -*
in
CO S Z.-- ^.
CM in LU i
-.<& cs<
4- -. r>-
CTi 2
^^^ fv_ ^> ^\1
1^1 l^ป ^f \^4
G' GiC
- 1 UJ CO
z r M CD in
C_'t CS" 1 d -^
o: < co
T
=
K
M.
ffi
s
UK
X
ฃ
' X
ฅ
UJ
"CM
^-
in
CO
-
o
i-*
o
a
o
9~*
O
, ป*
"I
yj ^ MซM
*
.
~ , r *
o " '
in
CO
es>
"co
&l
- ID
i GSCDv^ v^LD
^i "^ ^^ ^^
a. >-iei: MJ
2: CM 30.2: ct: x
ซ CM c: o s
U-i 0 CCCiC^MCi.
G-25
c
-^
re
a>
a.
ro
o
4J
a>
4-^
fl3
Q.
r~
"O
re
, ..
"">-. O)
X -M
(U -r-
.C to
r O
>-. Q-
e- ฃ
ij Q
^^ v^
CD O
1
CM CO
tO -r
r | '
^J (O
M- "o
O >
c "i
O r_
^_ ,^
fO "
CL to
E
o s-
u o
1 LJ-
_
s_ 25
5S
LJ ซซSlii^
S tn
ฐ- ,-)
to
i^>
to 1
to
-------
in I'V
CS
i a:
_
ฃ3
in
U
LU
Ul
in
03
ซ*
CO
s?
133 S|!
in o
in TO
+ in
in oo
go
Sw =
iN LU ป -"
CM CO Z> t
"J1 CJ UJ
LU
d
I
CD
in
LU
%
ฃ
5^
i
(N
O
in
OC1
co
ts> LU
'g
o
Ol
o
o
jQ
0) (U
fO <-
I t/1
ft3 O
-C CL
-t-> E
J= O
0. U
3 ->
JD ro
*- "o
O >
c "i
O (U
in 10
03 !-
O. (/I
O U
u o
CO
to
-------
-
nj cs
1/1
o
LU
in o
o.
ro
O
s_
fO
s_
ปo
u
CS>
c
o
(/) OJ
1- -I-J
s_ <-
to w
O- O
E Q-
O E
u o
o
're cu
4-> !-
u -i->
a> re
Q-i
to o
>
1/5 -i-
vo E
re QJ
- CN
rri < -
in
CM
i
a>
s-
3
cn
cn
LU
s
CTI3M i iN-fv-
cog
-------
r^ in
co oo
7.2
'.n O
CD
in
CM
o
CM
lf>
Q.
-ง
cn
O
Lu
O
IT)
LO
CO
OJ
Q.
n:
O
O
S_ -r-
cn
Ci o
E Q.
O E
O O
u
S~ r-
O -4->
OJ R}
Q. i
t/1 O
(/I -t
to E
-------
c
o
-O
si
C
5
o
o
l/J
OJ
o
o
S-
QJ
4J
O
ro
S-
fD
JT
O
CT
o
4J
fD
E
CO
CNJ
I
o>
i-
csi in
G-29
-------
en ID
w co
~ง
rvi
O
m i
N. C*)
CO
ii: CM
LD IK ""ป
CM ID O
0 CMLU
O O
jv. O
Of-
*^ ซJ
Ul
Oi N LU -i-
i in
CVJ O
Q- E
ฃ ^
O m
(J
(O
1. -r-
+J S-
(J O
-------
en
ซ in
LO
fU
LU ..
ac -"
CD a:
in
at
a*
Q: CM
ซu, o uฐ>
G> * * 11 til
O"l *^^ f^t ^j
N- OO t
I LD
O I
i cn
K - i
a- i
>- co >
o: v LU ซ f ซ4
ac -a- _i Ui ซ
o; -^ Q- o in
CD x s: s
-> LO -
c
cu
O
O
T
e
ro
-O
c
o
O)
S- <-
m io
Q. O
e a.
O E
o o
o
to
en -i-
w E
o
ro
i
a
i.
3
CD
6-31
-------
CM G>
-* CO
CN
ru
LjJ mm
1.0 o
rs. o
,fe
%ฃ
CM I/I
v in
_ v
Z S
-,ฃ>
v^
^2
<^
zz
J*
So
I CO
- N. z
si U5 r><
iS> CD =>
I C 00
I 00 Ul \D
O IT' I Sป ซ
>- CO LU
o; N LU o
OJ
O)
-o
(1)
-M tn
C O
in t-
Q- E
E (!)
O (/>
u
i. -1-
+-> s-
o o
0*4
CO
I
O
O)
3
CD
LU
Ul
o
LDC4OCN| CMN
MJ
G-32
-------
50272-101
REPORT DOCUMENTATION 1. REPORT NO. 2.
PAGE 560/5-89-003A
4. Tltto and Subtitle
Identification of SARA Compounds in Adipose Tissue
7. Authors)
Jon D. Onstot, John S. Stanley
9. Performing Organization Nam* and Address
Midwest Research Institute
425 Volker Boulevard
Kansas City, MO 64110
12. Sponsoring Organization Nam* and Addraaa
J.S. Environmental Protection Agency
Office of Toxic Substances (TS-798)
Field Studies Branch. 401 M Street, S.W.
Washington, DC 20460
3. Recipient's Accession No.
5. Raport Data
August, 1989
6.
8. Performing Organization Rapt. No.
8862-A
10. Pro)ect/Taปk/Work Unit No.
Work Assignment 23
1 1 . Contract(C) or Orant(Q) No.
(C) 68-02-4252
(0)
13. Typa of Raport & Parted Covered
Final Report 8/88-8/89
14.
15. Supplementary Notes
16. Abstract (Limit: 200 words)
The National Human Adipose Tissue Survey (NHATS). administered by EPA/OTS, is an on-going chemical
monitoring network designed to detect levels and prevalences of toxic substances in the adipose tissue of the
general U.S. population. Adipose specimens collected in fiscal year 1982 were analyzed as composites for
volatile and semivolatile organic compounds via HRGC/MS as part of a previous effort. The data files were
then processed to determine the occurrence of compounds selected from the Superfund Amendments and
Reauthorization Act (SARA) Title III Toxic Chemical Listing, and from the SARA Section 110 CERCLA listing
of 100 hazardous substances. A total of 61 volatile and 120 semivolatile target compounds were selected for
analysis from these listings based on their predicted suitability to the analytical method.
Application of target compound analysis fTCA) to 46 composited adipose tissue samples resulted in the
identification of 13 volatile and 19 semivolatile compounds. Frequency of occurrence data was compiled with
respect to three age groups, four census regions and nine census divisions.
17. Document Analysis a. Descriptors
Adipose Tissues
Mass Spectrometry
Chemical Analysis
b. Identifiers/Open-Ended Terms
Gas Chromatography
c. COSATI Field/Group
18. Availability Statement
19. Security Class (This Raport)
Unclassified
21. No. of Pages
136
20. Security Class (This Page)
Unclassified
22. Price
(See ANSI-Z39.18)
OPTIONAL FORM 272 (4-77)
(Formerty KTIS-35)
Department of Commerce
-------
U.S. Environmental Protection Agency
Region 5, Library (PL-12J)
77 West Jackson Boulevard, 12th Floor
Chicago, IL 60604-3590
-------
------- |